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Abstract 
FoxP3+ regulatory T cells (Tregs) play an important role in controlling inflammation and 
maintaining homeostasis at mucosal sites. Tregs may also limit immunopathology during 
infection but their role in this context remains poorly understood. CD4 T helper (Th) cells 
are important drivers of immune responses and can express master transcription factors 
(TFs) including T-bet, GATA3 and RORγT, which identify Th1, Th2 and Th17 cells, 
respectively. Tregs can also express these TFs, and recent research suggests that Tregs 
expressing master TFs may be able to selectively suppress their corresponding Th 
subsets. T-bet+ Tregs have been shown to selectively target Th1 cells in some contexts, 
but it is unclear whether the same dynamic occurs with Tregs expressing other TFs. It is 
also unclear whether selective suppression can influence the overall CD4 T cell bias 
during infection. To address these questions, an infection model using Salmonella 
enterica serotype Typhimurium (STM) was developed to induce non-lethal colitis. This 
allowed STM-specific and polyclonal CD4 T cells to be tracked in multiple tissues.  
Using this model, a dynamic and site-specific CD4 T cell response was revealed. An early 
and transient colonic Th17 response was followed by a sustained Th1 bias. This Th 
response develops in parallel with an early increase in the proportion of T-bet+ Tregs and 
a later increase in the proportion of RORγT+ Tregs. This reciprocal dynamic between Th 
subsets and Tregs expressing the same TF is consistent with the hypothesis that specific 
populations of Tregs selectively suppress Th subsets. To determine if Tregs are required 
for the dynamic Th bias, Treg depletion experiments were carried out at different 
timepoints. Results show that Tregs are essential for both the early Th17 response and 
the later Th1 response. Together, these results support the hypothesis that Tregs shape 
the dynamic Th bias by selective suppression. Further research is needed to address 
what mechanism might drive this targeted regulation. This research shows the potential 
for Tregs to not just inhibit the overall T cell response, but to actively shape Th bias. This 
highlights the potential for Tregs expressing specific TFs to be used in targeted 
therapeutic approaches. Further work is warranted to improve our basic understanding of 
how Tregs shape immunity and to develop appropriate clinical applications. 
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Chapter 1 General Introduction 
1.1 The intestinal immune system 
The intestines are essential for nutrient absorption and host a vast microbial ecosystem 
that shapes our health and behaviour. Close contact with a complex and dynamic 
microbiome and exposure to dietary antigens and potential pathogens make the intestines 
a critical barrier site. The intestinal immune system is required to perform a delicate 
balancing act between tolerance to dietary antigens and commensal microbiota, and 
prevention of infection by microbial pathogens. If the balance between immune tolerance 
and activation is skewed towards inflammation, immunopathology including food 
intolerance and chronic inflammation can result. On the other hand, excessive tolerance 
can lead to increased susceptibility to infection or cancer. The intestinal immune system 
must therefore be tightly regulated to facilitate both tolerogenic and inflammatory 
responses and to restore balance quickly following physical damage or infection. 
1.1.1 Gross anatomy of the intestines 
Although the intestinal tract is a contiguous tube-like structure, the intestines comprises 
multiple organs with distinct characteristics, structural morphology, cellular components 
and microbial symbionts (Agace and McCoy, 2017; Mowat and Agace, 2014). The small 
intestine (SI) includes the duodenum, which begins at the pyloric sphincter, the jejunum, 
and the ileum, which terminates at the caecum. The inner wall of the small intestine is 
covered in finger-like villi, which maximise surface area exposed to the luminal contents 
to facilitate nutrient absorption. Peyer’s patches (PPs) are visible through the outer layer 
of the SI and are important components of the gut-associated lymphoid tissue (GALT).  
The large intestine begins at the ileocaecal valve that separates the terminal ileum from 
the caecum. The large intestine includes the caecum and colon, which terminates at the 
anal canal. The luminal side of the large intestine does not contain villi but is covered with 
embedded crypts. The lack of villi underlies a functional difference between the SI and 
colon; instead of nutrient absorption, the colon primarily reabsorbs water from luminal 
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contents. Two layers of mucus line the colon, which provides the first defence against 
infection by potentially pathogenic microbes (Hansson, 2012; Swidsinski et al., 2007). The 
large intestinal lumen is less acidic than the SI, and there is high abundance and diversity 
of commensal bacteria (Gu et al., 2013; Quigley, 2013). The microbiome plays an import 
role breaking down complex carbohydrates into readily absorbed metabolites such as 
short-chain fatty acids (SCFA) (Cho et al., 2012; Fleming and Floch, 1986; Morrison and 
Preston, 2016). There are no PPs in the large intestine although a caecal patch is present 
in the caecum; in humans this is located in the appendix. Throughout the SI and large 
intestine, there are thousands of microscopic lymphoid aggregates known as solitary 
intestinal lymphoid tissues (SILT). 
Despite differences between the large and small intestines, there are structural 
similarities. The inner layer of the intestines is mucous-covered epithelium, which is a 
barrier between the luminal contents and the underlying lamina propria (LP). The LP 
contains a wide range of immune cells and contains SILTs. Together, the epithelium and 
LP comprise the intestinal mucosa. Beneath the mucosa is the highly vascularised sub-
mucosa, which also contains lymphoid tissue such as PPs. Below the sub-mucosa is the 
lamina muscularis, which contains highly innervated musculature, and the serosa, which 
is the outermost layer of the intestines. Intestinal lymphatic vessels drain to mesenteric 
lymph nodes (MLN), which drain distinct intestinal regions (Fig 1.1). MLNs play an 
important role in initiating immune responses to antigen encountered in the intestines 
(Huang et al., 2000; Macpherson and Smith, 2006). The structure and cellular 
components of the MLN and intestinal mucosa including GALT are shown in Figs 1.2 and 
1.3, respectively. 
1.1.2 Intestinal epithelium 
The intestinal epithelium lines the luminal side of the intestines and contains enterocytes 
with microvilli. These enterocytes differentiate from stem cells within microscopic 
depressions or crypts (Barker et al., 2008; Bjerknes and Cheng, 1999; Clevers, 2013). As 
new epithelial cells are generated, older cells move out of the crypts and towards SI villi 
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or colonic apical surfaces, where they are eventually shed into the lumen. In this way, 
aging or damaged epithelial cells are constantly replaced every 2-5 days (van der Flier 
and Clevers, 2009; Garrett et al., 2010). In addition to enterocytes, the intestinal 
epithelium contains microfold cells (M cells), intra-epithelial lymphocytes (IELs) and 
secretory cells, such as goblet cells, Paneth cells and tuft cells. 
Goblet cells are mucus-secreting cells located throughout the intestines, but are enriched 
in the large intestine, where there is a thicker mucous lining comprising two layers 
(Ermund et al., 2013; McGuckin and Hasnain, 2017). Mucus facilitates passage of luminal 
contents and provides a crucial physical barrier between the host and the microbiota. 
Mucus contains mucins including Muc2 and salts, suspended in water, which form a 
dense glycoprotein gel (Lievin-Le Moal and Servin, 2006; Rodríguez-Piñeiro et al., 2013; 
Schroeder, 2019). The intestinal mucus layers are not only a barrier for pathogens, but 
provide a niche for commensal microbiota. Intestinal mucus can be broken down and 
consumed by specific species of bacteria, so mucus composition can selectively regulate 
the microbes that colonises the lumen (Marcobal et al., 2013; Martens et al., 2018; 
Sonnenburg, 2005). The importance of mucus for intestinal health is demonstrated by the 
finding that mucus thickness is reduced during intestinal inflammation and increases 
susceptibility to infection (Desai et al., 2016; Johansson et al., 2014; Swidsinski et al., 
2007). Indeed, reduced mucus production is associated with inflammatory bowel disease 
(IBD) and is a fundamental aspect of Dextran Sodium Sulfate (DSS)-induced colitis 
(Gersemann et al., 2009; Johansson, 2014; Schultsz et al., 1999). 
In addition to their role as mucous secretors, goblet cells facilitate the passage of luminal 
antigen to LP antigen presenting cells (APCs) through goblet cell-associated passages 
(GAPS). GAP-mediated antigen transport plays a role in maintaining tolerance to food- 
and microbial-derived antigen (McDole et al., 2012). GAPS have been identified in the SI 
and colon and have been shown to be blocked during intestinal infection (Knoop et al., 
2017; Kulkarni et al., 2018).  
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While goblet cells are enriched in the large intestinal epithelium, Paneth cells are primarily 
located in the SI epithelium. Paneth cells can detect inflammation through interleukin (IL)-
22 signalling or directly detect bacteria through toll-like receptors (TLRs) and Myd88 
signalling (Vaishnava et al., 2008). Following activation, they can produce antimicrobial 
and inflammatory proteins including defensins, lysozyme and tumour necrosis factor 
(TNF)α (Elphick, 2005; Vaishnava et al., 2008; Wilson, 1999).  
Tuft cells are chemosensory cells that differentiate from intestinal stem cells They are 
upregulated during helminth infection, produce the alarmin IL-25 and play an important 
role in anti-parasite responses (Gerbe et al., 2016; Harris, 2016; Howitt et al., 2016).  
Microfold cells (M cells) are specialised epithelial cells that differentiate in the follicle-
associate epithelium (FAE) above GALT. M cells transport microbes and microbial 
antigens from the intestinal lumen into the sub-epithelial dome (SED) of PPs/CPs, or into 
the LP. M cells deliver antigen to antigen presenting cells (APC) such as dendritic cells 
(DCs), and play an important role in initiating immune response (Kraehenbuhl and Neutra, 
2000; Mabbott et al., 2013). 
In addition to cells derived from intestinal stem cells, the epithelium also contains a 
population of intra-epithelial lymphocytes (IELs) that act as an early defence against 
pathogens. These lymphocytes are mostly CD3+ T cells, including those with αβ and γδ 
T cell receptors (TCRs). In humans, IELs are predominantly αα or αβ CD8+ T cells, 
although the frequency of γδ T cells is increased in inflammatory conditions such as 
coeliac disease (Meresse et al., 2012; Sollid, 2004). IELs are antigen-experienced cells 
and are primed to initiate rapid responses against pathogens (Mayassi and Jabri, 2018; 
Sheridan and Lefrançois, 2010). 
1.1.3 Intestinal lamina propria 
Separated from the intestinal lumen by the epithelium, the LP contains abundant immune 
cells including lymphocytes, granulocytes and mononuclear phagocytes (MNPs). MNPs 
include monocytes, macrophages and dendritic cells (DCs) that are important immune 
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sentinels. LP macrophages are resident phagocytic cells that clear apoptotic debris and 
detect microbial antigens, metabolites and other danger signals with pattern recognition 
receptors (PRRs). PRRs include surface-bound C-type lectin receptors (CLRs), cell 
membrane-bound TLRs and cytoplasmic NOD-like receptors (NLRs) and RIG-1 like 
receptors (RLRs). PRRs recognise structural motifs specific to bacteria, viruses, parasites 
or other pathogens, referred to as pathogen-associated molecular patterns (PAMPs). 
Once PAMPS are detected, macrophages may become activated, phagocytose microbes 
for lysosomal degradation, and produce cytokines or growth factors to recruit and regulate 
other immune cells (Bain and Mowat, 2014; Geissmann et al., 2010).  
In addition to similar phagocytic activity, DCs are specialised antigen presenting cells 
(APCs) that play a crucial role in driving adaptive, antigen-specific immune response. DCs 
are migratory cells and following activation, they upregulate C-C chemokine receptor 
(CCR)7, which facilitates migration to lymphoid tissues such as mesenteric lymph nodes 
(MLN) (Cerovic et al., 2014). Activated DCs upregulate major histocompatibility complex 
class II (MHC II), co-stimulatory molecules and cytokines that control the activation and 
differentiation of T cells (Jenkins et al., 2001; Langenkamp et al., 2000; Mondino et al., 
1996). 
Lymphocytes comprise an abundant and heterogenous group of cells in the LP that play 
fundamental roles in both innate and adaptive immunity. The role of T cells and B cells in 
the intestines are well characterised but innate lymphoid cells (ILCs) have recently been 
shown to play important roles in intestinal immune responses (Hepworth et al., 2013; 
Sonnenberg and Artis, 2012). ILCs lack both T cell receptors (TCRs) and B cell receptors 
(BCRs), and therefore respond to non-antigen-specific cues. Natural killer (NK) cells, are 
well-described ILCs that recognise host cells that are missing MHC class I proteins (Vivier 
et al., 2011). NK cells can be considered a population of ILC1 cells; ILC2 cells play an 
important role in early response to helminth infection; and ILC3 cells produce cytokines 
such as IL-22 and IL-17 early after infection and are a major source of IL-2 in the LP (Spits 
et al., 2013; Takatori et al., 2009; Zhou et al., 2019). Lymphoid tissue inducer (LTi) cells 
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are a specialised ILC3 type that is required for the genesis of lymphoid follicles such as 
cryptopatches and intestinal lymphoid follicles (ILFs) (Sonnenberg et al., 2011) (Fig 1.3). 
T cells differentiate from thymic precursors and include cells that require classical antigen 
presentation and innate cells that can respond quickly to non-specific stimuli, before 
adaptive responses can develop. Intestinal innate-like T cells include γδ T cells, which 
express TCRs with γ and δ chains and are typically IELs (Di Marco Barros et al., 2016; 
Holtmeier and Kabelitz, 2005). 
In contrast to innate-like T cells that can respond rapidly to infection, conventional CD3+ 
T cells express a single TCR clone that binds a specific peptide presented within MHC 
molecules. Conventional T cells can be broadly characterised by co-receptors CD8 or 
CD4. CD8+ T cells are cytotoxic cells that can target cells infected by intracellular 
pathogens, which they recognise by antigen presented by MHC I molecules. Following 
antigen recognition, CD8 T cells can respond by releasing inflammatory cytokines such 
as TNFα and IFNγ, by releasing granzyme and perforin to kill infected cells, or by inducing 
apoptosis through FasL-Fas interactions (Kägi et al., 1994; Rouvier et al., 1993). CD4+ T 
helper (Th) cells are classically activated by recognising cognate antigen presented in 
MHC II molecules in addition to co-stimulatory signals. Once activated, CD4 T cells can 
differentiate into different Th subsets and orchestrate a wide range of immune responses, 
including tolerogenic or inflammatory responses directed against a wide range of 
pathogens. The activation and differentiation of CD4 T cells will be discussed further 
below.  
B cells are another group of lymphocytes crucial to intestinal immunity and are both APCs 
and producers of Immunoglobulin (Ig) antibodies, that bind specific molecular epitopes on 
pathogens. B cells are produced in the bone marrow and express B cell receptors (BCRs) 
that are transmembrane Ig molecules that can bind cognate antigen independently of 
MHC molecules. Following activation, B cells can differentiate into antibody-producing 
plasmablasts, long-lived plasma cells or memory B cells, that can rapidly become 
activated during re-infection. In the intestine, B cells primarily produce IgA antibodies, 
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which are secreted by B cells in follicles of the MLN and locally in PPs or ILFs (Bouskra 
et al., 2008; Craig and Cebra, 1971; Reboldi and Cyster, 2016). 
The adaptive immune response requires multiple cell types to converge and communicate 
through antigen presentation, co-stimulation or cytokine production. The convergence of 
different cells to drive adaptive immunity in the intestines occurs in lymphoid tissue 
including MLNs and GALT. 
1.1.4 Mesenteric lymph nodes 
The MLNs are draining lymph nodes for the intestines and are important induction sites 
for adaptive immune responses to intestinal pathogens or other antigens. A chain of colon- 
and SI- draining MLNs (sMLN and cMLN respectively) each drain a distinct portion of the 
intestines (Houston et al., 2015), and this regionalised drainage is depicted in Fig 1.1.  
 
Figure 1.1 Mesenteric lymph nodes drain distinct regions of the intestines. 
Schematic representation of regionalised drainage of lymph from different areas or the murine SI (blue-green) 
or large intestine (purple-orange) into specific MLNs. cMLN1 and the sMLNs form a single chain in a layer of 
mesenteric adipose tissue, while cMLN2 and cMLN3 are located separately along the distal colon and rectum. 
MLNs, like other LNs are encapsulated tissues with distinct regions, populated with 
resident and migratory cells, facilitating the presentation of antigen to both T cells and B 
cells (Fig 1.2). Lymphatic fluid, containing migratory cells including T cells, B cells and 
DCs, flows from the intestines through afferent vessels into the MLN subcapsular sinus 
(SCS), which contains CD169+ SCS macrophages that can bind and phagocytose lymph-
borne pathogens (Junt et al., 2007; Kuka and Iannacone, 2014). Migratory cells in afferent 
lymph transit into the cortex, containing B cell follicles with B cells and follicular DCs 
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(FDCs), and interfollicular regions. The interfollicular regions and neighbouring paracortex 
contain T cell zones populated with DCs, naïve T and FoxP3+ regulatory T cells (Liu et 
al., 2015; Mondino et al., 1996). The paracortex is vascularised with HEVs that are entry 
points for naïve lymphocytes arriving from the peripheral blood.  
MLN fibroblastic reticular cells (FRCs) express C-C motif chemokine ligand (CCL)19 and 
CCL21, ligands for CCR7. CCR7 is expressed by migratory DCs, activated B cells, naïve 
T cells, regulatory T cells (Tregs), and a sub population of memory T cells (Kain and 
Owens, 2013). CCR7 expression by migratory cells and CCR7 ligand expression by FRCs 
are required for optimal induction of adaptive immunity (Luther et al., 2000). The medullary 
sinus, containing medullary macrophages and plasma cells, provides a conduit for 
migrating cells to pass from the cortex into the efferent lymphatic vessels. Once efferent 
lymph exits the MLN, it travels through the lymphatics into the thoracic duct, from where 
it drains into the subclavian veins. 
 
Figure 1.2 Structure and cells of a mesenteric lymph node. 
Cartoon depiction of a lymph node, which is capsulated and divided into distinct regions. Afferent lymphatic 
vessels carry lymph into the subcapsular sinus (SCS), which surrounds cortex encompassing B cell follicles 
and interfollicular regions. The sub-cortex includes T cell zones and high endothelial venules (HEV) that 
deliver lymphocytes from circulating peripheral blood. The medullary sinus feeds from the cortex into efferent 
lymphatic vessels that carry lymph out of the nodes. Mφ, macrophage; DC, dendritic cell.  Adapted from Girard 
et al. (2012). 
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In summary, MLNs facilitate a convergence of lymph-borne cells migrating from the 
intestines with lymphocytes circulating in peripheral blood. This convergence is essential 
for the development of antigen-specific immune responses to pathogens or tumours and 
the maintenance of tolerance to microbial and food antigen. In addition to being important 
sites for the induction of adaptive immunity, MLNs have been shown to play an important 
role in limiting dissemination of intestinal pathogens, including Salmonella (Griffin et al., 
2011; Voedisch et al., 2009). Together, these functions make the MLNs crucial tissues for 
the intestinal immune system. 
1.1.5 Gut-associated lymphoid tissue 
The GALT are a network of lymphoid tissue containing aggregates of immune cells in the 
intestines. While MLNs are sometimes characterised as part of the GALT, here the term 
is used to specify tissue within the intestines. The GALT include a series of Peyer’s 
patches (PP), which are multi-follicle lymphoid aggregates located along the SI; the caecal 
patch (CP), which is a similar tissue in the mouse caecum or human appendix; and solitary 
intestinal lymphoid tissues (SILT). The intestines contain thousands of SILT including a 
developmental continuum of aggregates from microscopic cryptopatches to ILFs. The 
structure and cellular components of the GALT are shown in Fig 1.3. 
Peyer’s patches and caecal patches 
PPs and CPs develop embryonically and occupy areas in the intestinal wall that extend 
from the intestinal submucosa to the sub-epithelial dome (SED) beneath follicle-
associated epithelium (FAE) (Jung et al., 2010). The structure of PPs is similar to MLNs, 
with multiple B cell follicles surrounded by areas containing T cells and DCs. SED-
associated CCR6+ DCs populate an area beneath the FAE, which itself is enriched with 
M cells  (Iwasaki and Kelsall, 2000). These DCs are poised to phagocytose microbiota 
and food antigen that transit through M cells and have also been shown to acquire antigen 
by extending dendrites through the FAE (Allen et al., 2016; Lelouard et al., 2012; Niess, 
2005). Once antigen is acquired by PP DCs, they can present this to CD4 T cells that are 
recruited to the PPs by B cells expressing CXCL9 (Iwasaki and Kelsall, 1999; Wang et 
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al., 2018). Unlike MLNs, there are no afferent lymphatics for PPS or CPs, although they 
contain HEVS, where naïve lymphocytes can enter from the peripheral blood.  
PPs/CPs have several important roles in the intestinal immune system. Like MLNs, they 
are induction sites for adaptive immunity, including priming and activation of T cells and 
maturation of B cells. Their position adjacent to the M cell-enriched FAE, means that SED 
DCs have access to antigen as it passes through M cells, and can present this antigen to 
T cells in situ without requiring lymphatic migration. PPs are therefore important tissues 
for rapid responses against pathogens or to maintain tolerance to dietary antigen. The 
location of the CP suggests that it may play a role in maintaining tolerance to microbial 
antigens, including the high abundance of aerobic microbiota in the caecum (Marteau et 
al., 2001). PPs have been shown to be major sources of intestinal IgA (Craig and Cebra, 
1971; Reboldi and Cyster, 2016) and their position below the FAE means that 
immunoglobulin A (IgA) produced by follicle plasma cells can be released in close 
proximity to luminal pathogens. 
Solitary intestinal lymphoid tissues 
SILTs include a developmental continuum from microscopic cryptopatches to mature 
ILFs, which can be found throughout the SI and large intestine (Pabst et al., 2005). Unlike 
PPs/CPs, mouse ILFs do not develop embryonically but do so after birth. SI ILF formation 
is dependent on the microbiota and do not form in germ-free (GF) mice, although they 
quickly develop following microbial colonisation in a TLR-dependent manner (Bouskra et 
al., 2008; Herbrand et al., 2008). On the other hand, colonic ILFs have been shown to 
develop independently of microbiota and develop in GF mice (Donaldson et al., 2015). In 
contrast to mice, human ILFs develop in utero and play an important role in priming early 
intestinal responses and IgA production (Gustafson et al., 2014). 
ILF development begins with microscopic cryptopatches, which are small clusters of LTi 
cells and follicular DCs (FDCs) (Pabst et al., 2005). Cryptopatches develop into immature 
ILFs as B cells join the cluster of cells, and immature ILFs may then develop into mature 
ILFs. Intestinal ILFs can develop in the LP or the submucosa; as they mature, B cells and 
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FDCs develop into a follicle-like structure that can become vascularised by high 
endothelial vessels (HEVs) and lymphatics (Buettner and Lochner, 2016; Wang et al., 
2018). Mature ILFs contain DCs and CD4 T cells, including both conventional T cells 
(Tconv) and FoxP3+ Tregs. Following maturation, ILFs can regress to immature stages or 
disappear altogether (Bouskra et al., 2008; Pabst et al., 2005). The development of ILFs 
and cellular components of the intestinal mucosa are shown in Fig 1.3. 
The similarities between ILF and PP/CP structure, cellular components and location 
suggest that GALTs may have similar functions. Like PPs/CPs, ILFs are important 
sources of IgA (Knoop and Newberry, 2012; Lorenz and Newberry, 2004), and the 
accumulation of CD4 Tconvs and Tregs suggests that ILFs are localised induction sites 
for adaptive immunity (Hamada et al., 2002). The specialised role of ILFs compared to 
PPs/CPs is likely related to the large number and dispersal of ILFs throughout the 
intestines. Murine SI contain 50-60 ILFs/cm2, which is a similar density to the human SI 
(Pabst et al., 2005; Senda et al., 2019). In the colon, there are ~150 ILFs/cm2, which 
comprises 2.5-5.0% of the colonic surface area (Senda et al., 2019). This dense network 
of ILFs allows a rapid and highly localised response to be initiated to throughout the 
intestines. Further research is warranted to clarify how lymphocytes activated in ILFs, and 
the GALT in general, can disseminate to carry out more regional immune responses. 
28 
 
Figure 1.3 Cellular components of the intestinal mucosa with gut-associated lymphoid tissue. 
Cells of the SI (left) and colonic epithelium and LP (right) are diagrammed with luminal microbes and IgA. 
GALT follicles are shown, including a PP in the SI and an ILF in the colon. The development of a mature ILF 
from an immature follicle, which itself develops from a colonic cryptopatch, is indicated by arrows. Mature ILFs 
can become vascularised, with efferent lymphatics and HEV present. Bidirectional arrows represent the 
potential for mature ILFs to regress to immature stages or cryptopatches. DC, dendritic cell; FDC, follicular 
dendritic cells, IEL, intra-epithelial cell; HEV, high endothelial venule; ILF, isolated lymphoid follicle; LTi cell, 
lymphoid tissue inducers cells; M cell, microfold cell; Mφ, macrophage; Tconv, conventional T cell; Treg, 
regulatory T cell. Adapted from Buettner and Lochner (2016). 
1.2 Intestinal CD4 T helper cells 
CD4 T cells are also known as T helper (Th) cells to discriminate them from CD8+ cytotoxic 
T lymphocytes (CTLs). Here, CD4 T cells may be referred to as Th cells in reference to 
different Th subsets, or conventional T cells (Tconvs) to distinguish them from Tregs, 
discussed below. CD4 T cells play a major role in the intestinal immune system: 
orchestrating responses against pathogens; tolerance to microbes, food and self-
antigens; and maintaining immunological memory. They produce cytokines that modulate 
the function of cells including other lymphocytes, MNPs and stromal cells. The capability 
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of CD4 T cells to protect the host against pathogens and limit immune pathology requires 
a fine-tuned balance. The diversity and plasticity of CD4 T cells underlies their potential 
to coordinate complex, dynamic and highly regulated immune responses in the gut. 
CD4 T cells develop from haemopoietic progenitors in the thymus. Initially, positive 
selection leads to survival of T cells that recognise self-MHC and subsequent negative 
selection leads to the deletion of T cells that strongly recognise self-peptides. Following 
selection for survival, CD4 T cells emerge as naïve T cells expressing αβTCR clones 
specific for a peptide-MHCII complex (Hedrick et al., 1984; Yanagi et al., 1984). Naïve 
CD4 T cells express CCR7 and CD62L, which facilitates migration between secondary 
lymphoid tissues, where they may encounter cognate antigen, presented by DCs 
(Langenkamp et al., 2000; Sallusto and Lanzavecchia, 2000). 
1.2.1 CD4 T cell activation 
As previously mentioned, activation of naïve CD4 T cells occurs in secondary lymphoid 
organs following TCR and CD4 engagement with cognate antigen presented on the 
surface of APCs with MHC II molecules (Grakoui, 1999; Jenkins et al., 2001). In addition 
to TCR/CD4 engagement, T cell activation requires co-stimulation by APC surface 
molecules. These included CD80/CD86, which interact with T cell CD28, CD40 which 
interacts with T cell CD40L, and inducible T cell co-stimulator (ICOS), which interacts with 
T cell ICOS-L (Clark and Ledbetter, 1994; Dong et al., 2001; Mueller et al., 1989). If TCR-
MHC II engagement is accompanied with sufficient co-stimulation, TCR signalling can 
activate transcriptional programmes, leading to proliferation and upregulation of a wide 
range of proteins including chemokine receptors (Linsley, 1991; Sallusto et al., 1998). 
Depending on the cytokines present during activation, CD4 T cells can be induced to 
proliferate and differentiate into T helper (Th) subsets that can carry out various effector 
functions (Ivanov et al., 2006; Mosmann and Sad, 1996). On the other hand, if TCRs 
engage their cognate antigen without sufficient co-stimulation, they can become anergic, 
apoptotic or tolerised (Gimmi et al., 1993; Schwartz, 1990; Van Parijs et al., 1996).  
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1.2.2 Differentiation of T helper subsets 
Following activation, CD4 T cells can differentiate into T helper (Th) subsets including 
Th1, Th2 or Th17 cells (Fig 1.4) (Harrington et al., 2006; Langenkamp et al., 2000). Each 
of these subsets express a ‘master’ transcription factor (TF), that controls a transcriptional 
programme for protein expression and effector functions to target specific types of 
pathogens (Ivanov et al., 2006; Szabo et al., 2000; Zheng and Flavell, 1997). The 
differentiation of Th subsets is at least partially controlled by cytokines produced by cells 
including APCs, other T cells and innate lymphocytes (Hsieh et al., 1993; O’Garra, 1998). 
Th1 cells play an important role in host defence against intracellular pathogens including 
viruses and bacteria (Hsieh et al., 1993; Zhu and Paul, 2008). Cytokines IL-12 and 
interferon γ (IFNγ), produced by cells including ILCs and DCs, instruct Th1 differentiation. 
Th1 cells express the TF T-bet, which can drive expression of chemokine receptor CXCR3 
and cytokines including IFNγ and tumour necrosis factor (TNF) (Hsieh et al., 1993; 
Romagnani, 1997). Th1 cytokines can activate MNPs to enhance anti-bacterial and anti-
viral responses, and increase the activation of other Th1 cells and other type I 
lymphocytes including ILC1s (Macatonia et al., 1995; Szabo et al., 2000). 
Th2 cells are important for protection against helminths or other parasites and they also 
play a role in allergic responses (Pearce, 1991; Prescott et al., 1998). Th2 differentiation 
is instructed by IL-4, which is produced by cells including T cells, basophils and mast cells 
(Ballesteros-Tato et al., 2016; Coquet et al., 2015; Piehler et al., 2011), although IL-4 is 
not required for Th2 differentiation (Brewer et al., 1999). Th2 cells express the GATA 
binding protein 3 (GATA3), which can drive expression of chemokine receptors CXCR4, 
CCR8, and cytokines IL-4, IL-5 and IL-13 (Yamashita et al., 2004; Zheng and Flavell, 
1997). 
Th17 cells were first identified in 2005 and play an important role in defence against 
extracellular pathogens including bacteria and fungi (Harrington et al., 2005; Ivanov et al., 
2006; Park et al., 2005). Th17 cells are enriched at mucosal sites and have been shown 
to play a role in inflammatory diseases and autoimmunity (Fina et al., 2008; Wang et al., 
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2009a). Th17 differentiation is induced by IL-6, IL-23 and TGFβ via STAT3 signalling 
(Bettelli et al., 2006; Mangan et al., 2006). Conversely, the differentiation of Th17 cells is 
inhibited by Th1- and Th2-associated cytokines such as IL-12, IFNγ and IL-4 (Damsker et 
al., 2010; Olsen et al., 2011; Sallusto et al., 1998). Th17 cells express the TF Retinoic 
acid receptor-related orphan nuclear receptor gamma (RORγT), which can upregulate 
expression of the chemokine receptor CCR6 and cytokines including IL-17A, IL17F, IL-21 
and IL-22 (Liang et al., 2006; Mangan et al., 2006; Zhou et al., 2009). A simplified overview 
of Th subset differentiation pathways is outlined in Fig 1.4. 
 
Figure 1.4 Differentiation pathways of CD4 T helper subsets. 
The differentiation pathways of Th1, Th2 and Th17 subsets are shown from naïve CD4 T cells. ‘Master’ TF 
expression is noted within cell symbols. Cytokines that instruct differentiation are shown above arrows and 
cytokines produced by each population are listed to the right of cell symbols. Important chemokine receptors 
are noted. 
1.2.3 Conventional T cell trafficking to the intestines 
During intestinal infection or inflammation, Th cells migrate from lymphoid tissues where 
they are activated to locations where they can carry out effector functions and promote 
host defence against infection. 
Expression of Th subset ‘signature’ chemokine receptors (Fig 1.4) are important for 
directing Th cells to specific regions of inflamed sites throughout the body. CXCR3 
expression by Th1 cells directs migration to its ligands CXCL9 and CXCL10, expressed 
by multiple cell types including DCs and endothelial cells, and can be upregulated during 
inflammation (Hardison et al., 2006; Romagnani et al., 2004). CXCR3+ Th1 cells may 
therefore be preferentially recruited to sites of inflammation through chemokine gradients. 
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In the intestines, CXCR3 ligands are upregulated in mouse models of colitis and IBD, and 
anti-CXCL10 therapy has been promoted as a possible therapeutic for ulcerative colitis 
(UC) patients (Mayer et al., 2014b; Sasaki et al., 2002; Schroepf et al., 2010; Singh et al., 
2016). CCR6 expression by Th17 cells also plays an important role in migration to 
inflamed sites. CCR6 ligand CCL20 is upregulated by inflamed intestinal epithelium and 
is also expressed by FAE adjacent to GALT (Wang et al., 2009a). Mice with induced colitis 
and IBD patients have increased CCL20 expression, indicating an important role for 
CCR6-dependent migration in intestinal inflammation (Kaser et al., 2004; Teramoto et al., 
2005). CCR4 and CCR8 expression by Th2 cells facilitates migration to chemokines 
CCL17, CCL22, CCL1 and CCL18. As with CXCR3 and CCR6 ligands, Th2-associated 
chemokines have been shown to be upregulated during inflammation (Islam et al., 2011; 
Yoshie and Matsushima, 2015) 
While Th-associated chemokine receptors are important for recruiting T cell subsets to 
sites of inflammation, further homing instruction is required to specifically direct Th cells 
to the intestines. Site-specific homing can be imprinted during T cell priming and induces 
expression of various receptors and integrins that direct Th cells out of the MLN or GALT 
towards receptor ligands in intestinal vasculature, epithelium and LP. 
One well characterised receptor important for gut homing is the integrin α4β7, which binds 
mucosal vascular addressin cell adhesion molecule 1 (MADCAM-1), expressed by 
stromal cells in intestinal LP venules (Agace, 2010; Berlin et al., 1993; Campbell et al., 
2001). CCR9 is another homing receptor shown to direct T cells to the SI, where its ligand 
CCL25 is expressed by epithelial cells (Briskin et al., 1997; Kunkel et al., 2000). Receptors 
that instruct colon-specific trafficking has been more elusive, although the G-protein-
coupled receptor 15 (GPR15) has been shown to play an important role in homing of 
Tconvs and Tregs to the colon (Kim et al., 2013; Nguyen et al., 2015). GPR15 expression 
by Tconvs was required for a transfer model of colitis (Nguyen et al., 2015; Picarella et 
al., 1997) and is highly expressed on human colonic Tconvs, especially Th2 cells (Fischer 
et al., 2016; Kim et al., 2013). GPR15 is not expressed by T cells in the cMLNs, and are 
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upregulated in the colon, suggesting this receptor may play a role in colonic T cell retention 
rather than homing (Houston et al., 2015). GPR15 is not exclusively expressed in the 
colon however, and GPR15+ T cells have been identified in tissues including the skin and 
liver (Fischer et al., 2016; Lahl et al., 2014). 
A combination of GPR15 and α4β7 expression has been suggested to instruct colon-
specific homing or retention, but further research is required to clarify this. Difficulty 
identifying GPR15 ligands has added to uncertainty about its role as a homing receptor. 
One ligand, GPR15L, has recently been identified that is expressed in tissues including 
colonic epithelium, skin and the cervix; and another ligand, C10orf99, has been identified 
that is expressed by vascular endothelial cells (Pan et al., 2017; Suply et al., 2017). 
In summary, Th populations can be programmed to express subset-associated chemokine 
receptors that direct cells to sites of inflammation, and site-specific receptors that direct 
them to specific sites in the intestines. Together, these receptors can direct cell migration 
and retention to specific regions to carry out effector functions. This is a crucial aspect for 
Th cells to quickly and efficiently accumulate in areas where a response is required. A 
rapid and specific CD4 T cell response is crucial for host defence of the intestines. Once 
an inflammatory response is initiated, CD4 T cells orchestrate multiple cell processes, 
including affinity maturation and antibody production by B cells, and the development of 
a long lasting memory population. However, the immune response must be tightly 
regulated to prevent acute immunopathology and facilitate resolution of inflammation 
following infection or other injury. Tregs are a population of CD4 T cells that play a critical 
role in modulating immune responses and protecting the host from immunopathology. 
1.3 Intestinal regulatory T cells 
FoxP3+ Tregs play an integral part in intestinal immune responses: maintaining tolerance 
to dietary antigen, the microbiota and self-antigen; controlling immune response to limit 
immunopathology and restoring homeostasis following inflammation. The importance of 
Tregs is evident in Treg-deficient scurfy mice and in humans with IPEX syndrome, who 
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succumb to systemic immunopathology and autoimmunity (Barzaghi et al., 2012; Bennett 
et al., 2001; Clark et al., 1999). The essential role of Tregs in maintaining intestinal 
homeostasis is further validated by Treg depletion models that induce severe and 
potentially fatal colitis (Boehm et al., 2012; Coombes et al., 2005; Mottet et al., 2003). 
Intestinal Tregs are a heterogenous family of cells with diverse development pathways 
and functional roles. 
1.3.1 Regulatory T cell differentiation 
Thymically derived Tregs (tTregs) are self-reactive and are selected in the thymus. Their 
role in preventing autoimmunity is well described (Kim et al., 2007; Sakaguchi et al., 1995, 
2001). Peripherally induced (pTregs) can differentiate from naïve CD4 T cells and also 
play a crucial role in immune regulation (Bluestone and Abbas, 2003; Shevach and 
Thornton, 2014). pTregs can differentiate in environments where cognate antigen is 
presented in low doses, when induced by tolerogenic DCs, and in the presence of 
immunoregulatory cytokines including IL-10, TGFβ and IL-2 (Bluestone and Abbas, 2003; 
Chen et al., 2003; Earle et al., 2005). pTregs and tTregs both constitutively express the 
TF FoxP3, which is crucial for suppression and functional stability (Fontenot et al., 2003; 
Wing and Sakaguchi, 2012). FoxP3 can drive the expression of a wide range of surface 
receptors including high levels of IL-2R, several co-inhibitory molecules (discussed below) 
and cytokines including IL-10, TGFβ and IL-35 (Annacker et al., 2003; Collison et al., 
2007; Fahlén et al., 2005). Reliable markers that differentiate these two developmental 
pathways have been elusive. The TF Helios and the membrane protein neuropillin-1 (Nrp-
1) have been used to identify tTregs, but both markers can be expressed, at least at low 
levels, by in vitro induced Tregs and pTregs in vivo (Szurek et al., 2015; Weiss et al., 
2012; Yadav et al., 2012). 
In addition to FoxP3, Tregs can express Th ‘master’ TFs T-bet, RORγT or GATA3, which 
can upregulate the same ‘signature’ chemokine receptors as Th1, Th2 and Th17 subsets 
(Duhen et al., 2012; Halim et al., 2017; Levine et al., 2017; Sefik et al., 2015) (Fig 1.5). 
There is evidence that these ‘Th-like’ Treg populations differentiate in response to similar 
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cytokines but it is unclear if they differentiate from pTregs, tTregs or both (Chaudhry et 
al., 2009; Wing and Sakaguchi, 2012). 
 
Figure 1.5 Differentiation pathways of conventional and regulatory CD4 T cells. 
The differentiation pathways of FoxP3 ̄ Tconvs and FoxP3+ Tregs is shown from thymic precursors. ‘Master’ 
TF expression is noted within cell symbols. Cytokines that instruct differentiation are shown above arrows and 
cytokines produced by each population are listed to the right of cell symbols. Important chemokine receptors 
are noted and selective inhibition is represented by red T arrows. Where pathways of differentiation or 
inhibition are unknown or unclear, dashed lines are used. pTreg, peripherally induced Treg; tTreg, thymic 
derived Treg. 
The functional role of distinct Th-like Treg populations is the subject of ongoing research 
and there is evidence that Tregs expressing Th TFs may be able to selectively supress 
their respective Th subsets in some contexts (Chaudhry et al., 2009; Koch et al., 2009; 
Levine et al., 2017). 
1.3.2 Selective suppression of T helper subsets 
Selective suppression of Th subsets by Tregs expressing the same TFs has been 
hypothesised to be a natural consequence of Tregs and Tconvs being activated in the 
same setting and cytokine milieu. If this is true, then by sharing aspects of Tconv 
transcriptional programmes, Tregs have the potential to suppress inflammation in a 
targeted and fine-tuned manner (Wing and Sakaguchi, 2012). There is increasing 
evidence that this type of selective suppression occurs in vivo. For instance, Tregs have 
been shown to upregulate T-bet in response to type 1 inflammation and T-bet+ Tregs are 
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required for optimal control of Th1-mediated inflammation (Koch et al., 2009). It has also 
been demonstrated that Tregs express T-bet during Listeria infection, selectively suppress 
Th1 cells, and comprise a stable population that proliferates rapidly during reinfection 
(Levine et al., 2017). Furthermore, specific components of the microbiota induce RORγT+ 
Tregs that inhibit Th17-mediated colitis, and ablation of Treg-specific STAT3 (co-
expressed with RORγT) induces Th17 inflammation (Chaudhry et al., 2009; Sefik et al., 
2015). 
These findings support the model of selective suppression, but the extent of selective 
suppression in other contexts or its importance for the overall immune response is 
unclear. It is also unclear whether Tregs expressing TFs GATA3 can selectively suppress 
Th2 or if these TFs facilitate broader suppressive functions (Cretney et al., 2011; Wang 
et al., 2011; Zheng et al., 2009). Questions remain about mechanisms that facilitate 
selective suppression, although chemokine receptor-mediated colocalization is a potential 
mechanism supported by immunofluorescent imaging (Levine et al., 2017). Further 
research is warranted to address the question of whether colocalization of Tregs and 
Tconvs expressing the same TFs can drive selective suppression in other settings. 
1.3.3 Regulatory T cell intestinal trafficking 
Treg suppression can be carried out by contact-dependent and independent mechanisms 
to target Tconvs and DCs (discussed below). Furthermore, Tregs can exert suppressive 
functions in both lymphoid sites such as the MLNs and GALT, or in mucosal sites of 
intestinal inflammation. In both cases, homing to specific sites is essential for Treg 
function. Like other lymphocytes, Tregs can express CCR7, which recruits them via 
CCL19 and CCL21 to lymphoid tissue. Both tTregs and pTregs include populations of 
CCR7+ and CCR7  ̄  cells which have been referred to as central Tregs (cTregs) and 
effector Tregs (eTregs), respectively (Campbell, 2015; Hayatsu et al., 2017; Smigiel et al., 
2014). This classification system mirrors that of central and effector memory T cells, where 
‘central’ populations migrate between lymphoid tissues and ‘effector’ populations have a 
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more activated phenotype in peripheral effector sites such as the intestinal mucosa 
(Sallusto and Lanzavecchia, 2000; Sallusto et al., 1999). 
Like CD4 Tconvs, the integrin α4β7 has been shown to be important for Treg intestinal 
homing. Using a CD45RBhi transfer colitis model, researchers found that although β7-/- 
Tregs were able to rescue colitis, they were unable to accumulate in the colon as seen 
with WT Tregs (Denning et al., 2005). This suggests that although β7 integrins were 
required for Treg homing to the colon, suppression was not required in the intestines. 
CCR9 also plays an important role in Treg migration to the SI, as its expression has been 
shown to be required for Treg-mediated resolution of ileitis and for induction of oral 
tolerance (Cassani et al., 2011; Wermers et al., 2011). 
As with Tconvs, GPR15 expression by Tregs has been shown to be important for colonic 
homing. GPR15-deficient mice succumb to severe colitis during Citrobacter rodentium 
infection, which can be rescued by transfer of GPR15 sufficient Tregs (Kim et al., 2013). 
GPR15 is also expressed by human Tregs and IBD patients have an increased proportion 
of Tregs expressing GPR15 and α4β7 in PBMCs compared to healthy controls (Adamczyk 
et al., 2017; Fischer et al., 2016). In addition to gut-tropic receptors, Tregs can express 
the same chemokine receptors as Th subsets (Fig 1.5). As with Tconvs, these receptors 
may play a role directing Tregs to sites of inflammation and furthermore, may allow co-
localisation of Tregs with sites of Th-specific immune responses, potentially facilitating 
selective suppression. 
1.3.4 Antigen specificity of regulatory T cells 
Unlike Tconvs, which are classically activated in a well characterised antigen-specific 
process, the role of antigen specificity in Treg activation and differentiation is less well 
understood. Although tTregs are thymically selected for TCRs that recognise self-antigen, 
both tTregs and pTregs have been shown to recognise foreign antigen and play a role in 
maintaining tolerance and modulating immune response during infection (Lee et al., 
2012a; Pacholczyk et al., 2007; Shevach and Thornton, 2014; Taylor et al., 2009). The 
identification of pathogen-specific Tregs in the context of infection has been challenging, 
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although the use of peptide-MHC tetramers has facilitated their detection. Pathogen-
specific Tregs have been isolated from PBMCs with specificity for influenza, HIV and 
lymphocytic choriomeningitis virus (LCMV) antigens (Brincks et al., 2013; Su et al., 2016). 
While pathogen-specific Tregs have been identified, it is unclear whether immune 
regulation by Tregs requires pathogen-specificity. Once activated by cognate antigen, 
Tregs can supress nearby T cells regardless of their TCR specificity. More research is 
required to delineate the importance of Treg antigen specificity in regulating immune 
responses. 
1.3.5 Mechanisms of Treg suppression 
Tregs can suppress Tconvs in multiple ways. These include production of 
immunomodulatory cytokines, cytolysis, metabolic disruption, and inhibition of DC-
mediated Tconv activation (Fig 1.6).  
Immunomodulatory cytokines 
The production of cytokines IL-10, TGFβ and IL-35 have been well characterised as 
important aspects of Treg suppression (Asseman et al., 1999; Collison et al., 2007; 
Hawrylowicz and O’Garra, 2005). Despite being known as a ‘signature’ Treg cytokine, IL-
10 is not always necessary for Treg suppression of inflammation (Joetham et al., 2007; 
Kearley et al., 2005). The requirement for TGFβ signalling is also context-dependent but 
has been shown to play important roles in controlling intestinal inflammation (Fahlén et 
al., 2005; Li et al., 2006). In addition to the secreted form, membrane-bound TGFβ has 
been shown to mediate contact-mediated suppression (Green et al., 2003; Nakamura et 
al., 2001). Finally, IL-35, which is in the IL-12 cytokine family, has been shown to be 
necessary for optimum Treg suppression and sufficient to inhibit intestinal inflammation in 
vivo (Collison et al., 2007; Gavin et al., 2007). Although the necessity for each of these 
cytokines for Treg suppressive potency is context dependent, immunomodulatory 
cytokines are an important aspect of Treg suppression. 
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Cytotoxicity 
Although cytotoxic functions are best characterised in CTLs and NK cells, human and 
mouse FoxP3+ Tregs have been shown to be capable of targeting Tconvs and B cells for 
cytolysis in a granzyme-dependent manner (Grossman et al., 2004; Herman et al., 2004; 
Zhao, 2006). This cytolytic activity has been reported to be enhanced in tumour sites, 
where this mechanism is perforin-dependent (Cao et al., 2007). In addition to granzyme-
induced cytolysis, there have also been reports of Treg-induced apoptosis by contact-
dependent interactions of Treg Galactin-9 with Tconv Tim-3. This mechanism has been 
disputed however, and the in vivo relevance of this interaction is unclear (Leitner et al., 
2013; Wang et al., 2009b). It has also been reported that human Tregs can target Tconvs 
through FasL binding of Fas on Tconvs, although this has not been well described in mice 
(Baatar et al., 2007). 
Metabolic disruption 
Tregs have been shown to disrupt Tconv metabolic pathways in three ways. First, there 
is evidence that high expression of IL-2 receptors by Tregs can lead to IL-2 deprivation in 
Tconvs, which can lead to increased levels of intracellular cyclic adenosine 
monophosphate (cAMP) and apoptosis (Duthoit et al., 2005; de la Rosa et al., 2004). 
While this mechanism may play a role in Treg suppression in some contexts, acting as an 
IL-2 ‘sink’ is not required for in vivo suppression in some models (Duthoit et al., 2005; 
Fontenot et al., 2005). A second mechanism of Treg disruption of Tconv metabolism is 
the co-expression of CD39 and CD73, which converts adenosine triphosphate (ATP) to 
adenosine monophosphate (AMP) and releases adenosine (Deaglio et al., 2007; Kobie et 
al., 2006). Adenosine can then engage Tconv adenosine receptor 2A (A2AR), leading to 
accumulation of intracellular cAMP (Borsellino et al., 2007; Deaglio et al., 2007). Finally, 
cAMP can be transferred directly from Tregs to Tconvs through membrane gap junctions 
(Bopp et al., 2007). In all three cases, increased levels of intracellular cAMP dysregulate 
Tconv metabolism and can induce apoptosis.  
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Targeting dendritic cells 
In addition to directly targeting Tconvs, Tregs can suppress immune responses by 
targeting DCs (Houot et al., 2006; Lewkowich et al., 2005; Misra et al., 2004). A well 
characterised mechanism of DC targeting is suppression of co-stimulatory molecules 
CD80/CD86 (Linsley et al., 1991; Wing et al., 2008a). Cytotoxic T-lymphocyte antigen 4 
(CTLA-4) is constitutively expressed by Tregs and binds CD80/86 with higher avidity than 
CD28. Once bound by CTLA-4, CD80/CD86 cannot bind CD28 and CTLA-4 can 
effectively capture CD80/86 molecules from DC surfaces, leading to their uptake and 
degradation by Tregs (Qureshi et al., 2011; Tadokoro et al., 2006). Although Tconvs can 
also express CTLA-4, the importance of CTLA-4 on Treg suppression has been shown in 
vivo, where selective depletion of CTLA-4 on Tregs led to severe autoimmunity (Wing et 
al., 2008b). Besides blocking Tconv co-stimulation, CTLA-4 engagement with CD80/86 
has been shown to drive a regulatory phenotype in DCs through induction of indoleamine 
2,3-dioxygenase (IDO) (Fallarino et al., 2003; Mellor and Munn, 2004). IDO expression 
induces expression of kynurenine metabolites which can bind intracellular aryl 
hydrocarbon receptors (AhR) to promote suppression (Cherayil, 2009; Nguyen et al., 
2010). Another mechanism of DC targeting by Tregs is through lymphocyte-activation 
gene 3 (LAG3). LAG3 is a CD4 homologue that can bind MHCII with high affinity to inhibit 
antigen presentation and suppresses DC maturation and activation (Baecher-Allan and 
Hafler, 2004; Huang et al., 2004; Workman and Vignali, 2005). 
In summary, Tregs have a wide range of potential mechanisms to regulate Tconv 
activation: whether through secreted cytokines, contact-dependent mechanisms or 
targeting DCs (Fig 1.6). The wide range of mechanisms highlight questions about which 
are sufficient and which are necessary to regulate Tconv responses in vivo, and which 
mechanisms are important for suppression during infection. 
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Figure 1.6 Proposed pathways of regulatory T cell suppression. 
(A) Metabolic disruption of Tconvs can be induced by expression of CD39 and CD73, which metabolise ATP 
into AMP and produce adenosine that binds Tconv A2AR, leading to accumulation of intracellular cAMP. cAMP 
can also be passed from Tregs to Tconvs directly through membrane gap junctions. High CD25 expression 
by Tregs may also act to deprive Tconvs of IL-2. Together, these processes induce upregulation of ICER, 
inhibit IL-2 and NFAT expression and drives apoptosis. (B) Tregs can target DCs by binding MHC II with 
LAG3, which inhibits antigen presentation. Tregs can inhibit DC activation by sequestering CD80 and CD86 
with CTLA-4, which inhibits co-stimulation of T cells, and upregulates DC expression of IDO and metabolism 
of Kynurenine, which can suppress Tconvs by binding intracellular (AhR). (C) Tregs may induce Tconv lysis 
by secreting granzyme and perforin, and might be able to induce apoptosis by binding Fas or Tim-3 with Fas-
L and Galectin-9, respectively. (D) Tregs can also inhibit Tconvs by producing inhibitory cytokines TGFβ, IL-
10 and IL-35. Abbreviations: ATP, Adenosine Triphosphate; AMP, Adenosine monophosphate; A2AR, A2a 
receptor, cAMP, Cyclic adenosine monophosphate; ICER, Inducible cAMP early repressor; NFAT, Nuclear 
factor of activated T cells; LAG3, Lymphocyte activation gene 3; CTLA-4, Cytotoxic T-lymphocyte-associated 
protein 4; IDO, Indoleamine 2,3-dioxygenase; AhR, Aryl hydrocarbon receptor; TGFβ, Transforming growth 
factor β. Adapted from Safinia et al., 2015; Shevach, 2018; Vignali et al., 2008. 
1.4 Salmonella enterica serotype Typhimurium 
1.4.1 Overview of Salmonella infection 
Salmonella species are Gram negative, facultative intracellular bacteria that comprise 
over 2,600 serotypes, including important pathogens of humans and other animals. 
Salmonella enterica species present a serious public health burden, causing 
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gastroenteritis or systemic infection in humans and domestic animals. S. enterica serovars 
Typhi and Paratyphi cause systemic typhoid fever in humans; with over 14 million cases 
and 130,000 deaths annually (Radhakrishnan et al., 2018; Stanaway et al., 2019). 
Salmonella enterica serovar Typhimurium (STM) infects a wide range of animals and is 
one of the most common non-typhoidal Salmonella (NTS) serotypes in humans. NTS 
strains are a common cause of localized gastroenteritis, but virulent STM strains have 
recently emerged in sub-Saharan Africa with 20-25% mortality (Feasey et al., 2012). While 
there are two vaccines available for typhoid-causing Salmonella strains, there are no 
vaccines in use for NTS strains (Guzman et al., 2006; Tennant et al., 2016). While the 
development of STM vaccines remain elusive, many STM strains have been generated 
to study Salmonella infection and the immune response to it (Dougan et al., 1987; 
Mastroeni et al., 2001; Strugnell et al., 1992). 
1.4.2 Murine models of Salmonella infection 
STM can be used in mice to induce typhoid-like systemic disease or intestinal infection 
and inflammation (Barthel et al., 2003; Santos et al., 2001; Tsolis et al., 2011). Wild mice 
are inherently resistant to STM but laboratory strains including C57BL/6 and BALB/c carry 
a mutation in the Slc11a1 (Nramp1) gene, which encodes a phagolysosome trans-
membrane protein. Slc11a1-/- species have increased susceptibility to STM infection and 
increased bacterial replication and systemic disease, even following oral administration 
(Caron et al., 2002; Vidal et al., 1996). As such, this model has similarities with human 
typhoid fever and has been widely used to study systemic STM infection and immunity 
(Fritsche et al., 2012; Griffin and McSorley, 2011; Tsolis et al., 2011). To study STM 
intestinal infection and inflammation, as seen in human Salmonella-induced enter-colitis, 
a streptomycin pre-treatment model has been developed. 
It has been known for over 60 years that streptomycin treatment increases susceptibility 
to Salmonella entero-colitis, although the reasons were not known (Bohnhoff et al., 1954).  
Almost 50 years later, Wolf Dietrich Hardt and others developed a now well-characterised 
streptomycin model of Salmonella-induced colitis (Barthel et al., 2003; Hapfelmeier and 
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Hardt, 2005; Kaiser et al., 2012). In this model, streptomycin treatment 24 hours before 
oral infection clears >90% of the intestinal microbiome, reducing bacterial abundance and 
diversity, creating a niche for STM to colonise (Hapfelmeier and Hardt, 2005; Kaiser et 
al., 2012; Stecher et al., 2007). As such, this model not only facilitates intestinal 
colonisation, it also improves the reliability and reproducibility of infections across 
facilities. This has been a long-term disadvantage of some other models. Recent work 
has shown that high variability in STM susceptibility is caused by variations in the 
microbiota of mice in different facilities. In particular, the colonisation with 
Enterobacteriaceae was shown to reduce susceptibility to STM infection (Velazquez et 
al., 2019).  
Streptomycin pre-treatment induces consistent intestinal infection and colitis in both 
resistant and susceptible mouse strains, with pathology including oedema, mucosal 
ulcerations, colonic shortening, transmural inflammation and fibrosis (Grassl et al., 2008; 
Stecher et al., 2006). However, the use of virulent STM strains in susceptible mice causes 
high mortality. Using attenuated STM strains is one approach to maintain consistent 
intestinal infection while reducing pathology and mortality. Infection with attenuated strains 
can induce colitis and provide an opportunity to study longer processes including the 
development of adaptive immune responses, the resolution of infection and protective 
immunity (Kaiser et al., 2012).  
Attenuated STM strains used in infection models include auxotrophic vaccine strains, 
which have deficient biosynthesis pathways for essential metabolites (Hoiseth and 
Stocker, 1981; Poirier, 1988; Ward et al., 1999). AroA mutants are strains auxotrophic for 
aromatic amino acids that have limited availability in mammalian hosts (Dougan et al., 
1987; Hoiseth and Stocker, 1981). These strains have been widely used to study adaptive 
immune responses to STM infection (Griffin and McSorley, 2011; Hess et al., 1996; Lee 
et al., 2012b; Tsolis et al., 2011). While most of this work has focused on the adaptive 
response to systemic Typhoid-like STM infection, the adaptive immune response to STM-
induced colitis has been less well-characterised. Further work with this model has 
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potential to improve our understanding of the adaptive immune response to intestinal 
pathogens and gut inflammation in general. 
1.4.3 Innate immune response and bacterial dissemination 
Following oral ingestion, STM passes into the intestinal lumen where bacteria upregulate 
virulence factors (Lawley et al., 2008; Tsolis et al., 1999; Yoon et al., 2009). STM may 
then pass through the mucous layer, especially where it is thinner over GALT, and contact 
the intestinal epithelium. STM has been shown to cross the epithelium via M cells, by 
trans-epithelial sampling by mononuclear phagocytes or by transcytosis of epithelial 
enterocytes (Griffin and McSorley, 2011; Jones, 1994; Müller et al., 2012; Sansonetti, 
2004). STM employ a type 3 secretion system (T3SS) to target M cells, which disrupts 
tight junctions, increases epithelial permeability and enhances further bacterial invasion 
(Jepson and Clark, 2001; Martinez-Argudo and Jepson, 2008). This process can lead to 
penetration of the FAE over PPs in under 1 hr post-infection (p.i.) and has also been 
shown to occur in colonic GALT, including ILFs (Halle et al., 2007). The importance of M 
cells at the frontline in STM infection is highlighted by research showing STM can induce 
differentiation of M cells to promote infection and recent work showing that host 
nociceptors can sense STM and suppress M cell differentiation as a host defence 
mechanism (Lai et al., 2019; Tahoun et al., 2012). 
Once STM breaches the epithelium, there is an influx of host cells including neutrophils, 
monocytes, DCs, and ILCs. There is a concurrent release of inflammatory cytokines in the 
LP, including IL-1β, IL-12 and IL-18 produced by MNPs and epithelial cells; and IFNγ and 
IL-17A, produced by innate cells including neutrophils, ILCs and γδ T cells (Broz et al., 
2010; Kupz et al., 2013; Miao et al., 2006; Rydstrom and Wick, 2007; Spees et al., 2014; 
Tam et al., 2008). Additionally, CD4 T cells have been shown to respond to STM infection 
in an innate, non-cognate capacity. This ‘bystander’ T cell response includes IFNγ 
production and has been shown to depend on IL-18R expression by T cells and Myd88 
signalling (McSorley, 2014; Pham et al., 2017). In this complex inflammatory setting, STM 
can be rapidly phagocytosed by MNPs such as DCs and macrophages, that detect 
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PAMPs with PRRs including TLRs and NLRs and sequester bacteria in phagolysosomes 
and inflammasomes (Barton, 2003; Man et al., 2014). Despite cellular defences, STM can 
survive and replicate intracellularly by employing a T3SS and other virulence factors to 
evade lysosomal killing (Arpaia et al., 2011; Bueno et al., 2008). 
Following phagocytosis of STM, DCs can become activated and upregulate expression of 
MHC II, CD40, CD80, CD86 and CCR7, which facilitates migration to MLNs (Reis e 
Sousa, 2006; Yrlid et al., 2001). Migration of infected DCs and other cells to MLNs is 
important to establish adaptive immunity but can also be a route of bacterial 
dissemination. (Bravo-Blas et al., 2018; Tam et al., 2008). Indeed, the MLNs are known 
to be an important firewall against systemic STM dissemination (Griffin et al., 2011; 
Voedisch et al., 2009; Wick, 2011). Antigen presentation by DCs is a crucial aspect for 
driving STM-specific CD4 T cells and adaptive immunity, and STM employs multiple 
strategies to block this process (Cheminay et al., 2005; Lapaque et al., 2009; Rydstrom 
and Wick, 2010; Tobar et al., 2006). Despite multiple evasion strategies, antigen 
presentation by DCs can occur rapidly in MLNs or the GALT, where transferred STM-
specific T cells can be activated just 3 hrs p.i., (McSorley et al., 2002; Salazar-Gonzalez 
et al., 2006).  
1.4.4 Adaptive immune responses to Salmonella 
CD4 T cells have been well established as critical for both clearance of STM infection and 
protection from re-infection (Hess et al., 1996; Nauciel, 1990). While CD8 T cells 
contribute to the anti-STM response, CD8 T cell depletion has been shown to have no 
impact on the outcome of infection (Kupz et al., 2014). B cell depletion has also been 
shown to have little impact on STM clearance, although B cell deficient mice fail to develop 
protective immunity (Kupz et al., 2014; Mastroeni et al., 2000; Mittrücker et al., 2000). 
While B cells are essential for protection from re-infection, this protective immunity is not 
dependent on antibody (Nanton et al., 2012).  
Th1 cells and IFNγ have been well characterised as requirements for STM clearance and 
protective immunity in systemic infection (Hess et al., 1996; Kupz et al., 2014; Pie et al., 
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1997; Ravindran and McSorley, 2005; Srinivasan et al., 2004). As with antibodies, transfer 
of circulating lymphocytes fails to confer protective immunity, masking the cellular 
correlate of STM immunity. However, recent work has identified tissue-resident memory 
(TRM) Th1 cells as an essential component of protective immunity (Benoun et al., 2018). 
These cells were isolated from livers of mice infected using a Typhoid model; it would be 
interesting to investigate if intestinal TRMs were also protective in colitis-models of STM 
infection. 
In addition to Th1 cells, an early Th17 response has been reported in the intestines (Lee 
et al., 2012b). Targeting Th17 cells by genetic mutation, HIV infection, or genetic 
disruption of IL-17A signalling each increases epithelial damage or the risk of systemic 
infection (Godinez et al., 2011; Mayuzumi et al., 2010; Raffatellu et al., 2008). In humans, 
patients with IL-12 or IL-23 deficiencies have increased susceptibility to NTS infection and 
systemic bacteraemia, suggesting an important role for both Th1 and Th17 cells in 
controlling infection in humans (Sanal et al., 2006; van de Vosse and Ottenhoff, 2006). 
Taken together, these studies suggest that an effective immune response to STM 
incorporates a dynamic CD4 T cell response including an early Th17/IL17A response and 
a Th1 response including TRM cells. How the response of these different Th subsets and 
cell types is controlled and balanced is unclear. 
1.4.5 Tracking Salmonella-specific T cells 
The capability to track antigen-specific CD4 T cells following infection is a valuable tool 
for understanding the development and control of the T cell response to infection. Several 
tools for tracking STM-specific T cells have been developed, including transfer of 
transgenic T cells with TCRs specific for ovalbumin (OVA) expressed by STM-OVA, or 
naturally occurring STM flagellin peptides (Bumann, 2003; Chen and Jenkins, 1999; 
McSorley et al., 2002; Salazar-Gonzalez et al., 2006). More recently, peptide:MHCII 
tetramers have been developed to label endogenous CD4 T cells expressing STM-
specific TCRs without requiring transfer of transgenic T cells (Moon et al., 2007). STM 
strains have been generated that express 2W1S, a peptide for which a relatively high 
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frequency of naïve CD4 T cells are specific. STM-2W1S strains integrate a peptide tag 
downstream from the 3’ portion of the OmpC gene, and have been used to successfully 
track STM-specific T cells for many months in vivo (Benoun et al., 2016; Moon and 
McSorley, 2009; Nelson et al., 2013). These constructs have been engineered with 
virulent SL1344 and attenuated BRD509, an auxotrophic aroA mutant (Benoun et al., 
2018; Mooney et al., 2015). The use of STM-2W1S as part of an in vivo infection model 
is depicted in Fig 1.7. 
 
Figure 1.7 Identification of Salmonella-specific CD4 T cells using STM-2W1S and IAb:2W1S 
tetramers. 
Cartoon depiction of STM expressing 2W1S peptide, represented as yellow circles. Following oral infection, 
DCs phagocytose STM-2W1S and migrate to lymphoid tissue where they present 2W1S:MHC II complexes 
to 2W1S-specific naïve T cells. These cells proliferate, differentiate into Tconvs and migrate to the intestinal 
LP. Following digest, intestines are processed into single cell suspension, and 2W1S-specific T cells are 
labelled with IAb:2W1S tetramers and identified by flow cytometry. 
1.4.6 The role of Tregs in Salmonella infection 
While the CD4 T cell response has not been well characterised in the STM colitis model, 
the role of Tregs has been poorly studied in Salmonella infection generally. It has been 
suggested that Tregs constrain the Tconv response to STM, which leads to reduced 
bacterial clearance, increased bacterial proliferation and a worse outcome for the host. 
This view is supported by Johanns et al. (2010), who show that Treg depletion or anti-
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CTLA-4 treatment 5 days p.i. led to increased Tconv activation and decreased bacterial 
burden 6 days later. The authors also report decreased CTLA-4 expression and 
suppressive potency in Tregs at 37 days p.i., when the Tconv response is more robust 
and the infection is naturally cleared. These data support the hypothesis that Treg 
suppression during STM infection is deleterious for the host. However, this research 
utilised an infection model where resistant Slc11a1+/+ mice were infected i.v. with a virulent 
STM strain. As such, this model is not physiologically relevant to natural infection in terms 
of host strain or route of infection. This raises questions about whether similar results 
would be found in susceptible mouse strains with intestinal disease. More generally, this 
raises questions about the Treg response to STM infection: including whether responding 
Tregs have a thymic or peripheral ontogeny, if they are STM-specific, and whether they 
exert their suppressive function in lymphoid tissue, in the intestinal mucosa or both sites. 
1.4.7 Conclusions 
STM can be used as a versatile tool to study systemic and intestinal infection. There are 
many bacterial strains available and a wide range of pathology and outcomes can be 
induced depending on STM strain, route of infection, host strain and host microbial 
colonisation. While this versatility is an advantage, it presents a challenge when assessing 
previous research using known and unknown adaptations to these models. 
The focus of this research is the CD4 T cell response to intestinal infection and 
inflammation; as such, the STM colitis model is an appropriate tool to study site-specific 
T cell responses to be tracked over time. Previous STM research leaves many 
unanswered questions about the response to STM in the gut and associated lymphoid 
tissue. The CD4 T cell response to STM colitis has not been well characterised and it is 
unclear how Th1 and Th17 responses develop in the intestinal mucosa and draining lymph 
nodes. The role of Tregs during STM infection is also unclear and the Treg response itself 
is poorly characterised, especially in the intestines. Research characterising the Tconv 
and Treg response to STM intestines has potential to elucidate how the CD4 T cell 
response to intestinal pathogens is controlled.  
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1.5 Hypothesis and Aims 
In this introduction, questions have been highlighted about how the CD4 T cell response 
is controlled in the intestines. These include what directs CD4 T cell differentiation and to 
one Th subset over another, and where the response develops over time. Unanswered 
questions remain about Treg ontogeny, differentiation, antigen-specificity, migration, and 
the selective suppression of Th subsets during infection. The STM-colitis model will be 
used to address these questions and achieve the primary aim of this work: Investigate 
the role of Tregs in shaping the CD4 T cell response to Salmonella. 
Previous research highlights that Tregs comprise diverse and highly plastic cells that can 
modulate inflammation in a more nuanced way than previously appreciated. Recent 
advances from researchers including Levine et al. (2017), Tosiek et al. (2016) and Britton 
et al. (2019) have contributed to the key hypothesis: Regulatory T cells can actively 
shape the CD4 T cell response in a temporal and site-specific manner. 
To test this hypothesis, experiments were carried out to achieve three major objectives:  
1) Develop a STM model to induce non-lethal colitis and track STM-specific CD4 T cells. 
This will allow analysis of temporal and site-specific dynamics of antigen-specific and 
polyclonal T cells during intestinal infection. 
2) Characterise the CD4 T cell response to a colitis model of STM infection. There has 
been surprisingly little research characterising the CD4 T cell response to STM-induced 
colitis. This objective includes analysis of Th subsets and Tregs expressing Th ‘master’ 
TFs in lymphoid and mucosal sites. 
3.) Investigate the potential for Tregs to shape the CD4 T cell response. To address the 
third objective, Tregs will be manipulated to determine if they are necessary and sufficient 
for the bias of the Tconv response in the intestines. 
Together, these objectives address important questions about the site-specific CD4 T cell 
response to STM, and the role of Tregs in controlling this response. Beyond the scope of 
Salmonella infection, this work has potential to highlight the role of Tregs in shaping the 
CD4 T cell response during intestinal infection and inflammation in general.  
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Chapter 2 Materials and methods 
2.1 Mouse strains 
Male C57BL/6J mice were purchased from Envigo (Huntingdon, UK) at 5-6 weeks of age 
and housed in individually ventilated cages (IVCs) prior to procedures, when they were 
transferred to conventional cages. FoxP3GFP mice were kindly provided by Prof. Rick 
Maizels (University of Glasgow, UK) and bred and maintained in conventional cages. 
FoxP3RFP RORγTGFP (FoxROR) mice were a kind gift from by Dr David Withers (University 
of Birmingham, UK) and bred and maintained in IVCs. FoxP3DTR/eGFP depletion of 
regulatory T cell (DEREG) mice were a kindly provided by Prof. Mark Travis (University 
of Manchester, UK) with permission from Prof. Tim Sparwasser (Medizinische Hochschule 
Hannover, Germany). DEREG mice were maintained and bred in IVCs. Genotyping of 
DEREG and FoxROR mice was carried out on ear clip samples by Transnetyx (Cordova, 
TN, USA).  
All mice were maintained under specific pathogen-free (SPF) conditions at the University 
of Glasgow Central Research Facility or Veterinary Research Facility (Glasgow, UK). All 
procedures were conducted under licenses issued by the UK Home Office under the 
Animals (Scientific Procedures) Act of 1986 and approved by the University of Glasgow 
Ethical Review Committee. 
2.2 Salmonella infections 
2.2.1 Salmonella strains 
Salmonella enterica serotype Typhimurium (STM) strains SL1344-2W1S and BRD509-
2W1S were kindly provided by Prof. Stephen McSorley (University of California, Davis, 
USA). The 2W1S strains expresses the 2W1S (EAWGALANWAVDSA) epitope in frame 
with OmpC (Mooney et al., 2015; Nelson et al., 2013). BRD509 was generated as an aroA 
aroD mutant strain, although more recent genotyping of BRD509-2W1S revealed this 
strain had lost the aroD mutation (Benoun et al., 2018). STM strains SL1344, BRD509 
51 
and pGFP were kindly provided by Dr Dónal Wall (University of Glasgow). STM strains 
JH3008 and JH3016 were kindly provided by Prof. Jay Hinton (University of Liverpool, 
UK). 
2.2.2 Bacterial culture 
STM cultures were streaked out on Luria-Bertani (LB) agar plates before culturing in LB 
broth for 5 hrs at 37°C in an incubator shaking at 180 rpm. Cultures were then back-diluted 
1:10 in LB broth before static culture at 37°C overnight (O/N). Cultures were then adjusted 
to an OD600 of 1.00, centrifuged at 5,000G for 10 min, and resuspended in sterile 
phosphate buffered saline (PBS) at an estimated concentration of 1.0-1.5 x 109 CFU/ml 
or as stated in the results. Following infections, actual bacterial dosage was confirmed by 
plating serial dilutions of STM inocula onto LB agar plates.  
2.2.3 In vivo infections 
6-10 week old mice were pre-treated with 20 mg streptomycin (Sigma-Aldrich, USA) 
suspended in 100 µl sterile PBS by oral gavage 24 hrs before STM infection. Mice were 
infected by administration of 100 µl of STM inoculum by oral gavage. 
2.2.4 Enrofloxacin treatment 
Antibiotic treatment of STM-infected mice was carried out by adding enrofloxacin (Bayer, 
Germany) to drinking water at 2 mg/ml. Enrofloxacin treatment was provided from day 10- 
21 post infection (p.i.) and water was replaced every 72 hrs. 
2.2.5 Bacterial recovery 
Single cell suspensions from tissues were pelleted by centrifuging at 400 G for 5 mins and 
resuspended in 0.1% Triton X-100 (Sigma-Aldrich) in PBS and incubated at room 
temperature (RT) for 10 mins. Samples were then washed and pelleted by centrifugation 
at 5,000 G for 10 mins, before being resuspended in PBS, serially diluted and plated on 
MacConkey agar No. 2 (ThermoFisher Scientific, UK) containing 5 µg/ml streptomycin 
(Sigma-Aldrich) and incubated O/N at 37°C before CFUs were calculated. Bacteria were 
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recovered from faeces and caecal contents, which were collected, aliquoted into 100 µg 
samples, homogenised and suspended in 1.0 ml PBS. These solutions were then serially 
diluted and plated on MacConkey agar plates as described above. 
2.2.6 In vitro infections 
STM was prepared as above and used to infect RAW 264.7 cells and intraperitoneal (IP) 
macrophages. IP macrophages were harvested by injecting 8 ml of PBS into the 
peritoneal cavity of humanely sacrificed mice, recovering the wash fluid, and 
resuspending cells in RPMI 1640 media with 2 mM L-Glutamine, 100 µg/ml streptomycin, 
100 units/ml penicillin and 10% FCS (All Gibco, UK). Cells were then cultured for 24 hrs 
at 37°C in 24 well plates before non-adherent cells were washed off with RPMI. RAW 
264.7 cells and IP macrophages were cultured in 24 well plates in RPMI media with 10% 
Foetal calf serum (FCS) and 1% L-glutamine at 37°C until confluent. Lipopolysaccharide 
(LPS) was added to cultures at 1.0 µl/ml for 4-6 hrs before infection. STM was cultured as 
described above, and following static incubation, OD600 was adjusted to 0.5 before being 
diluted 1:5 in RPMI with 5% FCS. This inoculum was then adding to macrophage cultures 
in 24 well plates. Cells were left at 37°C for 1 hr before washing with RPMI containing 5% 
FCS and 50 µg/ml gentamycin. The infection was then left to progress for 6 hrs at 37°C 
before collection. 
2.3 Tissue harvest and processing 
All murine tissues were collected into Hanks' Balanced Salt Solution (HBSS) with 2% 
foetal calf serum (FCS) (Gibco) and stored on ice before processing. 
2.3.1 Intestines 
Intestines were emptied of luminal contents, washed in HBSS and stored on ice until 
further processing. External fat, Peyer’ patches (PP) and caecal patches (CP) were 
removed and the remaining tissue was chopped with scissors into ~5 mm pieces. Next, 
samples were washed in HBSS with 2 mM Ethylenediaminetetraacetic acid (EDTA) 
(Gibco) at 37°C in an incubator shaking at 205 rpm for 10 mins. Following incubation, 
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samples were washed with HBSS. EDTA incubations and HBSS washes were repeated 
three times before tissues were digested. Digest enzyme cocktails were prepared in 
complete RPMI media (RPMI 1640 with 100 µg/ml streptomycin, 100 U/m penicillin, 2 mM 
L-Glutamine and 50 µm 2-Mercaptoethanol) with 10% FCS (all Gibco). Colon and caecal 
tissue were digested in an enzyme cocktail of 0.45 mg/ml collagenase V (Sigma-Aldrich), 
0.65 mg/ml collagenase D (Roche, Switzerland), 1.0 mg/ml dispase (Gibco) and 30 µg/ml 
DNAse (Roche) in complete RPMI. Small intestines were digested with 0.5 mg/ml 
collagenase V (Sigma-Aldrich) in complete RPMI. Tissues were added to respective 
digest cocktails, shaken vigorously by hand and then incubated at 37°C in an incubator 
shaking at 205 rpm. Digests were carried out for 15-20 mins, with manual shaking 
continued every 5-6 mins. Following digests, samples were returned to ice, filtered 
through 100 µm filters, washed twice with fluorescence activated cell sorting (FACS) 
buffer (PBS with 2% FCS and 2 mm EDTA) and filtered through a 40 µm filter before 
further processing. 
2.3.2 Lymph nodes, Peyer’s patches and caecal patches 
Lymph nodes, Peyer’s patches (PPs) and caecal patches (CPs) were washed in HBSS 
and maintained on ice. Fat, luminal contents or non-lymphoid tissue was carefully 
removed. Tissues were chopped into ~1 mm pieces, passed through a 40 µm filter and 
suspended in FACS buffer before further processing.  
2.3.3 Spleens 
Spleens were cleaned and fat was removed before being chopped into several pieces 
and passing through a 40 µm filter with FACS buffer. Samples were suspended in 
Ammonium-Chloride-Potassium (ACK) lysing buffer (ThermoFisher) for 3-5 mins at RT, 
before washing and resuspending in FACS buffer. 
If lymphoid tissues were being processed to analyse or isolate lymphocytes, tissues were 
processed without digestion. If mononuclear phagocytes (MNPs) were being analysed or 
isolated, tissues were digested in complete RPMI with 10% FCS, 0.75 mg/ml DNAse I 
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(Roche) and 0.40 mg/ml collagenase-dispase (Roche). Digestion was 20 mins at 37°C 
and shaking at 205 rpm. Following digest, samples were washed with FACS buffer and 
passed through 40µm filters before further processing. 
2.4 Staining for flow cytometry 
Following preparation of single cell suspensions, samples can be stained for flow 
cytometry. Staining for extracellular surface markers, including peptide:IAb tetramer 
staining can be carried out immediately. But staining for intracellular markers including 
transcription factors or cytokines, requires a fixation and permeabilization step. 
2.4.1 Tetramer staining 
2W1S:I-Ab  tetramer was kindly provided by the NIH tetramer core facility (USA). Following 
infection with STM-2W1S strains, tissues were harvested and processed as described 
above. Samples were transferred into 96 well round bottom plates, centrifuged for 5 mins 
at 400G, and resuspended in 25µl of tetramer mix containing complete RPMI with 10% 
FCS, 7 µg/ml 2W1S:IAb tetramer, 20 µl/ml mouse serum and 10 µl/ml Fc block (CD16/32) 
(Biolegend, USA). Once cells were resuspended in the tetramer mix, plates were 
incubated for 2 hrs at 37°C, with plates briefly vortexed every 30 mins. Following tetramer 
staining, antibodies for extracellular surface markers were added directly into tetramer-
stained wells. 
2.4.2 Surface staining 
Following tissue processing or tetramer staining, samples were stained with fixable 
viability dye at a 1 µl/ml in PBS. Next, antibodies for extracellular markers were prepared 
at 1:100 or 1:200 dilutions in FACS buffer, as specified in the list of antibodies used (Table 
2.1). Surface staining was performed at 4°C for 30 mins before diluting with FACS buffer, 
centrifuging at 400 G for 5 mins, and resuspended pellets in FACS buffer. After surface 
staining, cells can be analysed, sorted or fixed and stained for intracellular markers. 
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2.4.3 Transcription factor staining 
Transcription factor (TF) staining was carried out after cells were fixed using one of three 
methods. If cytokine staining was not planned and there were no fluorescent reporters, 
the eBioscience FoxP3 transcription factor staining kit (ThermoFisher) was used 
according to manufacturer’s instruction. If cytokine staining was to be carried out, BD 
Cytofix (BD Biosciences, Belgium) was used to manufacturers instructions. If fluorescent 
reporters were being used, cells were fixed with 4% paraformaldehyde (PFA) in PBS. In 
all cases, cells were fixed for 1 hr at room temperature (RT) in the dark before washing 
and resuspending in eBioscience FoxP3 permeabilization buffer (PB) (ThermoFisher). 
Following fixation, TF antibodies were diluted in PB at concentrations listed in Table 2.1, 
added to samples and incubated O/N at 4°C. The next morning, cells were washed in PB 
and resuspended in FACS buffer for analysis or further staining. 
2.4.4 Cytokine staining 
For cytokine staining, cells are initially stimulated by suspending them in complete RPMI 
with 10% FCS and a 2 µl/ml of eBioscience cell stimulation cocktail (ThermoFisher) 
containing phorbol 12-myristate 13-acetate (PMA), ionomycin, brefeldin A and monensin. 
Cells were suspended at 1 x 106 cells/100µl of stimulation buffer and incubated for 4 hrs 
at 37°C before washing with FACS buffer and staining. Following surface staining, 
samples were fixed with BD Cytofix (BD Biosciences) according to manufacturer’s 
instructions and stained with cytokine antibodies diluted in PB and incubated for 2 hrs at 
RT. Following cytokine staining, cells were washed and resuspended in FACS buffer. 
2.4.5 Flow cytometry 
Samples were analysed using the BD LSR Fortessa analyser or sorted using the BD 
FACSAria IIu or III (BD Biosciences) at the Institute of Infection, Immunity and 
Inflammation Flow Core Facility (University of Glasgow). For cell sorting experiments, 5 
µl of 7AAD viability dye (Biolegend) was added to samples 10 mins before sorting, and 
cells were collected in complete RPMI with 10% FCS. 
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Table 2.1 Antibodies used for flow cytometry 
Marker Fluorochrome Clone Conc. Manufacturer 
Mouse samples: 
7AAD N/A N/A 5µl/sample Biolegend 
B220 BV510 RA3-6B2 1:200 Biolegend 
B220 PerCP/Cy5.5 RA3-6B2 1:200 Biolegend 
CCR6 BV605 29-2L17 1:100 Biolegend 
CD25 PE/Cy7 PC61 1:200 Biolegend 
CD3 BV605 17A2 1:100 Biolegend 
CD3ε AF700 eBio500A2 1:100 eBioscience 
CD3ε BUV395 145-2C11 1:100 BD Biosciences 
CD4 BUV805 GK1.5 1:200 BD Biosciences 
CD4 AF647 GK1.5 1:200 Biolegend 
CD4 AF647 RM4-5 1:200 Biolegend 
CD4 PE/Cy7 GK1.5 1:200 Biolegend 
CD4 AF700 GK1.5 1:200 Biolegend 
CD44 PerCP/Cy5.5 IM7 1:200 Biolegend 
CD44 BV510 IM7 1:100 Biolegend 
CD44 BV605 IM7 1:100 Biolegend 
CD44 BV785 IM7 1:100 Biolegend 
CD44 BUV395 IM7 1:200 BD Biosciences 
CD45 BUV395 30-F11 1:200 BD Biosciences 
CD45 BV785 30-F11 1:200 Biolegend 
CD45 AF700 30-F11 1:200 Biolegend 
CD64 PercP/Cy5.5 X54-5/7.1 1:200 Biolegend 
CD8α BV510 53-6.7 1:200 Biolegend 
CD8α PerCP/Cy5.5 53-6.7 1:200 Biolegend 
CXCR3 PE CXCR3-173 1:100 Biolegend 
CXCR3 BV421 CXCR3-173 1:100 Biolegend 
CXCR3 BV605 CXCR3-173 1:100 Biolegend 
F4/80 PercP/Cy5.5 BM8 1:200 Biolegend 
F4/80 BV510 BM8 1:200 Biolegend 
Fixable viability eFluor 780 N/A 1:1000 Invitrogen 
FoxP3 APC FJK-16s 1:100 eBioscience 
FoxP3 PE FJK-16s 1:100 eBioscience 
FoxP3 AF700 FJK-16s 1:100 Invitrogen 
FoxP3 BV421 MF-14 1:100 Biolegend 
FoxP3 AF488 MF-14 1:100 Biolegend 
GATA3 eFluor660 TWAJ 1:100 eBiosciene 
GATA3 PerCP/Cy5.5 TWAJ 1:100 eBioscience 
Helios AF488 22F6 1:100 BD Biosciences 
Helios PerCP/Cy5.5 22F6 1:100 Biolegend 
I-A/I-E BV510 M5/114.15.2 1:200 Biolegend 
I-A/I-E PerCP/Cy5.5 M5/114.15.2 1:200 Biolegend 
IFNγ PE 3E4 1:100 eBioscience 
IFNγ  PerCP/Cy5.5 XMG1.2 1:100 Biolegend 
IL-10 PerCP/Cy5.5 JES5-16ES 1:100 Biolegend 
IL-17A BV605 TC11-18H10.1 1:100 Biolegend 
RORγT PE AFKJS-9 1:100 eBioscience 
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RORγT APC B2D 1:100 Invitrogen 
T-bet BV421 4B10 1:100 Biolegend 
T-bet PE/Cy7 eBio4B10 1:100 eBioscience 
Human samples: 
CCR6 PE/Cy7 G034E3 5µl/sample Biolegend 
CD127 BV421 A019D5 5µl/sample Biolegend 
CD25 PE BC96 5µl/sample Biolegend 
CD25 APC BC96 5µl/sample Biolegend 
CD3 AF700 HIT3a 5µl/sample Biolegend 
CD3 PE/Cy7 OKT3 5µl/sample Biolegend 
CD3 PerCP/Cy5.5 HIT3a 5µl/sample Biolegend 
CD4 BV785 OKT4 5µl/sample Biolegend 
CD4 BUV395 RPA-T4 5µl/sample BD Biosciences 
CD4 PerCP/Cy5.5 RPA-T4 5µl/sample Biolegend 
CD45 BV510 HI30 5µl/sample Biolegend 
CD45 BUV805 HI30 5µl/sample BD Biosciences 
CD8α BUV395 RPA-T8 5µl/sample BD Biosciences 
CD8α BV605 RPA-T8 5µl/sample Biolegend 
CD8α PE/C7 RPA-T8 5µl/sample Biolegend 
CXCR3 PerCP/Cy5.5 G025H7 5µl/sample Biolegend 
CXCR3 G025H7 BV510 5µl/sample Biolegend 
CXCR3 AF647 G025H7 5µl/sample Biolegend 
Fixable viability dye eFluor 780 N/A 1:000 eBioscience 
FoxP3 AF488 PCH101 5µl/sample eBioscience 
FoxP3 APC PCH101 5µl/sample eBioscience 
RORγT PE AFKJS-9 5µl/sample eBioscience 
T-bet PE/Cy7 eBio4B10 5µl/sample eBioscience 
 
2.5 Regulatory T cell depletion 
Diphtheria toxin (DT) (Sigma-Aldrich) was suspended in sterile PBS at a concentration of 
10.0 µg/ml. DT was administered intraperitoneally (IP) twice and 24 hrs apart, at a volume 
of 50-100 µl, equivalent to of 30 ng/g mouse weight. DT was administered to DTR+ 
DEREG mice and DT  ̄littermates as wild type (WT) controls. 
2.6 Regulatory T cell transfer 
Regulatory T cells (Tregs) were isolated from peripheral lymph nodes including brachial, 
axillary, cervical, inguinal, lumbar, inguinal and mesenteric lymph nodes (MLNs). 
Following processing as described above, CD4 T cells were pooled and isolated using 
EasySep CD4 negative selection kits (STEMCELL, Canada) according to manufacturer 
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instructions. Cells were then washed and stained for surface markers and subsequently 
sorted as live, single, RFP+ CD4+ T cells. Following sorting, cells were washed twice in 
PBS, counted, and resuspended in PBS at concentrations of 3-6 x 106 cells/ml. Cell 
suspensions were kept on ice and 100 µl volumes were transferred into recipients by 
intravenous (IV) injection into a lateral tail vein. 
2.7 Treg suppression assay 
Suppression assay experiments were adapted from methods previously described 
(Collison and Vignali, 2011). Tregs were isolated from lymph nodes of STM-infected or 
uninfected donors, as described above for Treg transfers. Conventional T cell responder 
cells (Tresps) were sorted as RFP ˉ CD4+ T cells and were stained with a CellTrace Violet 
(CTV) cell proliferation kit (ThermoFisher) according to manufacturer instructions. 
Dendritic cells (DCs) were isolated from digested spleens of uninfected C57BL/6 mice 
using CD11c UltraPure micro beads (Miltenyi Biotec, Germany) according to 
manufacturer instructions. 
Briefly, assays were carried out in 96 well round bottom plates (ThermoFisher) by 
combining 1.0 x 105 Tresps, 5.0 x 104 DCs and 1:2 serial dilutions of Tregs from 5.0 x104 
cells to 6.3 x 103 cells/well. The number of Tregs corresponded to Tresp:Treg ratios of 
1:2, 1:4, 1:8 and 1:16. Cells were suspended in 200 µl complete RPMI with 10% FCS and 
5 µl/ml αCD3ε antibody, to provide T cell receptor (TCR) stimulation. All conditions were 
repeated in triplicate and incubated at 37°C for 84 hrs before harvest. Following 
incubations, plates were washed with FACS buffer and each well was divided into two 
samples to be stained with surface antibodies only, or fixed with 4% PFA and stained for 
TF expression, as described above.  
2.8 Human colon biopsies 
Colon biopsies were kindly provided by Dr Daniel Gaya at the Glasgow Royal Infirmary 
(United Kingdom), who received patient consent before colonoscopies were performed. 
Samples were managed by the National Health Service Greater Glasgow and Clyde 
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(NHSGGC) Research Tissue Bank under ethics granted by the West of Scotland 
Research Ethics committee (REC 14/WS/1035). 
Ulcerative colitis (UC) patients were classified as having active inflammation or being in 
remission by the attending gastroenterologist at the time of colonoscopy. Following 
collection, samples were stored in sterile PBS on ice and delivered to the laboratory for 
analysis. Biopsies were incubated in HBSS with 2 mM EDTA for 10 minutes, shaking at 
220 rpm at 37°C. This incubation was repeated three times with fresh EDTA HBSS buffer 
each time. Biopsies wee then digested in complete RPMI with 10% FCS containing 0.5 
mg collagenase VIII (Sigma-Aldrich), 0.6 mg collagenase D (Roche), 1mg/ml dispase 
(Gibco) and 0.015 mg/ml DNAse (Roche). The digest was carried out for 10 mins at 37°C, 
shaking at 220 rpm, with vigorous manual shaking every 2-3 mins. Following digest, 
samples were added to FACS buffer on ice and filtered through 100 µm then 40 µm 
strainers, centrifuged at 400 G for 10 mins at 4°C, then resuspended in FACS buffer for 
staining with antibodies listed in Table 2.1. 
2.9 Immunofluorescent imaging 
Immunofluorescence (IF) images were produced from colonic sections and RAW 264.7 
cells infected with STM strain JH3016, which expresses green fluorescent protein (GFP). 
Colonic tissues were harvested from C57BL/6 mice, as described above. Tissues were 
washed with PBS and 5 cm ‘donut’ sections were frozen in optimal cutting temperature 
(OCT) compound (Sakura Finetek, Netherlands) using dry ice and isopentane. Samples 
were then stored at -80°C O/N before sectioning with a Cryotome cryostat 
(ThermoFisher). Sections were then mounted on Superfrost Plus slides (ThermoFisher) 
for further processing. RAW 264.7 were infected in vitro as described above, and round 
coverslips (ThermoFisher) were placed into wells before culturing. These were 
subsequently stained and mounted for imaging. 
Colon sections or infected RAW 264.7 cells were processed for IF imaging using the same 
method. Briefly, samples were washed three times with PBS containing 0.1% Tween 
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(PBST) (Sigma-Aldrich) and fixed with 4% PFA in PBS for 20 mins at RT. Samples were 
washed again and blocked with PBS containing 10% goat serum (ThermoFisher), 1% 
bovine serum albumin (BSA) (Sigma-Aldrich) and 0.1% Triton X-100 (Sigma-Aldrich) for 
20 mins at RT. Samples were washed and stained with 5 units/ml of Phalloidin-AF647 
(ThermoFisher) in PBS. Samples were washed and cover slips were mounted onto slides 
using Vectashield mounting medium with DAPI (Vector Labs, USA). Images were 
acquired with a Zeiss LSM510 confocal microscope (Carl Zeiss, Germany) at the 
University of Glasgow. 
2.10 Statistical analysis and software 
Statistical analysis was performed using Prism Graphpad (USA). Statistical difference 
between two groups were calculated using a two-tailed Student’s t test or a Mann Whitney 
test. One way ANOVA was used to calculate statistical difference between three or more 
groups. A Holm-Šídák test was applied if specific groups or pairs were compared, and a 
Tukey’s test was applied if all groups were compared. Two way ANOVA was used to 
determine significance between groups when multiple parameters were measured. 
Analysis of flow cytometry data including proliferation analysis was performed with Flowjo 
version 10 (FlowJo LLC, USA). IF images were processed and analysed using ImageJ 
(NIH, USA). Finally, figures were created using Powerpoint (Microsoft, USA) and 
Biorender (Canada). 
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Chapter 3 Optimisation of Salmonella Models to 
Track Bacteria and CD4 T Cells  
3.1 Introduction 
CD4 T cells play an essential role in clearing Salmonella enterica serotype Typhimurium 
(STM) infection but there are unanswered questions about how the T cell response 
develops and is controlled. Two important factors that underlie the outcome of infection 
are the dissemination of bacteria within the host and the development of an STM-specific 
CD4 T cell response. An early aim of this work was to optimise infection models that allow 
these dynamics to be studied. As previously discussed, STM-2W1S strains allow STM-
specific CD4 T cells to be tracked using 2W1S: IAb tetramers. To track bacteria in vivo, 
STM strains have been developed that express fluorescent reporters including green 
fluorescent protein (GFP). 
The in vivo dissemination of STM has been studied for 50 years and continues to reveal 
important aspects of infection dynamics (Goldberg et al., 2018; Jones, 1994; Takeuchi, 
1967). STM-GFP strains can be used to track bacteria by fluorescence microscopy and 
flow cytometry. Recent work from our lab characterised the dissemination of STM from 
the intestines to the MLNs in lymph (Bravo-Blas et al., 2018). Other recent research has 
identified sites of persistent infection including the MLNs (Goldberg et al., 2018; Griffin et 
al., 2011). As previously discussed, different STM models can induce systemic disease 
or localised infection within the intestines. Unanswered questions remain about which 
tissues are infected, for how long they remain colonised and how bacterial persistence 
influences the CD4 T cell response. An early objective of this project was to develop a 
model of infection with an STM-GFP strain to address these questions. 
The potential to identify STM-specific CD4 T cells is a valuable tool for studying how the 
CD4 T cell response develops and is controlled. Where and when the STM-specific T cells 
response develops during STM colitis is not fully understood and questions remain about 
how the response is controlled over time. 
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The following experiments were conducted to achieve two aims. First, protocols were 
developed to optimise a non-lethal STM colitis model using strains expressing GFP or 
2W1S. Second, an STM-specific CD4 T cell response was characterised in multiple 
tissues following infection. These experiments help elucidate where and when the STM-
specific CD4 T cell response develops and lays the groundwork for later research into 
how this response is controlled. 
3.2 Selection and optimisation of Salmonella strains for 
in vivo infection 
The first step to studying the immune response to STM is developing an appropriate in 
vivo infection model. Two groups of STM strains were considered for use. The first are 
GFP reporter strains developed to track STM in vivo. These include two chromosomal 
constructs engineered from a virulent SL1344 parent: JH3016 is a constitutive GFP 
reporter and JH3008 is a conditional reporter that expresses GFP upon activation of SPI1 
proteins within phagolysosomes. A plasmid GFP (pGFP) construct was also considered 
because these have been shown to express higher levels of GFP than chromosomal 
constructs at early timepoints (Wendland and Bumann, 2002). The second group of STM 
strains tested are 2W1S-expressing constructs. Infection with these strains induce a 
population of 2W1S-specific CD4 T cells trackable using 2W1S-MHCII tetramers. Two 
2W1S strains evaluated are unattenuated SL1344-2W1S and attenuated BRD509-2W1S, 
a construct engineered from an aroA mutant strain. Besides expression of GFP or 2W1S, 
any strain used for in vivo infections must establish consistent and non-lethal infection. 
3.2.1 In vitro culture of virulent and attenuated Salmonella strains 
expressing GFP or 2W1S reveals similar growth dynamics  
Initially, STM strains were cultured in vitro to assess growth dynamics under the same 
conditions used for preparation of in vivo infections. GFP reporters, 2W1S strains, and 
their parent strains were cultured in lysogeny broth (LB) in a 37C shaking incubator for 5 
hrs before 1:10 back dilution and static incubation. During static incubation, optical density 
(OD) was measured and a sample was plated in LB agar plates to identify colony forming 
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units (CFU). Growth curves for GFP reporters (Fig 3.1A) show similar OD dynamics 
between the four strains, with an early lag phases preceding exponential growth from 1-2 
hrs following back-dilution. When CFUs from each time point were counted however, 
fewer CFUs were recovered from the pGFP construct during the exponential phase. After 
3-6 hrs of static culture, pGFP cultures contained >20% fewer CFU than the SL1344 
parent strain or chromosomal GFP constructs. Growth curves of 2W1S strains show 
similar dynamics. The BRD509 cultures had marginally lower OD than the SL1344 strains, 
with BRD509-2W1S having a slightly lower OD than the parent strain. Similar numbers of 
CFUs were recovered from the 2W1S strains, with the SL1344 parent strain yielding 
slightly more CFUs than the 2W1S expressing strains during the exponential phase. 
 
Figure 3.1 Growth curves for Salmonella strains expressing GFP or 2W1S. 
(A) STM strains JH3008 and JH3016, incorporating chromosomally integrated GFP genes, show similar 
growth dynamics as parent strain SL1344. STM strain pGFP, with a plasmid GFP construct, shows similar 
growth to SL1344 when measured by OD (left) but reduced growth of viable bacteria measured by CFU(right). 
(B) STM strains expressing 2W1S show similar growth dynamics as their virulent (SL1344) or attenuated 
(BRD509) parent strains. Growth curves are representative plots of two independent experiments. 
These experiments indicate that despite the differences noted, all strains have similar 
dynamics, reaching logarithmic growth by 3 hrs. In terms of inter-strain differences, pGFP 
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has a lower CFU:OD ratio, requiring higher OD values to attain the same CFUs as other 
strains (Fig 3.1A). Following the characterisation of these growth dynamics, experiments 
were carried out to detect and image GFP reporter strains. 
3.2.2 Detection of GFP+ Salmonella in vitro and in vivo 
To assess GFP expression, STM strain JH3016 was selected to begin flow cytometry 
experiments and immunofluorescence (IF) imaging of infected cells. JH3016 was selected 
because of its constitutive GFP expression and more robust in vitro growth dynamics than 
STM pGFP (Fig 3.1A). In vitro infections were initially carried out with RAW 264.7 
macrophage-like cells (Fig 3.2A) and then with peritoneal macrophages harvested from 
C57BL/6 mice (Fig 3.2B). Following 1 hr infections, cells were washed with gentamycin 
media before flow cytometry analysis. Following infection with JH3016, 15.1% of RAW 
264.7 cells were in the GFP+ gate, compared to 0.3% following infection with non-GFP 
expressing SL1344 (Fig 3.2A). In peritoneal macrophages, 43.3% of JH3016-infected 
cells were in the GFP+ gate compared to 4.3% of STM SL1344-infected controls (Fig 
3.2B). JH3016-infected RAW 264.7 cells were also stained with phalloidin and DAPI and 
imaged using fluorescence confocal microscopy (Fig 3.2C). Images show intracellular 
STM bacteria in green, including clusters of bacteria and dividing bacteria. 
Next, JH3016 was used to orally infect C57BL/6 mice that were sacrificed 24 hrs later. 
Colonic and SI LP were sectioned and stained with phalloidin and DAPI before imaging 
by fluorescence confocal microscopy (Fig 3.2D and E). Imaging ten sections of colonic 
mucosa identified just one green area that resembles a GFP+ bacterium (Fig 3.2D, 
enlarged in Fig 3.2E). 
While JH3016 was validated as a useful tool to detect STM bacteria by flow cytometry 
and fluorescence microscopy, imaging of infected tissue, even 24 hrs p.i., made it 
apparent that tracking bacteria in vivo would be challenging. While this could be a 
potentially valuable direction for ongoing research, interest in characterising the adaptive 
immune response and the successful importation of 2W1S strains shifted the project 
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towards optimising 2W1S-expressing STM strains to detect and characterisation antigen-
specific CD4 T cells. 
 
Figure 3.2 Detection of GFP+ STM strain JH3016 by FACS and fluorescence confocal microscopy. 
STM strains JH3016 or SL1344 were used to infect cells in vitro and C57BL/6 mice in vivo. (A) RAW 264.7 
macrophage-like cells or (B) peritoneal macrophages were cultured and infected with STM SL1344 (left) or 
GFP expressing STM JH3016 (centre) before FACS analysis. Histograms show JH3016-infected cells (in 
green) overlaid by non-GFP STM infected cells (in red) (C) RAW 264.7 macrophage-like cells were infected 
with STM JH3016, stained with phalloidin and DAPI, and imaged using fluorescence confocal microscopy. (D, 
E) STM JH3016 was used to infect mice in vivo, colons were harvested 24 hrs p.i. and stained as in (C). 
 
3.2.3 In vivo pathology induced by 2W1S Salmonella strains 
To track T cell responses to STM infection, a model was sought that caused consistent 
infection but low mortality. To assess the pathology caused by infection with 2W1S-
expressing strains, a series of experiments were conducted to assess the severity of 
infection induced in C57BL/6 mice. The objective of these experiments was to select an 
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appropriate strain, dosage and streptomycin pre-treatment schedule to induce infection 
with low mortality. To assess pathology, mice were infected with different strains and 
dosages, and weight change was monitored daily for 2 weeks p.i. 
These are adaptations to the well-established STM colitis model, where mice are orally 
infected 24 hrs after treatment with streptomycin (Barthel et al., 2003)(Fig 3.3A). When 
mice are infected with 5x107 CFU of virulent SL1344-2W1S, weight loss was severe and 
all mice reached the terminal endpoint of 20% weight loss by day 11 p.i. (Fig 3.3B). 
Another group was infected with the same dose of SL1344-2W1S but without 
streptomycin pre-treatment (Fig 3.3C). In this group, 50% of infected mice survived.  
Next, the dosage of SL1344-2W1S was serially diluted and mice were infected with doses 
from 1x105-5x107 CFU (Fig 3.3D). In this group, 33% survived to day 14 p.i. and lower 
doses did not correlate with higher survival rates. Unexpectedly, the two mice that 
received the lowest doses did not survive. The last group received 1x108 CFU of BRD509-
2W1S, a dose that has been used previously (Nelson et al., 2013) (Fig 3.3E). In this group 
all mice survived, with only one losing more than 5% of its initial body weight. In Fig 3.3F, 
the survival rates of mice from these four groups are shown, based on data from three 
experiments. 100% of uninfected mice, 33% of mice infected with SL1344-2W1S, 50% of 
infected with SL1344-2W1S without streptomycin and 83% of mice infected with BRD509-
2W1S survived. In Fig 3.3G, representative caeca and colons are shown from mice that 
were mock-infected with PBS (top), infected with BRD509-2W1S (middle) or SL1344-
2W1S (bottom). Signs of colitis increase from top to bottom and include emptied and 
shrivelled caeca, shortened colons and thickened intestinal walls indicating oedema. 
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Figure 3.3 Weight loss, colitis and mortality following infection with 2W1S expressing STM strains. 
Mice were orally infected with variable doses of attenuated and virulent STM-2W1S strains, with and without 
streptomycin pre-treatment. (A). Weight loss is plotted for 14 days post-infection (p.i.) in mice infected with 
virulent SL1344-2W1S or mock infected with PBS (B), without streptomycin pre-treatment (C), with serial 
dilutions of STM doses (D), or with attenuated strain BRD509-2W1S (E). Dashed lines represent the humane 
endpoint of 80% weight loss. (F) The percent survival of groups mock-infected, SL1344-2W1S infected with 
and without streptomycin, or BRD509-2W1S infected. (G) Representative image are shown of colons and 
caeca from mock-infected (top) BRD509-2W1S (centre) or SL1344-2W1S (bottom) mice. Each line (B-E) 
represents a single animal and survival graphs represent data pooled from three independent experiments 
(n=3-4). Mean ± standard error of the mean (SEM) are plotted. 
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Based on these results, BRD509-2W1S was selected for further study because it induces 
colitis but only moderate weight loss and mortality. Further experiments characterised 
gross pathology, infection and cellular changes to infection (Fig 3.4). C57BL/6 mice 
infected with 1x108 CFU BRD509-2W1S lost <5% of initial weight, which recovered to 
levels of mock-infected controls by 14 days p.i. (Fig 3.4A). At 6 days p.i., intestinal and 
lymphoid tissues were processed into single cell suspensions, permeabilised with Triton 
X-100 and plated on MacConkey agar, which is selective for Gram-negative intestinal 
bacilli, with streptomycin, to which STM is naturally resistant (Fig 3.4B). STM CFUs were 
recovered from the colon and small intestine (SI), although significantly more were 
recovered from the colon than the SI. STM CFU were also recovered from the MLN and 
Peyer’s patches but not from the spleen. Representative images of caeca, colons (Fig 
3.4C) and MLN chains (Fig 3.4C) are shown from infected (top) and uninfected (bottom) 
animals. As shown in Fig 3.3G, infected colons show signs of colitis including colonic 
shortening, oedema, and an enlarged caecal patch (Fig 3.4C, inset). In Fig 3.4D, specific 
colon- and caecum-draining lymph nodes (cMLN1, far left and cMLN2, far right) are also 
enlarged in infected animals. 
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Figure 3.4 BRD509-2W1S induces intestinal infection and colitis but only moderate weight loss. 
(A) Weight loss for 30 days following infection with BRD509-2W1S or mock infection with PBS. (B) STM CFUs 
recovered from five tissues 6 days post-infection. (C) Representative image of colons and caeca from infected 
(top) and uninfected (bottom) mice. Inset shows the tip of a BRD509-2W1S infected caecum with enlarged 
caecal patch. (D) Representative images of MLN chains from BRD509-2W1S infected (top) and mock infected 
(bottom) mice. cMLN1 is shown far left. (A) Weight charts show data from two independent experiments (n=3-
5) and CFU data (B) is from one experiment (n=3). Mean ± SEM are plotted. Statistical significance between 
weights at specific time points and CFUs between tisssues are calculated by one-way ANOVA with Tukey’s 
test. *p<.05; **p<.01. MLN, mesenteric lymph nodes; PP, Peyer’s patches; SI, small intestine. 
Having a clearer understanding of gross physiological changes during infection, 
experiments were next conducted to assess organ-specific changes in cell numbers 
following infection. A major aim of this project is understanding the control of the CD4 T 
cell response to STM, so changes in cell numbers, CD4 T cells and FoxP3+ regulatory T 
cells (Tregs) were enumerated. Cell numbers were calculated at 6, 30 and 60 days p.i. in 
the colon, caecal patch (CP), MLNs and the spleen (Fig 3.5). In the colon there was a 
significant increase in the number of total cells, CD4 T cells and Tregs at day 6 p.i. Total 
cell numbers remained elevated at 60 days p.i., although the number of colonic CD4 T 
cells and Tregs returned to normal levels by 30 days p.i. The number of total MLN cells 
also increased 6 days p.i., but this increase was resolved by day 30 p.i. Unlike in the colon, 
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there was no significant increase in the number of MLN CD4 T cells or Tregs. Changes in 
splenic cells showed an inverse dynamic to that seen in the colon, with decreased 
numbers of total cells and CD4 T cells at day 6 and day 30 p.i., which resolved to normal 
numbers by day 60 p.i. In the CP, the trend was similar to that seen in the colon, with 
increased CD4 T cells at day 6 p.i., resolving to normal levels by day 30 p.i. The increase 
in total CP cells is not significant however, potentially because harvest of the tissue is less 
precise, and samples include variable quantities of surrounding non-lymphoid tissue.  
 
Figure 3.5 Change in the number of total cells, CD4 T cells and Tregs following BRD509-2W1S 
infection. 
Total cells were enumerated from single cell suspension by haemocytometer, CD4 T cells were identified by 
flow cytometry as live, single CD45+, CD3+, Dump- (MHCII, B220, CD8, CD64) CD4+ cells. FoxP3 Tregs were 
identified by FACS as FoxP3+ cells that are CD4 T cells. Uninfected cells are from mice mock-infected with 
PBS. Data points represent individual animals from two independent experiments (n=4-8). Mean ± SEM are 
plotted. Statistical significance calculated by a one-way ANOVA with Tukey’s test. ns, not significant; *p<.05; 
**p<.01; ***p<.001; ****p<.0001. 
In summary, BRD509-2W1S infection induces an increase in total cells, CD4 T cells and 
Tregs in the colon that at least partially resolves by day 60 p.i. There is a short-term 
increase in total MLN cells but not CD4 T cells. In the spleen there is a decrease in the 
number of total cells and CD4 T cells that resolves by day 60 p.i. (Fig 3.5). These cellular 
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changes, with weight loss and STM plating data reflect an STM infection model that 
induces consistent non-lethal infection with limited bacterial dissemination but clear signs 
of colitis. This fulfils the requirement for a model of non-lethal infection, so the next 
experiments use this model to optimise detection of STM-specific CD4 T cells. 
3.3 Tracking Salmonella-specific CD4 T cells  
To identify antigen-specific CD4 T cells following BRD509-2W1S infection, samples are 
stained with 2W1S:1-Ab tetramers. These tetramers bind 2W1S-specific T cell receptors 
(TCR) and are conjugated to Phycoerythrin (PE) fluorophores, allowing tetramer+ (2W1S-
specific) cells to be identified by flow cytometry. Since 2W1S is not an endogenous 
peptide, activated tetramer+ cells can be characterised as an STM-2W1S-specific T cell 
population. 
3.3.1 Optimisation of BRD509-2W1S infection and MHCII tetramer 
staining to detect Salmonella-specific CD4 T cells 
2W1S:1-Ab tetramer+ CD4 T cells are identified by flow cytometry with the gating strategies 
shown in Fig 3.6. Following MHC II tetramer and surface staining, CD4 T cells are 
identified as live, single, CD45+, CD3+, MHCII-, B220-, CD8-, CD64-, CD4+ cells. Tetramer+ 
CD4 T cells are then identified as CD44hi Tetramer+ cells. This strategy can identify 
2W1S-specific CD4 T cells in mucosal tissue, such as colon (Fig 3.6A) or lymphoid tissue, 
including MLNs (Fig 3.6B). 
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Figure 3.6 Gating strategy for tetramer+ CD4 T cells in the colon and MLN. 
Representative plots of cells from BRD509-2W1S infected mice 6 days p.i. Tetramer+ CD4 T cells are 
identified from single cell suspension of colonic cells (A) and MLN cells (B). Cells are identified as live, single 
CD45+, CD3+, Dump- (MHCII, B220, CD8, CD64), CD4+, CD44hi and tetramer+ cells. 
The tetramer staining protocol was optimised by staining splenocytes from BRD509-
2W1S infected mice with serial dilutions of 2W1S:1-Ab tetramers (Fig 3.7). An increased 
proportion of tetramer+ cells was observed in the 2W1S exposed mice but not in non-
2W1S infected mice. Based on these results, 7.0µg/ml was the concentration selected for 
future experiments as a balance between a high proportion of tetramer+ cells labelled and 
conserving tetramer stocks. 
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Figure 3.7 Detection of 2W1S- specific CD4 T cells using titrated tetramer.  
Representative plots of splenic CD4 T cells from BRD509-2W1S infected (top) and non-2W1S BRD509-
infected mice (bottom), stained with serial dilutions of 2W1S:IAb tetramer. Spleens were harvested 6 days p.i. 
and were stained with tetramer for 2 hrs at 37C, before surface staining and analysis by flow cytometry. 
After developing a gating strategy and optimising tetramer staining, the next objective was 
to track tetramer+ cells across tissues at multiple time points. Initially, MLN and spleens 
were harvested at day 6 and day 30 p.i. (Fig 3.8). Representative plots showing tetramer+ 
CD4 T cells in both tissues from BRD509-2W1S-infected mice but not mock infected 
controls are shown in Fig 3.8A. Charts showing the proportion of CD4 T cells that are 
tetramer+ are shown for the MLN (Fig 3.8B) and spleen (Fig 3.8C). These data confirm 
specific tetramer staining in both tissues. At day 6 p.i., 0.20% and 0.27% of CD4 T cells 
are tetramer+ in the MLN and spleen respectively. Unexpectedly, the mean proportion of 
CD4 T cells that are tetramer+ in the spleen increased to over 1.5% at day 30, while the 
proportion of tetramer+ cells in the MLN was unchanged (Fig 3.8B and C). 
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Figure 3.8 Detection of 2W1S-specific tetramer+ CD4 T cells 6 days and 30 days p.i. 
(A) Representative plots of tetramer+ CD4 T cells (as gated in Fig 3.6) from MLN (top) and spleen (bottom) at 
6 days and 30 days p.i. with BRD509-2W1S or mock-infected with PBS. The proportion of CD4 T cells that 
are tetramer+ in the MLN (B) and spleen (C) are plotted at day 6 and 30 p.i. Data points represent individual 
animals from two independent experiments (n=3-8). Mean ± SEM are plotted. Statistical significance 
calculated by a one-way ANOVA with Tukey’s test. *p<.05; **p<.01; ***p<.001; ****p<.0001. 
The high proportion of 2W1S-specific splenocytes at 30 days p.i., prompted analysis of 
tetramer+ cells in multiple intestinal and lymphoid tissues at day 6 and day 30 p.i. 
Representative plots from the colon, caecum, CP, spleen, MLN, SI and PP at day 30 p.i. 
are shown in Fig 3.9. CD4 T cells in the colon and caecum are 7.33% and 8.95% 
tetramer+, respectively. These figures dwarf the proportion of CD4 T cells that are 
tetramer+ in the SI and PPs, which are only 0.05% and 0.02% tetramer+ respectively (Fig 
3.9). This paucity of CD4 T cells in the SI informed the decision to focus subsequent 
analyses of intestinal LP to colonic and caecal tissue. 
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Figure 3.9 Tetramer+ CD4 T cells are detected in multiple intestinal and lymphoid sites 30 days p.i., 
with the highest proportion in the colon and caecum. 
Representative plots of tetramer+ CD4 T cells from 7 tissues at day 30 post-infection with BRD509-2W1S 
(top) or mock-infected with PBS (bottom). 
The high proportion of tetramer+ cells at day 30 p.i. in colonic and caecal LP raises 
questions about what drives this response. Further infections with larger groups were 
carried out to assess the tetramer+ response across tissues and to investigate the 
possibility that persistent infection is increasing the tetramer+ CD4 T cell response. 
3.3.2 BRD509-2W1S infection drives a sustained tetramer+ CD4 T cell 
response that is reduced following antibiotic treatment 
To assess whether persistent infection is driving the tetramer+ T cell response, mice were 
infected with BRD509-2W1S or mock-infected, as described above. One group of each 
cohort was harvested 6 days p.i. and half of the remaining animals were treated with 
enrofloxacin in drinking water from day 7 until day 28 p.i., as previously described to treat 
persistent STM infection (Griffin et al., 2009). Enrofloxacin-treated and untreated groups 
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were harvested at day 30 p.i. for analysis (Fig 3.10A and B). Additionally, tissue and 
intestinal contents from both groups, and an untreated group infected for 60 days, were 
plated to identify the presence of STM CFUs (Fig 3.10C).  
From day 6 to 30 days p.i., the proportion of tetramer+ CD4 T cells increased 5-10 fold in 
all tissues analysed except the MLN (Fig 3.10A). These increased proportions correspond 
to increased absolute numbers of tetramer+ cells in the spleen, colon and caecum (Fig 
3.10B). At 30 days p.i., enrofloxacin-treated mice had lower proportions of tetramer+ cells 
in all tissues except the MLN and a lower number of colonic tetramer+ cells than untreated 
mice. Although enrofloxacin treatment reduces the proportion of tetramer+ cells in most 
tissues, these levels remain higher than values observed at day 6 p.i. in in the spleen, 
colon and caecum (Fig 3.10A).  
When tissues and intestinal content were plated at day 6 p.i., STM CFUs were recovered 
from caecal content (~1x106 CFU/mg), faeces (~1x105 CFU/mg), colon and caecal LP, 
CP and MLN (~1x103-1x104/organ) (Fig 3.10C). At day 30 p.i., <1x102 CFU/mg were 
recovered from caecal contents and <5x102 CFU were recovered from the CP and spleen. 
Following enrofloxacin-treatment, no bacteria were recovered from intestinal contents or 
tissues. STM bacteria was also not recovered from untreated mice that were harvested 
60 days p.i. (Fig 3.10C). These data indicate that the STM-specific response at day 30 
p.i. is at least partially driven by persistent infection in lymphoid tissues such as the spleen 
or CP.  
Considering the potential for persistent, low-level infection, tetramer+ cells were tracked 
across intestinal and lymphoid tissues up to 90 days p.i. At 60 days p.i., the proportion 
(Fig 3.11A) and absolute number (Fig 3.11B) of tetramer+ cells were not significantly 
reduced in any tissues. This stability of 2W1S-specific CD4 T cells at 60 days p.i. occurs 
despite a paucity of detectable STM CFUs (Fig 3.10C) and a concurrent reduction in the 
number of CD4 T cells at this time point in the colon, caecum and CP (Fig 3.5). 
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Finally, 2W1S-specific T cell were tracked at 90 days p.i. to try to identify a time point 
where tetramer+ CD4 T cells are reduced (Fig 3.11). Even after 90 days, the proportion of 
CD4 T cells that are tetramer+ remains near peak levels in the colon and caecum (Fig 
3.11A). There is a trend towards reduced proportions of tetramer+ cells in the CP, and 
MLN, but the spleen is the only organ showing a significant reduction in the proportion of 
tetramer+ cells from levels observed at 30 days p.i. There is a consistent trend of 
decreased numbers of tetramer+ cells at day 90 compared to day 60 and day 30 p.i. This 
trend is observed in all tissues analysed (Fig 3.11B). 
78 
 
Figure 3.10 Enrofloxacin treatment reduces the number of tetramer+ CD4 T cells and STM CFUs 
recovered 30 days p.i. 
The proportion (A) and absolute number (B) of CD4 T cells that are tetramer+ at day 6, 30 or 60 p.i. is shown 
following 3 weeks of treatment with enrofloxacin in drinking water from 6 days p.i. (C) Samples of caecal 
content, faeces and tissues were plated following harvest and the number of STM CFUs recovered / organ or 
mg of intestinal content was plotted. Data points represent individual animals from two independent 
experiments (A, B) or one experiment (C) (n=3-8). Mean ± SEM are plotted. Statistical significance calculated 
for each tissue by a one-way ANOVA with Tukey’s test. ns, not significant; *p<.05; **p<.01; ***p<.001; 
****p<.0001; ND, not detected). 
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Figure 3.11 The proportion of tetramer+ CD4 T cells remains elevated in the large intestine 90 days 
p.i. 
The proportion (A) and absolute number (B) of CD4 T cells that are tetramer+ 6 days, 30 days, 60 days or 90 
days p.i. Data points represent individual animals from three independent experiments (n=3-8). Mean ± SEM 
are plotted. Statistical significance calculated for each tissue by a one-way ANOVA with Tukey’s test. ns, not 
significant; *p<.05; **p<.01; ***p<.001; ****p<.0001. 
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In vivo infections with STM BRD509-2W1S allows tracking of 2W1S-specific CD4 T cells 
in multiple sites over months following infection. These data show that a long lasting STM-
specific T cell response occurs in the large intestine and MLNs, and peaks between day 
6 and day 60 p.i., after weight loss and other signs of pathology have resolved. The colon 
and caecum are the sites with the highest proportion and number of tetramer+ cells in the 
intestines, with a 100-200 fold higher proportion of tetramer+ CD4 T cells than in the SI at 
30 days p.i. (Fig 3.9). 
The greater STM bacterial burden and CD4 T cell response in the large intestine than the 
SI, the muted changes in MLN cell numbers following infection (Fig 3.5) and the selective 
enlargement of infected cMLNs (Fig 3.4D) led to the hypothesis that STM-specific T cells 
are primarily induced in the cMLN instead of the sMLNs. This hypothesis is consistent 
with previous work from our lab showing different intestinal sites drain to specific MLNs 
(Houston et al., 2015; Mayer et al., 2017). If the STM-specific T cells are primarily present 
in the cMLNs. analysis of the entire MLN chain may dilute the previously observed MLN 
T cell response, measured in pooled MLNs in the experiments above. With the aim of 
improving sensitivity of detecting STM responses in the MLNs, a comparison of CD4 T 
cells in the cMLN and sMLN was conducted following STM infection. 
3.3.3 The CD4 T cell response to Salmonella is constrained to colon 
draining mesenteric lymph nodes 
BRD509-2W1S or mock-infected mice were harvested 6 days p.i. and CD4 T cells were 
compared between cMLNs (cMLN1 and cMLN2) and the sMLN chain (Fig 3.3A). The 
number and proportion of total cells, CD4 T cells and CD4 T cells expressing CXCR3 and 
2W1S-specific TCRs (representative plots shown Fig 3.12B) are charted in Fig 3.12C. 
The increase in total cells is constrained to the cMLN (Fig 3.12C, top left). Following 
infection, the number of sMLN cells is unchanged but the number of cMLN cells increases 
by >300%, skewing the ratio of sMLN to cMLN cells from 1:1 to 1:3. The number of CD4 
T cells significantly increases in the cMLN but not the sMLN (Fig 3.13C, top right), 
indicating that the unchanged number of CD4 T cells observed in total MLN cells (Fig 3.5) 
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masks a cMLN-specific CD4 T cell increase. Most cells entering the cMLN following STM 
infection are not CD4 T cells however, as the proportion of total cells that are CD4 T cells 
decreases in the cMLN (Fig 3.13C, top right). Other cells known to migrate into MLNs 
during infection include CD8 T cells and B cells. When characterising CD4 T cells by 
expression of CXCR3 expression, a chemokine receptor used to identify Th1 cells, there 
is a significant increase in the proportion and number of CXCR3+ cells only in the cMLN 
(Fig 3.13, bottom left). Finally, when analysing 2W1S-specific CD4 T cells, 2W1S:IAb 
tetramer+ cells are only found in the cMLNs, indicating that at this timepoint the STM-
specific response in the MLNs are confined to colon and caecum draining LNs (Fig 3.5C, 
bottom right). 
Together, these data show that in this model, the STM-specific CD4 T cell response in the 
MLN is restricted to the cMLN, which reflects the colon and caecal-specific pathology and 
T cell responses observed in the intestinal LP. This helps characterise how the CD4 T cell 
response develops and guides our approach to upcoming experiments. In following 
experiments, only cMLN will be harvested and future reference to ‘MLN’ will specifically 
refer to cMLN. 
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Figure 3.12 The T cell response to STM in the MLN is confined to colon and caecum draining nodes. 
(A) Schematic representation of intestines and MLNs, including small intestine draining MLNs (sMLN), and 
colonic draining MLNs (cMLN). (B) Representative plots of CD4 T cells from sMLN (left) and cMLN (right) that 
are CXCR3+ (top) and tetramer+ (bottom), 6 days p.i. (C) Graphs showing the number and proportion of total 
cells, CD4 T cells, and of CD4 T cells that are CXCR3+ or tetramer+ at day 6 p.i. Data points represent 
individual animals (n=4). Mean ± SEM are plotted. Statistical significance calculated by a one-way ANOVA 
with Tukey’s test. *p<.05; **p<.01; ***p<.001; ****p<.0001. 
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3.4 Discussion 
The initial aim of this project was to optimise in vivo models of STM infection and to 
characterise antigen-specific CD4 T cells following infection. This is an important step to 
investigate how the T cell response to STM is controlled. The STM infections described 
here are based on a streptomycin pre-treatment model developed as a model of non-
typhoid intestinal infection (Barthel et al., 2003). Streptomycin treatment removes >90% 
of the intestinal microbiota and reduces colonisation resistance, allowing consistent 
infection by STM, which is naturally streptomycin-resistant (Hapfelmeier and Hardt, 2005; 
Kaiser et al., 2012).  The first step to optimise an in vivo infection model for this project 
was selecting STM strains that could be easily cultured and establish consistent, non-
lethal infections. The next step was to test strains for expression of GFP or 2W1S, to track 
bacteria or responding T cells respectively. 
Growth dynamics were plotted to identify differences between strains or inconsistency in 
the ratio between OD and CFUs in culture. This was important because cultures are 
prepared for infection by OD, before CFU can be confirmed by overnight (o/n) growth on 
plates. These experiments are also useful to identify the time required for cultures to move 
from static to exponential growth, the target phase for initiating infections. Data show that 
all strains exhibit similar growth dynamics and enter an exponential phase within three 
hours of culture and extend for over six hours (Fig 3.1B). These results were consistent 
with other strains used in our lab, so infection experiments were conducted following 
established protocols for o/n static incubation. 
GFP reporter strain JH3016 was selected for initial imaging experiments because it 
incorporates a chromosomal GFP insert. Previous work in our lab (Bravo-Blas et al., 2018) 
revealed plasmid constructs such as STM-pGFP quickly lose GFP expression in vivo, so 
chromosomal constructs were preferable for durable GFP expression. The in vitro 
detection of macrophages infected by JH3016 was successful by both FACS (Fig 3.2A,B) 
and fluorescence microscopy (Fig 3.2C), but in vivo imaging was more difficult (Fig 
3.2D,E). Colon and SI sections were processed from JH3016 and SL1344 (non-GFP 
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control) 24 hrs p.i. to attempt identification of GFP+ bacteria by fluorescence microscopy. 
This time point was selected because intestinal LP penetration has been documented 
within 12 hrs p.i. and this is before severe pathology and weight loss is detected in mice 
infected by virulent STM (Barthel et al., 2003; Coburn et al., 2005). GFP+ rod-shaped 
bacteria were detectable in the luminal contents of JH3016 infected mice by 
immunofluorescence microscopy, but not SL1344 infected controls. However, no GFP+ 
bacteria were identified in the SI LP and only one GFP+ bacterium was detected in 10 
sections of JH3016-infected colon (Fig 3.2D,E). This highlighted the challenge of tracking 
bacterial dissemination in vivo. Following these initial experiments to track GFP+ STM, 
focus shifted to examining the immune response against STM, using 2W1S strains to 
track STM-specific CD4 T cells. 
3.4.1 Tracking 2W1S-specific T cells 
2W1S-expressing STM strains integrate a peptide tag downstream from the 3’ portion of 
the OmpC gene (Nelson et al., 2013). These constructs have been engineered with 
virulent SL1344 and attenuated BRD509, an auxotrophic aroA mutant (Mooney et al., 
2015). The choice of STM strain to use must consider the host strain to be infected. 
Nramp1-/- mice, including C57BL/6-derived strains, are highly susceptible to infection with 
virulent STM and succumb to infection within 1-2 weeks. Conversely, Nramp1+/+ mice, 
including 129SvJ, are resistant to virulent STM and survive infection (Brown et al., 2013; 
Fritsche et al., 2012). Therefore, most STM infection models use either attenuated STM 
with Nramp1-deficient mice or virulent STM with Nramp1+/+ mice. Because of the wide 
range of C57BL/6-derived strains available, an attenuated STM strain was sought for this 
work. Since the 2W1S insert itself may attenuate bacteria in vivo, SL1344-2W1S and 
BRD509-2W1S were both included in experiments to assess pathology induced in 
C57BL/6 mice. Weight loss and colitis were severe in SL1344-2W1S infected mice, with 
high mortality rates, even when dosage was decreased or streptomycin pre-treatment was 
omitted (Fig 3.3B-F). BRD509-2W1S was less virulent however, causing signs of colitis 
with less weight loss and higher survival rates (Fig 3.3E-G). As such, BRD509-2W1S was 
selected for future infections. 
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To assess bacterial dissemination, intestinal tissue was plated at 6 days p.i. The colon 
contained significantly higher bacterial loads than the SI, consistent with the specific 
enlargement of colon and caecal draining MLNs (Fig 3.4B,D). The colon and caecum were 
also the intestinal site with the highest number of 2W1S-specific T cells. These tissues 
contain >150-fold higher proportion of 2W1S-specific CD4 T cells than the SI LP (Fig 3.9). 
Consistent with the colon and caecum being the primary effector sites, we showed that 
colon and caecum-draining MLNs are the nodes with expanded total cells, CD4 T cells 
and 2W1S-specific T cells 6 days p.i. (Fig 3.13).  
The finding that the colon and caecum are primary sites of STM infection is consistent 
with previous characterisation of the streptomycin pre-treatment model, which was 
developed as a model of colitis (Barthel et al., 2003; Kaiser et al., 2012). Change in cell 
numbers following infection, including increased total cells in the MLN, colon and CP, are 
consistent with observed physical pathology in these tissues (Fig 3.4C). The decreased 
number of cells in the spleen was unexpected, especially considering the moderate 
splenomegaly often observed following infection. One explanation for this is that splenic 
lymphocytes migrate from the spleen to effector sites like the colon following infection. 
This hypothesis is supported by findings that STM infection induces a large increase in 
the number of splenic red blood cells (RBC) and RBC pre-cursors, but a decrease in 
lymphocytes (Rosche et al., 2015). Together, these data form a coherent picture of organ-
specific pathology caused by a non-lethal model of STM infection and colitis. 
3.4.2 Tracking 2W1S-Specific CD4 T Cells 
After selecting of BRD509-2W1S for future experiments, the next objective was to use this 
model to characterise the 2W1S-specific T cell response to infection. Identifying and 
eventually characterising STM-specific CD4 T cells helps elucidate the immune response 
to infection in several ways. First, it allows an easy confirmation of infection. Second, it 
allows analysis of a STM-specific T cells and not T cells specific for other microbial or host 
peptides. Third, it allows STM-specific T cells to be tracked through time and across 
tissues. Tetramer staining of 2W1S-specific CD4 T cells was validated by comparing 
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splenocytes from mice infected with BRD509-2W1S to mice infected with the parent 
BRD509 strain. Tetramer+ cells were only detected from BRD509-2W1S infected mice, 
validating tetramer staining specificity. Once initially validated, infections were carried out 
using ‘mock-infected’ mice as controls. Mock infected mice are administered PBS by 
gavage 24 hrs after streptomycin treatment. This controls for any changes induced by 
streptomycin pre-treatment and allows analysis of differences between infected and 
uninfected mice. 
Following validation of tetramer staining (Fig 3.7), the next objective was to track 2W1S-
specific CD4 T cells through time and in multiple sites. Tissues were harvested 6 days 
and 30 days p.i. as examples of early and late time points. Day 6 p.i. corresponds to time 
points near to peak levels of CD4 T cell responses to viral infections like influenza (Román 
et al., 2002) and intracellular bacteria such as Listeria monocytogenes (Kursar et al., 
2002). In our model, day 6 p.i. corresponds to a period of weight loss and increased cell 
numbers in intestinal tissue, while at day 30 p.i. mice have recovered to normal weight 
and increased cell numbers have at least partially recovered to baseline levels. Initial 
analysis of MLNs and spleens revealed a significant increase in the proportion of CD4 T 
cells that were tetramer+ between 6 and 30 days p.i. in the spleen, while numbers of 
tetramer+ cells in the MLN remained stable (Fig 3.8). Subsequent tetramer staining of 
seven tissues showed a stable or increased number of tetramer+ cells in all tissues from 
6 days to 30 days p.i. 
The stable population of 2W1S-specific T cells is consistent with previous research using 
virulent STM with Nramp+/+ mice showing that a stable population of 2W1S-specific cells 
were detected in lymphoid tissue for >500 days (Nelson et al., 2013). As reported here, 
the colon and caecum were the tissues with the highest proportion of tetramer+ cells, while 
the SI and PP were the tissues with lowest proportion. This highlighted that the caecum 
and colon are important intestinal effector sites for STM-specific CD4 T cells. Following 
these tetramer staining experiments, the colon and caecum were selected as the intestinal 
sites to analyse in future experiments. 
87 
Infection experiments revealed a significant increase in the number of 2W1S-specific T 
cells in the colon, caecum and spleen between 6 days and 30 days p.i. One explanation 
for this delayed response is that BRD509-2W1S, although attenuated, can survive in vivo 
and cause persistent infection, as reported with virulent strains (Nelson et al., 2013). To 
test the hypothesis that persistent infection was driving the sustained 2W1S-specific T cell 
response, infected mice were either left untreated or treated with enrofloxacin in drinking 
water for 3 weeks prior to harvest at day 30 p.i. (Fig 3.10). Enrofloxacin treatment reduced 
the proportion and number of tetramer+ CD4 t cells and removed the small number of STM 
CFUs recoverable from untreated animals. This suggests that bacteria persist in vivo 
longer than 10 days p.i. and this persistence at least partially drives the 2W1S-specific T 
cell response at 30 days p.i.  
These data are consistent with previous studies showing that enrofloxacin treatment can 
reduce bacterial burden, but that this clearance reduces compromised protective immunity 
(Griffin et al., 2009, 2011). This prolonged T cell response might not be a detriment to the 
host however, since protective CD4 T cell responses often require prolonged antigen 
presentation (Obst et al., 2005; Rabenstein et al., 2014). Recent research has shown that 
early antibiotic treatment of Salmonella infection reduces protective immunity (Benoun et 
al., 2016; Griffin et al., 2009). As such, the persistent, low level infection we detect, without 
physical signs of pathology, may be an important aspect of the development of a robust 
protective immune response. Even without enrofloxacin treatment, by 60 days p.i., STM 
bacteria are not recoverable from any tissue analysed (Fig 3.10C). A lack of detectable 
bacteria does not preclude low level infection or infection in sites not sampled here, but 
these data indicate that any ongoing infection is diminished by 60 days p.i. 
3.4.3 Conclusion 
In summary, these experiments show infection with BRD509-2W1S causes short-term 
colitis with mild weight loss that resolves within 2 weeks. This strain allows tracking of a 
long-lasting STM-specific effector CD4 T cell response that is at least partially primed in 
the cMLN and detected in largest numbers in the colonic and caecal LP. This infection 
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model has many advantages: BRD509-2W1S is easy to culture and use for oral infection, 
it allows infection of various mouse strains on a C57BL/6 background, it causes consistent 
infection and colitis with low mortality, and it allows sensitive and specific identification of 
STM-specific T cells. Disadvantages include only being able to detect one TCR clone to 
an STM-exogenous peptide, and persistent infection may complicate the characterisation 
of an antigen-specific memory T cell response. Despite these limitations, this model is a 
valuable tool that I will use to characterise the CD4 T cell response to infection. This will 
include analysis of antigen-specific and overall T cell responses, and the dynamics 
between conventional T and regulatory T cells that shape the overall response. 
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Chapter 4 Characterisation of the CD4 T Cell 
Response Following Salmonella infection 
4.1 Introduction 
Previous experiments using STM strain BRD509-2W1S allowed us to track antigen-
specific CD4 T cells in multiple tissues following infection, elucidating when and where 
these cells are present. To better understand how the CD4 T cell response develops and 
is controlled, experiments were carried out to characterise changes to the CD4 T cell pool 
following STM infection. CD4 T cells were stained for transcription factors (TFs), cytokines 
and chemokine receptors to identify populations of conventional T cells (Tconvs), 
including subsets of T helper (Th) cells, and FoxP3+ regulatory T cells (Tregs). Results 
from these experiments highlight the dynamic nature of the response to STM and identify 
potential interactions between subpopulations of Tconvs and Tregs that may control the 
overall response. 
Here we describe a dynamic and multi-phase CD4 T cell response following STM 
infection, which raises questions about what drives Th differentiation and polarisation. 
Previous work has identified a wide range of factors that influence Th differentiation, 
including the mode of infection, the cognate antigen recognised by TCRs, the site of 
infection and the cytokine milieu (Constant, 1995; Lee et al., 2012b; Pepper et al., 2010). 
The potential for FoxP3+ Tregs to shape Th differentiation has also been demonstrated 
(Campbell et al., 2018; Chaudhry et al., 2009; Koch et al., 2009; Levine et al., 2017; Sefik 
et al., 2015).  
The Treg response to STM infection has been less studied than the Tconv response. 
There is an increased number of Tregs in colonic lamina propria following infection but 
their impact on the overall CD4 T cell response is unclear. Previous research has shown 
that Tregs play an important role in constraining the Tconv response to STM and depletion 
facilitates a more rapid bacterial clearance (Johanns et al., 2010). Tregs in the intestine 
are a heterogenous population and it is unclear which sub-populations play a role in 
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regulating the Tconv response, how they change following infection, and if they actively 
shape Th differentiation. 
The following experiments were conducted to characterise both Tconv and Treg 
responses following STM infection in the colon and MLN. TF, cytokine and chemokine 
receptor expression were assessed to elucidate site-specific and temporal aspects of the 
CD4 T cell response and address questions about how this response is controlled. 
4.2 Reciprocal dynamics between regulatory and 
conventional T cells 
4.2.1 TF expression by Tconvs following Salmonella infection 
The initial aim of characterising the CD4 T cell response to STM infection was to identify 
Th subsets and Tregs. CD4 T cells were stained for T-bet, RORγT and FoxP3; master 
TFs used to identify Th1 cells, Th17 cells and Tregs respectively (Ivanov et al., 2006; 
Szabo et al., 2000; Zheng and Flavell, 1997). Following infection with STM strain BRD509-
2W1S, CD4 T cells from colons and draining MLNs were stained for surface markers, TFs, 
and 2W1S:I-Ab tetramers to identify 2W1S-specific T cells. As such, a 2W1S-specific, 
tetramer+ population could be assessed independently of the tetramer- population, 
containing a presumably polyclonal pool of cells recognising diverse antigen (Fig 4.1). 
In Figure 4.1A, representative plots from colonic CD4 T cells 6 days p.i. show expression 
of T-bet, RORγT and FoxP3 by tetramer+ or tetramer- populations. While there are distinct 
populations of tetramer- cells that are either positive or negative for T-bet, RORγT and 
FoxP3, the tetramer+ cells are almost exclusively T-bet+. The Th1 phenotype of tetramer+ 
cells is sustained at 30 and 60 days p.i., in both tissues (Fig 4.1B). These data suggest 
that while the heterogenous CD4 T cell pool contains a mixed population of Th1 cells, 
Th17 cells, and Tregs, 2W1S-specific T cells are almost exclusively Th1 cells. 
To assess changes in Th subsets and Tregs following infection, the bulk CD4 T cell pool 
was also characterised by TF expression (Fig 4.2). Tconvs and Tregs were identified as 
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FoxP3- and FoxP3+ CD4 T cells, respectively. Representative plots show gating of colonic 
Tconvs as CD44hi FoxP3- cells, which are further characterised by T-bet and RORγT 
expression (Fig 4.2A). The proportion and number of Tconvs expressing T-bet, RORγT, 
T-bet and RORγT, or GATA3 were plotted (Fig 4.2B). Samples are from PBS (mock)-
infected mice or STM-infected mice harvested at 6, 30 or 60 days p.i.  
 
Figure 4.1  2W1S-specific CD4 T cells express T-bet but not RORγT or FoxP3. 
CD4 T cells (live, single, CD45+, dump (MHCII, B220, CD64, CD8)-, CD3+, CD4+ cells) were identified as 
2W1S:I-Ab tetramer- or tetramer+ and characterised by expression of T-bet, RORγT or FoxP3. (A) 
Representative plots are shown of colonic CD4 T cells that are tetramer- or tetramer+ stained for T-bet, RORγT 
and FoxP3. (B) TF expression by tetramer+ cells in the colon or MLN at day 6, day 30 and day 60 p.i. Data 
points represent individual animals (n=4) from a representative example of three independent experiments. 
Means ± SEM are plotted. 
Consistent with the increased number of colonic CD4 T cells following STM infection (Fig 
3.5), there is an increased number of Tconvs expressing T-bet (Th1) cells, RORγT (Th17) 
cells or T-bet and RORγT 6 days p.i. While both Th1 and Th17 cells increase in number, 
the increase in Th17 cells is greater; this underlies an increased proportion of Th17 cells 
and a decreased proportion of both Th1 cells and GATA3+ Th2 cells (Fig 4.2B). The 
reduced proportion of Th1 cells and the increased proportion of Th17 cells is indicative of 
a shift towards a Th17 bias 6 days p.i. This increased Th17 bias is transient however, and 
by day 30 p.i. there is a strong Th1 bias. The increased proportion and number of T-
bet+RORγT+ cells remain elevated and the proportion of Th2 cells remains reduced at day 
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30 p.i. (Fig 4.2B). The change in the proportions of colonic Tconvs that are T-bet+ Th1 
cells or RORγT+ Th17 cells are shown in line charts (Fig 4.2C). 
The proportion and number of Tconvs expressing TFs in the MLN are shown in bar charts 
(Fig 4.2D) and line charts (Fig 4.2E). In the MLN, there are increased proportions and 
numbers of Tconvs that are Th1 cells, Th17 cells and T-bet+RORγT+ cells 6 days p.i. 
These increases resolve by day 30 p.i. for all subsets except Th1 cells, which remain 
elevated until 60 days p.i. In summary, despite the increase in Th1 and Th17 cells in the 
MLN, there is no shift in Th bias as observed in the colon. 
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Figure 4.2 Transcription factor expression by CD4 Tconvs. 
(A) Representative plots of colonic Tconvs (CD44hi FoxP3- CD4 T cells, gated left) stained for T-bet and 
RORγT following STM or mock (PBS) infection. (B) Expression of TFs by colonic CD44hi Tconvs, shown as 
proportions or absolute number of Tconvs following infection. (C) Line charts show changes in in the 
proportion of colon Tconvs expressing T-bet or RORγT. (D) TF expression by MLN Tconvs following infection 
and (E) line charts show changes in the proportion of MLN Tconvs expressing T-bet or RORγT following STM 
infection. Data points represent individual animals (n=3-6) from a representative example of at least two 
independent experiments. Means ± SEM are plotted. Statistical significance calculated for each TF by one-
way ANOVA with Tukey’s test. ns, not significant; *p<.05; **p<.01; ***p<.001. 
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4.2.2 TF expression by Tregs following Salmonella infection 
Next, FoxP3+ Tregs were assessed for co-expression of the Th ‘master’ TFs used to 
identify Th subsets. Tregs were gated as FoxP3+ CD44hi CD4 T cells and representative 
plots showing T-bet and RORγT are shown in Fig 4.3A. The proportion and absolute 
number of Tregs expressing T-bet, RORγT, T-bet and RORγT, or GATA3 were graphed 
(Fig 4.3B). Groups include samples from PBS (mock)-infected mice and mice harvested 
at 6 days, 30 days and 60 days p.i.  
There is an increased number of Tregs that are T-bet+ and T-bet+RORγT+ at 6 days p.i., 
but no significant increase in the number of RORγT+ or GATA3+ Tregs (Fig 4.3B, right). 
These numerical changes correspond with an increased proportion of T-bet+Tregs and a 
reduced proportion of RORγT+ Tregs (Fig 4.3B, left). While these proportional changes 
are partially resolved by day 60 p.i., the percentage of Tregs that are T-bet+ remain higher 
and the proportion of RORγT+ Tregs remain lower than in mock-infected controls. The 
proportion and number of Tregs that are GATA3+ remained unchanged following infection 
(Fig 4.3B, left). In Fig 4.3C the change in the proportion of colonic Tregs that are T-bet+ 
or RORγT+ are shown (red lines) with green lines representing the proportion of Tconvs 
that express the same TFs (as shown in Fig 4.2C). These charts show that the transient 
decrease in the proportion of colonic Th1 cells occurs concurrently with a transient 
increase in the proportion of T-bet+ Tregs (Fig 4.3C, left). When assessing RORγT 
expression, the transient increase in the proportion Th17 cells corresponds with transient 
decrease in the proportion of Tregs that are RORγT+ (Fig 4.3, right). 
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Figure 4.3 Transcription factor expression in FoxP3+ Tregs. 
(A) Representative plots of colon Tregs (FoxP3+ CD4 T cells, gated left) stained for T-bet and RORγT following 
mock (PBS) or STM infection. (B) Expression of TFs by colonic Tregs are shown as absolute numbers and 
proportions of total Tregs. (C) Line charts show changes in in the proportion of Tregs expressing T-bet or 
RORγT (red) plotted with line charts showing the proportion of Tconvs expressing the same TFs (green). (D) 
TF expression by MLN Tregs following infection and (E) charts showing changes in the proportion of MLN 
Tregs expressing T-bet or RORγT (red) plotted with the proportions of Tconvs expressing the same TFs 
(green). Data points represent individual animals (n=3-6) from a representative example of at least two 
independent experiments. Means ± SEM are plotted. Statistical significance calculated for each TF by one-
way ANOVA with Tukey’s test. ns, not significant; *p<.05; **p<.01; ***p<.001. 
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The proportion and number of Tregs expressing TFs in the MLN are shown in bar charts 
(Fig 4.3D) and line charts (Fig 4.3E). In the MLN, as in the colon, there is an increased 
number of Tregs that are T-bet+ or T-bet+RORγT+ following infection, but no increase in 
the number of RORγT+ or GATA3+ Tregs (Fig 4.3D, right). These numerical changes 
correspond with an increased proportion of Tregs that are T-bet+ and reduced proportion 
that are RORγT+ (Fig 4.3D, left). In Fig 4.3E the change in the proportion of MLN Tregs 
that are T-bet+ or RORγT+ are shown (red lines) with green lines representing the 
proportion of Tconvs that express the same TFs (as shown in Fig 4.2E). These charts 
show that the increase in the proportion of MLN Th1 cells occurs concurrently with an 
increase in the proportion of T-bet+ Tregs (Fig 4.3E, left). The transient increase in the 
proportion of Th17 cells corresponds with transient decrease in the proportion of Tregs 
that are RORγT+ (Fig 4.3, right). These data highlight a reciprocal dynamic between 
Tconvs and Tregs expressing T-bet or RORγT in the colon. This tissue-specific reciprocity 
is most evident in the first 30 days p.i., which prompted a closer investigation of these 
dynamics with a tighter time-course. 
4.2.3 Reciprocal dynamics between colonic Tconvs and Tregs 
expressing the same TFs 
An infection time-course with 7-8 harvest timepoints in the first 30 days p.i. was carried 
out to validate the reciprocal dynamics highlighted in Fig 4.3 and outlined in Fig 4.4A. 
These data reveal a more convincing and detailed picture of reciprocity between colonic 
Tconvs and Tregs expressing the same TF (4.4B). These experiments indicate that day 
6 p.i. is the peak of the early Th17 response and a Th1 bias is established by day 11 p.i. 
On the other hand, these data suggest there is no clear reciprocity between MLN Tconvs 
and Tregs (Fig 4.4C). In summary, the early Th17 response in the colon coincides with an 
increased proportion of T-bet+ Tregs, and the later Th1 bias coincides with an increased 
proportion of RORγT+ Tregs. These results are consistent with the hypothesis that Th1 
cells are being selectively suppressed by T-bet+ Tregs early after infection and Th17 cells 
are being selectively suppressed by RORγT+ Tregs later. If validated, this could elucidate 
a mechanism for Tregs to shape the Tconv response in a nuanced and fine-tuned way. 
97 
 
Figure 4.4 Reciprocal dynamic between Tconvs and Tregs expressing T-bet or RORγT occur in the 
colon but not the MLN. 
CD4 T cells were identified as Tregs and Tconvs as described in Fig 4.1-4.3. (A) The expression of T-bet or 
RORγT by colonic Tconvs and Tregs described previously, was measured during a time course in the first 30 
days p.i. in the colon (B) and in the MLN (C). Data points represent groups of mice (n=4-6). Means ± SEM 
are plotted. 
4.3 Cytokine expression by CD4 T cells following 
Salmonella infection 
TF expression can be used to identify Th subsets and Tregs, but cytokine expression 
reveals functional characteristics that can be used with TF staining to validate the 
phenotype of Th populations. In the following experiments, we sought to characterise the 
cytokine expression by CD4 T cells following STM infection. Tregs and Tconvs were 
stained for TFs and IFNγ and IL-17A, cytokines expressed by Th1 and Th17 cells, 
respectively. The aim of these experiments was to characterise cytokine production 
following STM infection and to validate the classification of Th subset by TFs. 
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4.3.1 Cytokine expression by Tconvs 
Tconvs were assessed for expression of T-bet, RORγT, IFNγ and IL-17A following PMA 
Ionomycin stimulation (Fig 4.5). There were increased proportions of T-bet+ and T-
bet+RORγT+ Tconvs 11 days p.i., which is consistent with previous experiments (Fig 
4.5B). A smaller proportion of colonic Tconvs express cytokines compared to TFs, but 
there was an increased proportion IFNγ+, IL-17A+ and IFNγ+IL-17A+ Tconvs 11 days p.i. 
(Fig 4.5C). As in the colon, there was an increased proportion of MLN Tconvs that 
expressed T-bet+ or T-bet+RORγT+ 11 days p.i., and there was an increased proportion 
of IL-17A+ and IFNγ+ Tconvs (Fig 4.5D, E). Few MLN Tconvs expressed IFNγ or IL-17A 
following mock-infection, but ~50% were IFNγ+ and ~10% were IL17-A+ 11 days p.i. (Fig 
4.5E). These data show that following infection, an increased proportion of Tconvs 
expressed TFs and cytokines, with a bias towards T-bet and IFNγ expression. To 
determine if Th1 cells were producing IFNγ, and Th17 cells were producing IL-17A, as 
would be expected, further analysis was carried out. 
Representative plots of T-bet and IFNγ expression (Fig 4.6 A, left) show that 11 days p.i., 
>80% of IFNγ+ cells are T-bet+ cells and >75% of T-bet+ Tconvs are IFNγ+. Plots of RORγT 
and IL-17A expression (Fig 4.6A, right) show that 11 days p.i., >90% of IL-17A+ Tconvs 
are RORγT+ and >50% of RORγT+ Tconvs are IL-17A+. When IFNγ+ and IL-17A+ Tconvs 
are overlaid onto plots of T-bet and RORγT expression, the IFNγ+ cells are clearly focused 
over T-bet+ cells and the IL-17A+ cells are centred over the RORγT+ cells (Fig 4.6B). 
Finally, donut charts are shown that represent the proportional expression of IFNγ, IL-17a 
or IFNγ by T-bet+, RORγT+, or T-bet+RORγT+ Tconvs (Fig 4.6C). These charts 
demonstrate that >90% of T-bet+ Tconvs expressing cytokines in the colon and MLN are 
IFNγ+, as would be expected for Th1 cells. Cytokine producing RORγT+ Tconvs in the 
colon and MLN are >85% IL-17A+, consistent with a Th17 phenotype. Cytokine production 
by T-bet+RORγT+ Tconvs are heterogenous and include IFNγ+, IL-17A+ and IFN+IL-17A+ 
cells. These T-bet+RORγT+ Tconvs likely include a combination of Th1, Th17 cells and 
IFNγ+IL-17A+ Tconvs. Based on these analyses, T-bet+ Tconvs are validated as bona fide 
Th1 cells and RORγT+ Tconvs can be be considered Th17 cells. 
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Figure 4.5 Transcription factor and cytokine expression by Tconvs. 
(A) Isotype controls and representative plots of IFNγ and IL-17A expression in mock (PBS)- or STM-infected 
MLN Tconvs are shown at 11 days p.i. (B) T-bet and RORγT expression by mock- or STM-infected colonic 
Tconvs 30 days p.i. are graphed (left) and shown as pie charts (right). (C) IFNy and IL-17A expression by 
colonic Tconvs are graphed (left) or shown as pie charts (right).  MLN Tconv TF (D) and cytokine expression 
(E) are also depicted. Means ± SEM are plotted. Data points represent individual animals (n=4) from a 
representative example of two independent experiments. Statistical significance calculated by one-way 
ANOVA with Holm-Šídák test. ns, not significant; *p<.05; **p<.01; ***p<.001; ****p<.0001. 
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Figure 4.6 Cytokine expression by Tconvs expressing T-bet or RORγT. 
(A) IFNγ expression is plotted against T-bet expression and IL-17A expression is plotted against RORγT 
expression by MLN Tconvs from mock (PBS)- infected or STM-infected mice 11 days p.i. (B) IFNγ+ Tconvs 
(blue) and IL-17A+ Tconvs (red) are overlaid onto a FACS plot of total Tconvs showing T-bet and RORγT 
expression. (C) Expression of IFNγ and/or IL-17A by Tconvs that are T-bet+, RORγT+ or T-bet+RORγT+ are 
depicted in donut charts. 
4.3.2 Cytokine expression by 2W1S-specific T cells 
After characterising TF and cytokine expression in the heterogenous CD4 T cell pool, we 
sought to confirm if 2W1S-specific cells, shown to be consistently T-bet+, are also IFNγ+ 
as expected of Th1 cells (Fig 4.7). Representative plots of IFNγ and IL-17A expression by 
2W1S-specific T cells 11 days p.i. indicates that in both tissues, most of these cells are 
IFNγ+IL-17A-. The proportion and number of colonic tetramer+ cells that express T-bet 
and/or RORγT and IFNγ and/or IL-17A are graphed (Fig 4.7B). The proportion of 2W1S-
101 
specific cells that express TFs and cytokines are also represented in pie charts (4.7C). As 
previously shown, most 2W1S-specific cells are T-bet+ in both the colon and MLN (Fig 
4.7B). Approximately 55% of colonic tetramer+ T cells express cytokines, and >90% of 
these are IFNγ+ (Fig 4.7C, right). In the MLN, 2W1S-specific T cells are also mostly T-bet+ 
and are >85% IFNγ+ (Fig 4.7E, right). As such, 2W1S-specific CD4 T cells in both the 
colon and MLN have a Th1 phenotype, like the other T-bet+ Tconvs analysed. 
4.3.3 Cytokine expression by FoxP3+ Tregs 
The last group of T cells analysed for cytokine expression were FoxP3+ Tregs. Having 
previously shown that increased numbers and proportions of Tregs express ‘master’ Th 
TFs following infection, we aimed to determine whether Tregs expressed the same 
cytokines as their Th counterparts. Treg expression of T-bet, RORγT, IFNγ and IL-17A 
was analysed (Fig 4.8). The proportion and number of colonic Tregs expressing TFs and 
cytokines were graphed (Fig 4.8A) and the proportions of Tregs expressing TFs and 
cytokines were represented in pie charts (Fig 4.8B). Following infection an increased 
proportion of Tregs in both tissues were IFNγ+ and an increased proportion of MLN Tregs 
were IL-17A+, but the proportion of Tregs expressing these cytokines in either tissue 
remained small. Although the proportion of colonic Tregs expressing T-bet and/or RORγT 
11 days p.i. was almost 50%, the proportion of Tregs expressing IFNγ and/or IL-17A 
remained <5%. In the MLN, the proportion of Tregs expressing T-bet and/or RORγT at 11 
days p.i. was >30% but the proportion expressing IFNγ or IL-17A was <9% (Fig 4.8C,D). 
In summary, analysis of IFNγ and IL-17A expression reveals that STM infection induces 
a large increase in the number and proportion of Tconvs expressing cytokines in both the 
colon and MLN. In both tissues, IFNγ expression was predominantly by T-bet+ Th1 cells 
and IL-17A expression was by RORγT+ Th17 cells. This was the case for all Tconvs and 
for 2W1S-specific cells, which were mostly T-bet+IFNγ+ Th1 cells. On the other hand, only 
a small number of Tregs expressed IFNγ or IL-17A, despite increased expression of T-
bet or RORγT following infection. As such, T-bet, RORγT and FoxP3 are validated as 
markers of functional Th1, Th17 and Treg cells. 
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Figure 4.7 Transcription factor and cytokine expression by 2W1S:I-Ab tetramer+ CD4 T cells. 
(A) Representative plots of IFNγ and IL-17a expression by 2W1S-specific CD4 T cells from the MLNs and 
colon at 11 days p.i. (B) The proportion (left) and absolute number (right) of colonic tetramer+ CD4 T cells 
expressing TFs and cytokines are graphed. (C) The proportion of tetramer+ CD4 T cells expressing TFs and 
cytokines is depicted in pie charts. TF and cytokine profiles in the MLN are also shown in graphs (D) and pie 
charts (E). Means ± SEM are plotted. 
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Figure 4.8 Transcription factor and cytokine expression by FoxP3+ Tregs. 
(A) The proportion and absolute number of colonic FoxP3+ Tregs expressing TFs (top) and cytokines are 
shown from mock (PBS)- and STM–infected mice 11 days p.i. (B) The proportion of colon Tregs expressing 
TFs or cytokines 11 days p.i. is depicted in pie charts. (C) TF (top) and cytokine (bottom) expression by Tregs 
is also shown in the MLN and represented in pie charts (D). Data points represent individual animals (n=4) 
from a representative example of two independent experiments. Means ± SEM are plotted. Statistical 
significance for each cytokine or TF calculated by a one-way ANOVA with Holm-Šídák test. ns, not significant; 
*p<.05; **p<.01; ***p<.001; ****p<.0001. 
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4.4 Expression of chemokine receptors by CD4 T cells  
In addition to TFs and cytokines, expression of chemokine receptors can be used to 
characterise CD4 T cells and provide information about their potential migration and 
localisation (Kim et al., 2001; Lim et al., 2008; O’Garra et al., 1998). Chemokine receptors 
CXCR3 and CCR6, often used as surrogate markers for Th1 and Th17 cells, were 
examined on Tconvs and Tregs following STM infection to achieve three objectives: First, 
to validate whether these receptors identify Th or Treg subsets during STM infection; 
second, to identify changes in the proportion of Tconvs or Tregs expressing them; and 
third, to determine if changes in their expression might elucidate the potential for co-
localisation of Tconvs by Tregs expressing the same receptors. 
Representative plots of CXCR3 and CCR6 expression from mock- and STM-infected 
MLNs 11 days p.i. show CXCR3+ cells can be identified in Tconvs and Tregs, but CCR6 
staining has weaker separation (Fig 4.9A). Representative plots of CXCR3 and T-bet 
expression shows most CXCR3+ Tconvs from STM-infected mice are T-bet+, but this is 
not the case with Tregs or Tconvs from mock-infected mice (Fig 4.9B). The proportion of 
Tconvs or Tregs expressing CXCR3 or CCR6 are graphed in bar charts (Fig 4.9C) and 
the proportion of Tconvs and Tregs expressing each receptor is overlaid in line graphs 
(Fig 4.9D). At 6 days p.i., there is a decreased proportion of Tconvs that are CXCR3+ in 
the colon, a trend that is also seen in CXCR3+ Tregs and both Tconvs and Tregs 
expressing CCR6. Expression of either receptor by colonic Tconvs are <5%, a small 
proportion of the colon Tconvs that are T-bet+ following STM infection (Fig 4.4B).  
In the MLN, a higher proportion of Tconvs and Tregs express CXCR3 than in the colon, 
but <3% of either group are CCR6+ (Fig 4.9E, F). Following infection, an increased 
proportion of MLN Tconvs and Tregs express CXCR3, and this increase occurs at 
different timepoints. At 6 days p.i., the proportion of Tregs that are CXCR3+ increases 
>100% but the proportion of Tconvs that are CXCR3+ remains stable until 8 days p.i. (Fig 
4.9 E). Despite low expression levels in the MLN, the proportion of CCR6+ Tregs 
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decreases following infection and remains suppressed until 14 days p.i. This same trend 
is also seen in MLN Tconvs, although the changes are not significant (Fig 4.9E, F).  
In summary, few CXCR3+ or CCR6+ Tconvs are detected in the colon. In the MLN there 
is an increased proportion of Tregs that are CXCR3+ 6 days p.i., and this increase is 
followed by Tconvs 8 days p.i. The early decrease in the proportion of colonic Tconvs and 
Tregs expressing CXCR3 or CCR6 does not fit with the proportional changes of Th1 and 
Th17 cells. Low expression levels of colonic Tconvs and poor separation in CCR6 staining 
make these chemokine receptor data inadequate for identification of Th subsets. While 
changes in receptor expression following infection can be detected, their interpretation is 
difficult. 
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Figure 4.9 CXCR3 and CCR6 expression by Tconvs and FoxP3+ Tregs. 
(A) Representative plots of CXCR3 and CCR6 expression by Tconvs (top) and Tregs (bottom) from mock 
(PBS)- and STM-infected MLNs, 11 days p.i. (B) CXCR3 expression from the same samples are plotted 
against T-bet. (C) The proportion of colon Tconvs and Tregs expressing CXCR3 and CCR6 are graphed 
following infection and (D) overlaid as line charts. The same charts for MLN Tregs are shown in (E) and (F) 
respectively. Data points represent individual animals (n=4) from two experiments. Means ± SEM are plotted. 
Statistical significance calculated by a one-way ANOVA with Tukey’s test. ns, not significant; *p<.05; **p<.01; 
***p<.001. 
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4.5 Characterisation of Tregs by Helios 
The observation of reciprocal dynamics between Tregs and Tconvs that express T-bet or 
RORγT raises questions both about the function and ontogeny of these Treg sub-
populations. To address questions about the origins of T-bet+ or RORgT+ Tregs, we 
assessed their expression of Helios, a Treg-specific TF which has been used both as a 
marker of thymic ontogeny and Treg activation and stability (Akimova et al., 2011; Elkord 
et al., 2015; Sebastian et al., 2016). 
Tregs from mock- and STM-infected mice were stained for Helios and RORγT (Fig 4.10), 
molecules proposed as markers for tTregs and pTregs respectively, although this is 
controversial (Akimova et al., 2011; Elkord et al., 2015; Szurek et al., 2015; Thornton et 
al., 2019). The proportion of Tregs from mock-infected or STM-infected mice that are 
Helios- or Helios+ are graphed in Fig 4.10B. In both the colon and MLN, infection induces 
an increased proportion of Helios+ Tregs and a decrease in the proportion of Helios- Tregs 
at day 6 p.i. These changes are sustained at day 11 p.i. Next, Helios- and Helios+ 
populations were segregated by RORγT expression, distinguishing four populations 
including a Helios+RORγT+ population (Fig 4.10C). This characterisation demonstrates 
that in both tissues, the decreased proportion of Helios- Tregs is confined to Helios-
RORγT+ cells. On the other hand, the increased proportion of Helios+ Tregs in the colon 
6 days p.i. is confined to the Helios+RORγT- population. The apparent stability in the 
proportion of Helios+ Tregs from day 6 to day 11 p.i. conceals a significant decrease in 
the proportion of Helios+RORγT+ Tregs and a trend towards increased proportions of 
Helios+RORγT- Tregs (Fig 4.10C). The changes in these four populations following STM 
infection are represented in pie charts (Fig 4.10D). 
The changes in the proportion of Tregs expressing Helios and/or RORγT, including the 
increase in Helios+ Tregs following infection highlights unanswered questions about 
whether Helios is a reliable marker of ontogeny, activation or both. 
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Figure 4.10 Characterisation of FoxP3+ Tregs by expression of Helios and RORγT. 
(A) Representative plots of Helios and RORγT expression in colon and MLN Tregs from mock- and STM-
infected mice 11 days p.i. Quadrants separate populations that are Helios+RORγT- (light red), Helios+RORγT+ 
(dark red), Helios-RORγT+ (dark blue) and Helios-RORγT- (light blue) (B) The proportion of colonic and MLN 
Tregs that are Helios- or Helios+ are plotted from mock- or STM-infected samples (C) Helios- and Helios+ 
Tregs are further divided by RORγT expression and D) the means of these proportions are represented in pie 
charts. Data points represent individual animals (n=4) from a representative example from two independent 
experiments.. Means ± SEM are plotted. Statistical significance calculated by a one-way ANOVA with Tukey’s 
test. ns, not significant; *p<.05; **p<.01; ***p<.001. 
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To assess the co-expression of Helios and other markers by Tregs, t-SNE (t-Distributed 
Stochastic Neighbour Embedding) plots were generated (Fig 4.11). Parameters used to 
generate these plots include CD44, FoxP3, T-bet, RORγT, GATA3, Helios, CXCR3 and 
CCR6. Selected gates from representative plots are colour-coded and labelled (Fig 4.11A) 
to allow interpretation in t-SNE plots from mock-infected (4.11B) and STM-infected colons 
(Fig 4.11C). In the left column, CD44hiFoxP3- Tconvs (blue), CD44loFoxP3- naïve CD4 T 
cells (green) and FoxP3+ Tregs (red) are plotted. These populations form distinct clusters, 
with a reduced naïve CD4 T cell population apparent in infected samples. In the centre 
column, Tregs are gated as Helioshi (dark purple), Heliosint (pink) and Helioslo (lilac) 
populations. Tregs are split across two clusters, with Helios+ Tregs forming one lobe and 
Heliosint and Helioslo Tregs forming another. In the right column, CD4 T cells are identified 
as T-bet+ (light blue), RORγT+ (raspberry), T-bet+RORγT+ (dark blue) or GATA3+ (orange). 
Cells expressing these TFs overlay t-SNE clusters occupied by Tconvs and Tregs, but not 
naïve CD4 T cells. In the mock-infected Tconv cluster (Fig 4.11B, right) there are 
populations of T-bet+, RORγT+ and a smaller population of GATA3+ cells, identifying Th1, 
Th17 and Th2 cells respectively. In the STM-infected Tconv cluster (Fig 4.11C, right), the 
Th1 and T-bet+RORγT+ population is larger and the Th2 population is almost absent. In 
the uninfected Treg cluster (Fig 4.11B, right), there is a large RORγT+ Treg population 
overlaying the Helioslo/int cluster, GATA3+ Tregs overlay the Helioshi cluster and the few  
T-bet+ cells are present in both Treg clusters. In the STM-infected Treg cluster, T-bet+ 
Tregs are increased in size and overlay the Helioshi cluster and the Heliosint/lo cluster. As 
with the mock-infected sample, GATA3+ Tregs mostly overlay the Helios+ cluster. 
These t-SNE plots, while limited in terms of inputs, supports the idea that Helioshi Tregs 
comprise a distinct population from Helioslo/int Tregs. While T-bet+ Tregs overlay both 
Helioshi and Heliosint/lo Treg clusters, RORγT+ Tregs primarily overlay Helioslo/int Tregs and 
GATA3+ Tregs primarily overlay Helioshi Tregs. This adds to the characterisation of the 
Treg populations by T-bet and RORγT (Fig 4.3) and by Helios (Fig 4.10). However, 
unanswered questions remain about the role that these populations and their role in 
regulating the T cell response to STM. 
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Figure 4.11 t-SNE plots of colonic CD4 T cells from STM- and mock-infected mice. 
(A) Representative plots of CD4 T cells from STM-infected colons 11 days p.i. show gating and colour labelling 
of: CD44hi FoxP3- Tconvs, FoxP3+ Tregs and CD44lo FoxP3- CD4 T cells (left); Helioshi, Heliosint and Helioslo 
Tregs (centre); and T-bet+, RORγT+ and T-bet+RORγT+ CD4 T cells (right). (B) These populations (with 
GATA3+ cells in orange, right) are overlaid onto t-SNE plots of mock (PBS)-infected colons, generated using 
parameters of CD45, CD3, CD4, CD44, FoxP3, T-bet, RORγT,Helios, GATA3, CCR6 and CXCR3 expression. 
Grey areas are negative for all markers represented in plots above. (C) Populations of CD4 T cells are overlaid 
onto t-SNE plots of STM-infected colons at day 11 p.i., as described above. 
4.6 Transcription factor expression by Tconvs and 
Tregs in ulcerative colitis 
We have identified a reciprocal dynamic between Tconvs and Tregs that may play a role 
in shaping the CD4 T cell response in STM-induced colitis in mice. To understand whether 
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this dynamic might also be observed in humans, we sought to determine whether a similar 
dynamic could also be observed during inflammation in ulcerative colitis (UC). Colonic 
biopsies were acquired from UC patients with active disease or in remission. The gating 
strategy for analysing human colonic CD4 T cells identified live CD45+ CD3+ CD4+ single 
cells that are FoxP3+CD127lo Tregs or FoxP3- Tconvs (Fig 4.12A). Tconvs and Tregs were 
then analysed for expression of T-bet and RORγT (Fig 4.12B).  
The proportion of Tconvs (Fig 4.12C) and Tregs (Fig 4.12C) that are T-bet+, RORγT+ or    
T-bet+RORγT+ were compared between samples from active and remission UC biopsies. 
Surprisingly, a lower proportion of Tconvs from patients with active UC are T-bet+ or             
T-bet+RORγT+ compared to patients in remission, and there was no significant difference 
in the proportion RORγT+ Tconvs. A lower proportion of Tregs from patients with active 
UC are RORγT+ compared to those in remission. While not significant, there is a trend 
towards an increased proportion of Tregs that are T-bet+. Therefore, active UC is 
associated with a decreased proportion of T-bet+ Tconvs, decreased proportion of 
RORγT+ Tregs and a trend towards an increased proportion of T-bet+ Tregs. These data 
show that changes in T-bet expression almost fit a model of reciprocity between Tconvs 
and Tregs, but the same reciprocity does not apply to RORγT expression. 
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Figure 4.12 T-bet and RORγT expression by Tconvs and Tregs in active or remitted UC. 
(A) Gating strategy used to identify Tconvs (live, single CD45+ CD3+ CD4+ FoxP3-) cells and Tregs (live, single 
CD45+ CD3+ CD4+ CD127lo FoxP3+) cells. (B) Representative plots of T-bet and RORγT expression by colonic 
Tconvs (top) and Tregs (bottom). (C) The proportion of Tconvs expressing T-bet and/or RORγT in active UC 
(red) and remitted UC biopsies (blue) are shown, as well as (D) the proportion of Tregs expressing these 
transcription figures from the same samples. Data points represent individual samples (n=3-4) from 6 
independent experiments. Means ± SEM are plotted. Statistical significance between active and remitted 
samples calculated by a one-way ANOVA with Holm-Šídák test. ns, not significant; *p<.05; **p<.01. 
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4.7 Summary of results 
In this chapter, the CD4 T cell response to STM infection was characterised by populations 
of Th cells and Tregs expressing ‘master’ TFs that control gene expression programmes 
of Th subsets. These sub-populations were further characterised by cytokine, chemokine 
receptor and Helios expression. We identified a transient colonic Th17 response early 
after infection, which is followed by sustained Th1 response in both the colon and MLN. 
In the colon, the shift from an increased Th17 response to Th1 bias is concurrent with a 
shift from an increased T-bet+ Treg response to an increased RORγT+ Treg bias. This 
reciprocal dynamic is consistent with a targeted or selective suppression of Th subsets by 
Tregs expressing the same TFs. Following infection, there is an increased proportion of 
Helios+RORγT- Tregs, and T-bet+ is co-expressed by both Helios+ and Helios- Tregs. 
Finally, Tconvs and Tregs were characterised in active and remitted UC biopsies and a 
reciprocal dynamic was observed between cells expressing T-bet but not RORγT. 
Together, these results highlight the heterogeneity of Tconvs and Tregs, including tissue-
specific features and the complex dynamics between inflammatory and regulatory cells 
underlying the response to infection. 
4.8 Discussion 
4.8.1 Characterising the Tconv response to Salmonella 
In the previous chapter, 2W1S-specific T cells were tracked following infection and we 
initially sought to characterise this population. 2W1S-specific cells that consistently exhibit 
a T-bet+IFNγ+ Th1 phenotype, independent of tissue or time after infection (Fig 4.1). 
Conversely, the bulk CD4 T cell pool is phenotypically heterogenous and dynamic 
following STM infection. 2W1S:1Ab tetramer- Tconvs likely contain both STM-specific and 
non-specific cells, and changes in these mixed populations have the potential to reveal 
important dynamics that shape the T cell response to STM. 
Characterisation by TF and cytokine expression shows that underlying an increase in all 
Th subsets, there is a short-lived proportional shift towards a Th17 bias in the colon after 
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STM infection (Fig 4.2B). This comprises an increased proportion of Th17 cells and             
T-bet+RORγT+ cells and decreased proportions of Th1 and Th2 cells compared to 
uninfected animals. While the proportion of Th2 cells remains suppressed for >90 days 
p.i., a Th1 bias is established by day 11 p.i. when the number of colonic Th17 cells returns 
to baseline levels. This Th1 bias is sustained for >90 days p.i. in the colon but in the MLN, 
the number and proportion of each Th subset return to baseline levels by 60 days p.i. (fig 
4.2D). 
The T-bet+RORγT+ cells that expand following infection include cells that are IFNγ+, IL-
17A+ or IFNγ+IL-17A+ (Fig 4.6D). As such, this is a heterogenous population containing 
Th1- and Th17-like cells, in addition to IFNγ-IL-17A double-producers, sometimes referred 
to as Th17.1 cells. The heterogeneity of T-bet+RORγT+ cells may be a technical artefact 
of gating populations with reduced separation following PMA ionomycin stimulation (Fig 
4.6B). On the other hand, this heterogeneity could result from gating cells 
transdifferentiating from Th17 to Th1-like cells with intermediate stages included. Bona 
fide IFNγ+IL-17A+ Th17.1 cells have been reported as highly inflammatory, driving 
pathology in several mouse models including experimental autoimmune encephalomyelitis 
(EAE), transfer colitis and ocular surface autoimmunity (Chen et al., 2017; Duhen et al., 
2013; Harbour et al., 2015). There is evidence that these Th17.1 cells differentiate from 
Th17 cells that upregulate T-bet in the presence of IFNγ (Wang et al., 2014; Zielinski et 
al., 2012). This may be an important pathway in the differentiation of Th17.1 cells in 
response to STM infection, but delineating the differentiation and function of the small 
population of Th17.1 cells out of the total T-bet+RORγT+ cells would require further 
experiments, potentially using lineage tracking techniques. 
The Th1 response to STM infection has been well documented and both bacterial 
clearance and protection from re-infection are dependent on an IFNγ-Th1 response (Hess 
et al., 1996; Kupz et al., 2012; Pie et al., 1997; Ravindran and McSorley, 2005). An early 
Th17 response to Salmonella in the intestinal mucosa has also been reported, and 
disruption of Th17 cells by genetic mutation, HIV infection, or genetic targeting of IL-17A 
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signalling have all been shown to increase epithelial damage or risk of systemic infection 
(Godinez et al., 2011; Lee et al., 2012b; Mayuzumi et al., 2010; Raffatellu et al., 2008). 
Th17 cells are not the only intestinal cells producing IL-17A following infection however, 
and innate cells including γδ T cells and ILCs produce IL-17A during infection in the 
intestinal mucosa (Keestra et al., 2011; Schulz et al., 2008; Xu et al., 2012). As such, an 
effective immune response to STM in the intestines incorporates a dynamic Tconv 
response with both an early Th17/IL-17A response and a sustained Th1/IFNγ response. 
The factors that drive the early Th17 and later Th1 response are a fundamental aspect of 
how the CD4 T cell response to STM is controlled. Factors shown to influence Th 
differentiation and include the route and site of infection, the antigen and antigenic dose, 
and the cytokine milieu (Constant, 1995; Lee et al., 2012b; Pepper et al., 2010). Using a 
Listeria-2W1S model, Pepper et al. (2010) demonstrated that intranasal infection induced 
a short lived mucosal Th17 response, while i.v. infection induced a long-lasting Th1 
response. The cognate antigen that T cells respond to has also been reported to influence 
Th differentiation. STM flagellin has been shown to drive a mixed Th17 and Th1 response 
in the intestinal mucosa while T3SS-specific CD4 T cells are primarily Th1 cells. T3SS-
specific cells are detected at later stages of infection and are more prevalent in systemic 
tissue (Lee et al., 2012b). These findings raise the possibility that the dynamic Th 
response to STM may be an adaptation to target different stages of the Salmonella 
infectious cycle- from extracellular targets in the intestinal lumen to antigen upregulated 
as an intracellular pathogen. It has been reported that Th17 cells respond to extracellular 
bacteria and Th1 cells respond to intracellular pathogens (Harrington et al., 2006; Weaver 
et al., 2006), but it is unlikely that antigen alone is capable of driving divergent 
differentiation pathways between these Th subsets; other context-dependent cues are 
likely to be required.  
Tregs are another regulator of the Tconv response and have been shown to play a crucial 
role in controlling the CD4 T cell response to infection (Belkaid, 2007; Boer et al., 2015; 
Maizels and Smith, 2011). To analyse the role of Tregs in controlling the Tconv response 
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to STM, our first objective was to characterise the development of the Treg response 
following infection. 
4.8.2 Reciprocal dynamics between Tregs and Tconvs 
The regulation and control of T cells by Tregs has been widely reported in the contexts of 
homeostasis, infection, inflammatory diseases and cancer (Baecher-Allan and Hafler, 
2004; Belkaid et al., 2002; Mougiakakos et al., 2010; Sakaguchi, 2004). More recently, 
Tregs co-expressing conventional Th ‘master TFs’ have been identified in both humans 
and mice, in multiple tissues and in contexts of inflammation and homeostasis (Duhen et 
al., 2012; Halim et al., 2017; Levine et al., 2017; Sefik et al., 2015; Wing and Sakaguchi, 
2012). There is evidence that these Treg populations differentiate in response to similar 
environmental cues as Th subsets and have been described as ‘effector’ Tregs or ‘Thx’ 
Tregs (Chaudhry et al., 2009; Wing and Sakaguchi, 2012). Questions remain about the 
ontogeny and function of these populations, and their role in immune regulation is unclear. 
Characterising changes in these Treg populations following STM infection has potential 
to address these questions in the context of a T cell response incorporating Th17 and Th1 
biased phases. Our description of a reciprocal dynamic between colonic Tconvs and 
Tregs is intriguing but is only correlative. This dynamic may be explained by multiple 
hypotheses, including plasticity between inflammatory Th cells and Th-like Tregs, or 
selective suppression of Th subsets by Tregs expressing the same TF. 
Plasticity between regulatory and conventional CD4 T cells has been demonstrated in 
several reports. RORγT+ Tregs have been shown to downregulate FoxP3 in the absence 
of IL15 and become ‘ex-Tregs’ that drive TH17 mediated colitis (Tosiek et al., 2016). It 
has also been shown that Th1 cells have the potential to upregulate FoxP3 to become    
T-bet+ Tregs (Amarnath et al., 2011; Stathopoulou et al., 2018). On the other hand, 
evidence from lineage tracking models, transfers and in vitro experiments suggest that T-
bet+ Tregs are highly stable and retain FoxP3+ expression independent of environmental 
conditions (Daniel et al., 2015; Levine et al., 2017).  
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Using this concept of plasticity to explain the reciprocal dynamics described here (Fig 4.4), 
it could be argued that the initial decrease in the proportion of Th1 cells and increased 
proportion of T-bet+ Tregs could be the result of Th1 cells upregulating FoxP3 expression. 
Furthermore, the early Th17 response and decreased proportion of RORγT+ Tregs could 
be caused by RORγT+ Tregs downregulating FoxP3. On the other hand, for plasticity to 
explain these dynamics, the later increase in Th1 cells would result from T-bet+ Tregs 
losing FoxP3 expression and expressing IFNγ. Because of the demonstrated stability of 
T-bet+ Tregs, this explanation of reciprocal dynamics is less convincing for the later 
phases of infection. As such, this appears to be at best a partial explanation.  
The concept that Tregs selectively suppress Th subsets expressing the same TFs is 
consistent with the idea that Th-like Tregs can differentiate in the same setting as Tconvs 
and therefore respond to context-dependent inflammation in a targeted and fine-tuned 
manner (Wing and Sakaguchi, 2012). Increasing evidence demonstrates that this targeted 
suppression occurs in vivo with Th1 and Th17 cells. Tregs have been shown to upregulate 
T-bet in response to type 1 inflammation and T-bet+ Tregs are required to control Th1-
mediated inflammation (Koch et al., 2009). In the context of infection, it has been shown 
that Tregs upregulate T-bet expression during Listeria infection, selectively suppress Th1 
cells and comprise a stable population that proliferates rapidly during reinfection (Levine 
et al., 2017). It has been demonstrated that specific intestinal bacteria induce RORγT+ 
Tregs which limits Th17-mediated colitis and ablation of Treg-specific STAT3 induces 
Th17 inflammation (Chaudhry et al., 2009; Sefik et al., 2015). 
The model of selective suppression does not appear to apply to all Th subsets however, 
and it has been reported that GATA3+ Tregs do not selectively target Th2 cells (Ohnmacht 
et al., 2015; Wang et al., 2014). Instead, it has been suggested that GATA3 expression 
by Tregs plays an important role in maintaining FoxP3 expression and retaining a 
suppressive phenotype in the context of inflammation (Wang et al., 2011; Wohlfert et al., 
2011). Here we have shown that despite an early and sustained suppression of Th2 cells 
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in the colon, the proportion of colonic GATA3+ Tregs in the colon remains unchanged (Fig 
4.2B, 4.3B).  
Selective suppression of Th1 cells by T-bet+ Tregs and Th17 cells by RORγT+ Tregs could 
explain the reciprocal dynamics in the colon following STM infection. If the model of 
selective suppression were true, the early increased proportion of T-bet+ Tregs selectively 
targets Th1 cells, while the decreased proportion of RORγT+ Tregs contributes to an 
increased proportion of Th17 cells. During the later stages of infection, a decreased 
proportion of T-bet+ Tregs reduces the suppression of Th1 cells, allowing a Th1 
expansion; and an increased proportion of RORγT+ Tregs selectively suppresses the 
Th17 response. While this model of selective suppression is compatible with the reciprocal 
dynamics we demonstrate, further experiments are required to determine whether 
subpopulations of Tregs are actively shaping the T cell response to STM. 
The selective suppression model raises the question of how targeted suppression of Th 
subsets is mediated. Each ‘effector’ Treg subset have been shown to be suppressive in 
ex vivo suppression assays, and express IL10, TGFβ, CTLA4 (Duhen et al., 2012; Levine 
et al., 2017). However, Tregs expressing T-bet or RORγT have been shown to express 
CXCR3 and CCR6 respectively, which are signature chemokines for Th1 and Th17 cells. 
It is well established that Tregs, like Tconvs, are recruited to target tissues via chemokine 
receptors, and receptor-mediated migration is important for Treg modulation of 
inflammation (Erhardt et al., 2011; Koch et al., 2009; Lim et al., 2006; Villares et al., 2009; 
Yamazaki et al., 2008). This suggests that chemokine receptor-mediated colocalization 
may be an important mechanism that facilitates selective suppression. 
In contrast to previous research describing selective suppression (Koch et al., 2009; 
Levine et al., 2017), chemokine receptor data presented here does not reflect reciprocity 
between Tconvs and Tregs (Fig 4.9). This could be the result of analysing chemokine 
receptors at an effector site, where receptors are rapidly internalised following ligand-
receptor interactions (Moser et al., 2004; Thelen, 2001). Internalisation of receptors would 
explain the low levels of CXCR3 and CCR6 by colonic Tconvs (Fig 4.9C). There might 
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also be technical issues limiting detection of CCR6, which has poor signal separation in 
FACS plots and low levels of expression in the MLN (Fig 4.9A). Staining of CXCR3 in the 
MLN is the most convincing receptor data presented, and this shows that the proportion 
of Tregs expressing CXCR3 increases at least two days before that of Tconvs (Fig 4.9E). 
While not conclusive, this could be interpreted as suggesting that Tregs, upregulating 
CXCR3 before Tconvs in the MLN, may be migrating to the inflamed colon before Tconvs 
and potentially establishing early Th1-targetted suppression. Further work using 
immunofluorescence imaging of STM-infected colonic tissue would help establish whether 
co-localisation is occurring and potentially driving a targeted suppression. 
In summary, a reciprocal dynamic between Tconvs and Tregs during a multi-phase CD4 
T cell response is consistent with the concept that Tregs are selectively suppressing Th 
subsets and shaping Tconv bias. Such a fine-tuned and dynamic control of T cell 
responses by Tregs would be intriguing. But this prospect raises questions about potential 
mechanisms of selective suppression and the ontogeny of these Treg subpopulations. 
4.8.3 Characterisation of Tregs by Helios expression 
It is well established that FoxP3+ Tregs can differentiate in the thymus or be induced extra-
thymically, and I set out to assess whether the populations of Tregs identified following 
STM infection were tTregs or pTregs. Helios has been proposed as a marker of tTregs 
and it is expressed by Tregs in the thymus (Thornton et al., 2010). It has also been 
demonstrated that pTregs can upregulate Helios during activation and in these cells it is 
a marker of increased suppression and stability (Gottschalk et al., 2012; Kim et al., 2015). 
Although Helios is an imperfect marker of tTregs, recent research has shown that Helios 
expression delineates two distinct populations with phenotypic and functional differences, 
including non-overlapping TCR repertoires (Thornton et al., 2019). Furthermore, Helios+ 
and Helios- Tregs have been shown to provide non-redundant immunomodulation, with 
selective depletion of either subset inducing immunopathology (Akimova et al., 2011; 
Elkord et al., 2015; Kim et al., 2015; Sebastian et al., 2016). On the other hand, RORγT 
expression by Tregs has been used as a marker of pTregs, as the differentiation of 
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RORγT+ Tregs is dependent on the presence of microbiota (Ohnmacht et al., 2015; Sefik 
et al., 2015). While Helios and RORγT are imperfect markers of Treg lineage, they can be 
used to compliment other techniques to help decipher the ontogeny and function of Treg 
populations. 
Data presented here show that Tregs can be identified as Helios+RORγT-, Helios-RORγT+, 
Helios-RORγT- or Helios+RORγT+ cells (Fig 4.10A). In the colon, the Helios+RORγT- and 
Helios-RORγT+ cells are the largest populations. In the MLN, the majority of Tregs are 
Helios+RORγT-, followed by Helios-RORγT- cells. Following STM infection, the increased 
proportion of Helios+ Tregs could be interpreted as an increased proportion of tTregs, an 
increase in Treg activation or of both explanations being correct.  
Beyond a binary interpretation of Helios expression, Heliosint populations can be detected, 
and these are gated as separate population in Fig 4.11A. It could be hypothesised that 
Heliosint cells are an activated subpopulation of pTregs that upregulate Helios in response 
to environmental stimuli, as previously reported (Kim et al., Gottschalk et al., 2015). This 
population is gated within the Helios+RORγT+ population (Fig 4.10A), which trends 
towards an increased proportion 6 days p.i., before decreased proportions are observed 
at day 11 p.i (Fig 4.10C). If these are activated Tregs, these data suggest that their 
increase after infection is transient. Further experiments comparing Tregs with differential 
Helios expression could help characterise functional differences if combined with analysis 
of other markers of activation and suppressive potential, like CD25, CTLA4 or PD1. Ex 
vivo assays could also be used to identify differences in suppressive function. Finally. 
lineage tracking tools could be used to ascertain information about differentiation 
pathways of these cells. Together, these experiments could help elucidate the role of 
Helios in Tregs and how its expression contributes to the control of the Tconv response. 
To further assess our data shown here, t-SNE plots were generated to identify CD4 T cell 
populations by multiple parameters and to analyse co-expression of T-bet, RORγT and 
GATA3 with Helios (Fig 4.11). While t-SNEs of FACS data are limited in scope compared 
to those generated from data sets with higher dimensionality, these plots give simple 
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visual representations of multiple overlays. The t-SNE plots demonstrate that in both 
mock- and STM-infected colons: RORγT+ Tregs are mostly Helioslo/int cells, T-bet+ Tregs 
are distributed between Helioslo/int and Helioshi populations, and GATA3 expression is 
mostly confined to Helioshi Tregs (Fig 4.11B, C). While t-SNEs from STM-infected colons 
have larger T-bet+ Treg and Tconv clusters, the distribution of T-bet+ Tregs maintains its 
distribution pattern between Tregs expressing different levels of Helios expression. These 
data show that RORγT+ Tregs are mostly Helioslo/int, while T-bet+ Tregs can be Helioslo/int 
or Helioshi. If Helioshi Tregs are largely tTregs, this analysis suggests that RORγT+ Tregs 
are largely pTregs while T-bet+ Tregs appear to include both pTregs and tTregs. This is 
consistent with previous reports of T-bet expression being expressed in both Helios+ and 
Helios- Tregs in mice and humans (Daniel et al., 2015; Sebastian et al., 2016). This 
analysis does not provide definitive evidence about Treg lineage but contributes to our 
characterisation of the diversity and heterogeneity of the Treg compartment in the colon 
following STM infection. 
4.8.4 Reciprocal dynamics between Tconvs and Tregs in UC 
After characterising a reciprocal dynamic between Tconvs and Tregs during infection, the 
next objective was to determine if a similar reciprocity played a role in UC. Oral infection 
with BRD509-2W1S induces colitis with long-lasting alterations in the Tconvs and Tregs 
in the colon, with similar pathology as UC, which is thought to be driven by altered 
populations of Tconvs and Tregs and a dysregulated balance between them. Like mouse 
Tregs, human Tregs are heterogenous and include effector-like Tregs expressing the 
same TFs and chemokine receptors as Th subsets (Duhen et al., 2012; Miragaia et al., 
2019). Recent research highlighted a connection between mouse models of colitis and 
human disease, by showing that transfer of microbiota from IBD patients into germ-free 
mice induces increased colitis compared to mice that received microbiota from healthy 
donors (Britton et al., 2019). Interestingly, IBD microbiota lead to increased numbers of 
Th17 cells and reduced numbers of RORγT+ Tregs. This is important because it highlights 
another model with reciprocal dynamics between Tconvs and Tregs expressing the same 
‘master’ TF. 
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In Fig 4.12, we assess the proportion of Tconvs or Tregs expressing T-bet and/or RORγT 
in colonic biopsies from patients with active UC or UC in remission. We show that in 
samples from active UC, there is a decrease in the proportion of Tconvs that are T-bet+ 
(Th1), RORγT+ (Th17) or T-bet+RORγT+ (Fig 4.12C). In active UC biopsies the proportion 
of Tregs expressing RORγT is decreased but the proportion of T-bet+ Tregs trends 
towards an increase (Fig 4.13D). These results do not obviously fit with the pattern of 
reciprocal dynamics shown previously in STM-infected mouse colons. While there may 
be a trend towards reciprocity between Tconvs and Tregs expressing T-bet, the decrease 
in Th17 cells is in parallel with the decrease in RORγT+ Tregs. 
The decreased proportion of Th1 and Th17 cells is surprising because active UC 
pathology has been shown to be dependent on CD4 T cells and a commonly held view is 
that disease is at least partially Th17-mediated. (Caprioli et al., 2008; Kobayashi et al., 
2008; Sarra et al., 2010; Zenewicz et al., 2009). The view that Th17 cell drive UC 
pathology is not universal however, and there is a data demonstrating that there is an 
increase of Th2 cells or Th2-associated cytokines in the mucosa during active disease 
(Fuss et al., 1996; Heller et al., 2005; Li et al., 2016; Strober and Fuss, 2011). Indeed, for 
many years, UC was often considered a Th2-mediated disease while Crohn’s disease 
was considered a Th1-mediated. There are data supporting a role of Th17 cells in UC, but 
multiple reports of Th17 cells are based on analysis of PBMCs, while many reports of 
increased Th17-associated cytokines do not identify their cellular sources (Eastaff-Leung 
et al., 2010; Olsen et al., 2011; Sun et al., 2017). Research focus on PBMCs is 
understandable in human disease, where biopsies are difficult to obtain. Focus on 
cytokines instead of T cell phenotype is also understandable since cytokines are tractable 
therapeutic targets. However, a failure to appreciate tissue-dependent variables and cell-
specific dynamics can lead to poor understanding of pathogenesis, which can 
compromise the development of therapeutic targets.  
Our finding that Tconvs in active UC samples have lower proportions of Th1 and Th17 
cells might be explained by an increased proportion of Tconvs expressing GATA3, which 
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we did not assess, or by a decrease in all CD4 Tconvs expressing ‘master’ TFs. A previous 
study analysing active UC biopsies reported a reduction in IL-17A, IFNγ and IL4, but an 
increase in IL-8 (Pearl et al., 2011). Interestingly, the decreased expression of Th1, Th2 
and Th17 cytokines was specific to biopsies of active lesions compared to healthy tissue; 
no change was detected between non-lesioned tissue from active UC patients and healthy 
controls. This raises questions about which cells are driving pathology within UC lesions, 
if there are distinct sources of pathology outwith lesions, and if either is directly Th-
mediated or driven by other cells, such as neutrophils. 
Continued research into the dynamics between colonic Tconvs and Tregs in UC is 
warranted because it has the potential to elucidate the dysregulation reported in IBD. 
Future experiments could be expanded to analyse GATA3 expression to evaluate Th2 
cells, and intracellular cytokine staining could be incorporated to assess the functional 
role of Tconv and Treg subsets. Finally, analysis of more biopsies, including lesioned and 
non-lesioned mucosa from active UC could be compared to biopsies from both UC in 
remission and healthy controls, to elucidate differences between all four groups. This 
would provide a more complete picture of the changes in CD4 T cell populations during 
remission, active disease and in inflamed and uninflamed sites. 
4.8.5 Conclusion 
In this chapter, we have reported a dynamic and site-specific CD4 T cell response to STM 
infection, with complex interplay between heterogenous Treg and Tconv populations. We 
report a reciprocal dynamic between Tconvs and Tregs expressing the same TFs, which 
raises the possibility that this is driven by selective suppression of Th1 cells by T-bet+ 
Tregs and Th17 cells by RORγT+ Tregs. Analysis of cytokine, chemokine receptors and 
Helios added to the characterisation of the Th subsets and Tregs expressing shared TFs. 
Analysis of active and remitted UC biopsies did not fit the same pattern of reciprocity but 
highlighted important questions about the CD4 T cells driving pathology, which could 
inform future work investigating the balance between colonic Tconvs and Tregs during 
inflammation. 
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The reciprocal dynamics following STM infection, although only correlative, could be 
driven by Treg mediated selective suppression. This prospect is intriguing because it 
highlights the potential for Tregs to not only inhibit Tconvs, but to shape the CD4 T cell 
response in a fine-tuned way. To investigate whether Tregs are shaping the dynamic 
Tconv response to STM infection, we designed experiments to manipulate Tregs in vivo 
and assess the impact this has on the overall CD4 T cell response to infection. 
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Chapter 5 Investigating the Potential for Tregs to 
Shape Th Bias 
5.1 Introduction 
The reciprocal dynamics between Tregs and Tconvs during STM infection are consistent 
with the hypothesis that Tregs expressing ‘effector’ TFs selectively target Th subsets to 
skew Th bias. The aim of the following experiments is to determine if manipulating Treg 
populations affects Th bias following infection. Treg depletion and transfer experiments 
were carried out to determine whether Tregs are necessary and sufficient to control the 
dynamic Th bias following STM infection. While Tregs have been shown to selectively 
target Th subsets (Koch et al., 2009; Levine et al., 2017), the potential for Tregs to shape 
a multi-stage and dynamic CD4 T cell response has not been reported. 
To test the hypothesis that Tregs are necessary for the Th bias following STM infection, 
we carried out Treg depletion experiments using FoxP3DTR ‘DEpletion of REGulatory T 
cell’ (DEREG) mice. DEREG mice express a diphtheria toxin receptor (DTR) protein under 
control of a FoxP3 promoter in a BAC (bacterial artificial chromosome) construct, allowing 
selective ablation of FoxP3+ Tregs following treatment with diphtheria toxin (DT) (Kim et 
al., 2007; Lahl et al., 2007). If T-bet+ Tregs are actively suppressing Th1 cells and driving 
the early Th17 response, we would expect Treg depletion early after STM infection to 
increase the Th1 response. On the other hand, if RORγT+ Tregs selectively suppress 
Th17 cells at later time points, we would expect later Treg depletion to increase the Th17 
response and reduce the Th1 bias. 
To test the hypothesis that Tregs are sufficient to drive Th bias, transfer experiments were 
designed where Tregs expressing ‘effector’ TFs would be isolated from infected donors 
and transferred into STM-infected DEREG recipients. If subpopulations of Tregs are 
sufficient to shape Th bias, we would expect transfer of T-bet+ Tregs to drive an increased 
Th17 bias. Similarly, we would expect transferred RORγT+ Tregs to drive an increased 
Th1 bias. Following unexpected results from initial transfer experiments, we conducted in 
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vitro suppression assays to compare the suppressive capacity of Tregs isolated from 
STM-infected and uninfected donors. Together, these experiments highlight the important 
role for Tregs in actively shaping the dynamic Th response to infection. They also raise 
further questions about the function and plasticity of heterogenous Treg populations, their 
differentiation, and their impact on the overall CD4 T cell response to STM. 
5.2 Treg depletion following Salmonella infection 
Treg depletion in DEREG mice is a useful strategy to assess the temporal modulation of 
immune responses by Tregs without inducing systemic autoimmunity or high mortality. An 
advantage of using DEREG mice is an effective and highly specific Treg ablation. A 
disadvantage is DT toxicity, which has been shown to cause pathology independent of 
Treg depletion (Lahl and Sparwasser, 2011; Mayer et al., 2014a). As such, DT treatment 
must be optimised to minimise pathological effects while efficiently ablating Tregs in vivo.  
5.2.1 Optimisation of Treg depletion in DEREG mice 
DT was administered intraperitoneally (IP) on two consecutive days, at a dose of 30ng/g 
mouse weight. This is a lower dose than reported by other groups (Johanns et al., 2010; 
Lahl and Sparwasser, 2011; Mayer et al., 2014a) but did not compromise the depletion of 
Tregs (Fig 5.1). Because of potential DT-mediated effects independent of Treg depletion, 
WT littermates treated with DT were used as controls for these experiments. We planned 
to assess the effect of Treg depletion 4 days post-treatment, so the effect of DT treatment 
on FoxP3+ Tregs was monitored for up to 5 days. Tregs were not detectable in peripheral 
blood mononuclear cells (PBMCs) 24 hrs following treatment, but 5 days post-treatment, 
Tregs had re-emerged and were detected at ~33% of the proportion observed in littermate 
controls (Fig 5.1A). In the colon, 5 days post-treatment, Treg depleted mice had <10% of 
the Tregs as littermate controls (Fig 5.1B). While Tregs repopulate following depletion, the 
depletion is effective and sustained enough that a clear impact is expected. 
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Figure 5.1 DT-mediated Treg depletion in DEREG mice. 
CD4 T cells were identified as live, single, CD3+, Dump (MHCII, B220, CD8)- CD4+ cells. (A) Representative 
plots of CD4 T cells from PBMCs are shown from a WT littermate (left) and DEREG mouse at 1, 3 or 5 days 
following two daily DT treatments. Numbers represent the proportion of cells that are FoxP3+ (B) Plots 
represent the proportion of colon CD4 T cells that are FoxP3+ 5 days after DT treatment. 
5.2.2 Treg depletion 1-2 days p.i. prevents colonic Th17 bias 6 days 
p.i. 
The first depletion experiment was designed to determine if Tregs were necessary to 
enable the early colonic Th17 response at 6 days p.i. (Fig 5.2A). Tregs were depleted in 
DEREG mice by DT treatment at day 1 and 2 p.i. and were culled at day 6 p.i. (Fig 5.2B). 
Both DEREG mice and littermate controls lost ~5% of their initial body weight at day 4 p.i. 
and mean weights in both groups were stabilised by day 6 p.i. (Fig 5.2C). Treg depletion 
had no significant impact on STM CFUs recovered in faeces 6 days p.i., although there 
may be a trend towards decreased bacterial load in DEREG mice compared to littermate 
controls (Fig 5.2D). Treg depletion did not significantly increase the absolute number of 
total colon cells 6 days p.i. (Fig 5.2E), although there was an increased number of colonic 
CD4 T cells (Fig 5.2F) and CD44hi Tconvs (Fig 5.2G). 
Assessing the proportion of colonic Th1 and Th17 cells, DEREG mice have a clear 
increase in the proportion of T-bet+ Th1 cells and a decreased proportion of RORγT+ Th17 
cells 6 days p.i. (Fig 5.3A). This increased Th1 bias correlates with a specific increase in 
the absolute number of colonic Th1 cells, while the number of Th17 cells remains 
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unchanged compared to littermate controls (Fig. 5.3B). These data demonstrate that the 
increased proportion of Th17 cells 6 days p.i. (Fig. 4.2B) is dependent on the presence of 
Tregs, which include a higher proportion of T-bet+ cells at this time point (Fig 4.3B). These 
data support the hypothesis that Tregs are necessary to suppress the early Th1 response 
and shift the Tconv response towards a Th17 bias. 
 
Figure 5.2 Treg ablation at day 1-2 p.i. increases the number of colonic CD4 T cells. 
(A) Time course showing the proportion of colon Tconvs expressing T-bet (blue) or RORγT (pink), with the 
early increased proportion of Th17 cells highlighted at day 6 p.i. (B) Experimental design of Treg depletion 
with an endpoint 6 days p.i. (C) Weight loss in DEREG mice and WT littermates following STM infection DT 
treatments (represented by mustard dashed lines). (D) STM CFU recovered from faeces at day 6 p.i. (E) The 
absolute number of colon cells in DEREG mice and WT littermates are shown, in addition to the number of 
CD4 T cells (F) and CD44hi Tconvs (G). Data points represent individual animals (n=3-4) from one example 
of three independent experiments. Means ± SEM are plotted. Statistical significance calculated by Mann-
Whitney test. ns, not significant; *p<.05. 
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Figure 5.3 Treg ablation day 1-2 p.i. increases the colonic Th1 bias at day 6 p.i. 
The proportion (A) and absolute number (B) of colon Tconvs that are RORγT+ or T-bet+ are shown. Data 
points represent individual animals (n=3-4) from a representative example of three independent experiments. 
Means ± SEM are plotted. Statistical significance calculated by two-way ANOVA with Holm-Šídák test. ns, 
not significant; *p<.05; **p<.01; ***p<.001; ****p<.0001. 
 
5.2.3 Treg depletion at days 6-7 p.i. increases the Th17 response 11 
days p.i. 
The second depletion experiment was conducted to determine if Tregs were necessary 
to enable the Th1 response that becomes more prominent by day 11 p.i. (Fig 5.4A). DT 
was administered at day 6-7 p.i. and mice were culled at day 11 p.i. (Fig 5.4B). As such, 
mice were culled 4 days after completing DT treatment, consistent with the previous 
experiment. Following infection, both DEREG mice and littermate controls lost ~5% of 
their initial body weight in the first 4 days p.i., with mean weights in both groups stabilising 
by day 6 p.i. Following DT treatment, both groups lost weight again, although the amount 
of weight loss was variable (Fig 5.4C). Like the previous experiment, Treg depletion had 
no significant impact on faecal STM CFUs recovered (Fig 5.4D) and did not increase the 
absolute number of total colon cells (Fig 5.4E). There is a trend towards increased 
numbers of colonic CD4 T cells (Fig 5.4F) and CD44hi Tconvs (fig 5.4G), but these are not 
significant. 
Assessing the proportion of Th1 and Th17 cells in the colon 11 days p.i., DEREG mice 
have an increased proportion of RORγT+ Th17 cells while the proportion of T-bet+ Th1 
cells remains unchanged (Fig 5.5A). The increased Th17 bias correlates with an increase 
in the absolute number of both colonic Th1 and Th17 cells compared to littermate controls 
(Fig. 5.5B). These data show that, like the Th17 bias at day 6 p.i., the Th1 bias at day 11 
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days p.i. is dependent on Tregs, which include a higher proportion of RORγT+ cells at this 
time point (Fig 4.3B). This supports the hypothesis that Tregs to suppress colon Th17 
cells and shift the CD4 T cell response towards a Th1 bias. Together, these results show 
that Tregs are required for the early Th17 response, contribute to the later Th1 response, 
and balance the multi-stage and dynamic CD4 T cells to STM infection. Next, we aimed 
to determine whether Tregs expressing specific TFs were sufficient to drive Th bias 
following infection. 
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Figure 5.4 Treg ablation 6-7 days p.i. has less impact on CD4 T cell numbers than at 1-2 day 6 p.i. 
(A) The proportion of colon Tconvs expressing T-bet (blue) or RORγT (pink) are shown, with the initiation of 
a Th1 bias highlighted at 11 days p.i. (B) Experimental design of Treg depletion at 6-7 days p.i., with an 
endpoint 11 days p.i. is shown (C) Weight loss in DEREG mice and WT littermates following STM infection 
and two daily DT treatments (orange dashed lines) are indicated. (D) STM bacteria were recovered from 
faeces at day 11 p.i. (E) The absolute number of colon cells in DEREG mice and WT littermates are shown, 
in addition to the number of CD4 T cells (F) and CD44hi Tconvs (G). Data points represent individual animals 
(n=3-4) from a representative example of three independent experiments. Means ± SEM are plotted. 
Statistical significance calculated by Mann-Whitney test. ns, not significant. 
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Figure 5.5 Treg ablation 6-7 days p.i. increases the colonic Th17 bias at day 11 p.i. 
The proportion (A) and absolute number (B) of colon Tconvs that are RORγT+ or T-bet+ are shown. Data 
points represent individual animals (n=3-4) from one example of three independent experiments. Means ± 
SEM are plotted. Statistical significance calculated by two-way ANOVA with Holm-Šídák test. ns, not 
significant; *p<.05; **p<.01. 
 
5.3 Transfer of Tregs into Salmonella-infected DEREG 
recipients 
To assess the potential for specific Tregs to control the Tconv response to STM we 
designed transfer experiments into DEREG recipients. Tregs from FoxP3RFPxRORgTGFP 
(FoxROR) donors were isolated from peripheral lymph nodes using CD4 negative-
selection beads and FACS. Tregs were then transferred into DEREG recipients following 
DT treatment at day 1-2 p.i. (Fig 5.6). DEREG recipients were used to allow assessment 
of specific Treg populations after ablation of endogenous Tregs. If the hypothesis is 
correct that Tregs expressing specific TFs are sufficient to enable Th bias, we would 
expect transfer of T-bet+ Tregs to selectively suppress Th1 cells and increase the Th17 
bias. On the other hand, we would expect RORγT+ Tregs to selectively suppress Th17 
cells and increase Th1 bias. 
133 
 
Figure 5.6 Experimental design and cell sorting for Treg transfers into DEREG recipients. 
(A) Timelines outlining transfer of lymph node Tregs from STM-infected FoxROR donors into STM-infected 
DEREG recipients. (B) FACS plots show gating of RFP+ Tregs from CD4-enriched lymphocytes (top) and 
purity analysis of sorted cells using the same gates (below). Gating order is left to right, as indicated. 
 
5.3.1 Transfer of total Tregs from STM-infected donors 
Before sorting T-bet+ or RORγT+ Tregs, the first transfer experiment included transfer of 
total RFP+ Tregs. The aim of this initial transfer was to confirm that the dysregulated 
response following Treg depletion (Fig 5.3A,B) would be reduced by replacing ablated 
Tregs with transferred cells. In addition to confirming Treg-mediated regulation, a total 
Treg transfer was intended as a control for transfers of T-bet+ or RORγT+ Tregs. The 
gating strategy for total Tregs, sorted from CD4-enriched lymph node cells are shown with 
analysis of a sorted sample, confirming the purity of transferred cells (Fig 5.6B). Following 
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FACS sorting, 6x105 RFP+ Tregs or PBS only was injected i.v. into Treg-depleted DEREG 
recipients. The number of transferred cells corresponded to the mean number of Tregs 
harvested from each donor’s lymph nodes. Following infection, DT treatment and Treg or 
mock-transfer, recipients were culled at day 6 p.i. and colons and cMLNs were analysed. 
Mice exhibited moderate weight loss following infection and DT treatment, but there was 
no significant difference between mice receiving Tregs or PBS (Fig 5.5A). There was also 
no significant difference in the number of STM CFUs recovered from faeces at day 6 p.i. 
(Fig 5.5B). Differences were clear however, in the number of total cells and CD44hi Tconvs 
between groups. Representative plots of MLN CD4 T cells demonstrate that Treg 
recipients had a higher proportion of CD44hi Tconvs than mock-transfer recipients (Fig 
5.7C). In the colon and cMLN, the number of total cells (Fig 5.7D,F) and CD44hi CD4 T 
cells (Fig 5.7E,G) were increased in Treg recipients. This was a surprising result because 
it indicated that Tregs not only failed to reduce inflammation but increased signs of 
inflammation including higher cell numbers and CD44 expression. In addition to increased 
cell numbers, Treg recipients had an increased number of Th1 cells and increased Th1 
bias cells in the colon (Fig 5.8A). Treg recipients had a decreased proportion of Th17 cells 
in both the colon and cMLN (Fig 5.8A,B). Since Treg depletion was shown to increase the 
colonic Th1 bias at day 6 p.i. (Fig 5.3A,B), Treg transfer in this experiment exacerbated 
the dysregulated Th1 response instead of ameliorating it, as expected. 
This surprising result raised questions about what aspect of the Treg transfer increased 
dysregulation following Treg depletion. One possible explanation is that there is 
something about the Tregs themselves that exacerbated inflammation in DEREG 
recipients. Since the donors were STM infected, it was hypothesised that Tregs from 
infected animals might become inflammatory in a DEREG recipient. Another potential 
factor, although unlikely, is inflammation caused by a graft-versus-host disease (GvHD) 
reaction, independent of the type of cells transferred.  
To determine if Tregs from infected donors were more inflammatory than Tregs from 
uninfected donors, two experiments were planned. The first was another transfer using 
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uninfected donors. In this transfer, CD44lo naïve CD4 T cells were transferred as a non-
Treg control instead of PBS, to rule out potential effects of a GvHD-like response. The 
second experiment was an in vitro suppression assay comparing the suppressive 
potential of Tregs from STM-infected and uninfected donors.  
 
Figure 5.7 Treg transfer increases the numbers and activation of Tconvs 6 days p.i. 
(A) Weight loss following STM infection, DT treatment, and Treg or mock transfer. (B) STM bacteria recovered 
from faeces from Treg or PBS recipients (C) Representative plots of cMLN CD4 T cells that are CD44hi Tconvs 
from PBS (left) and Treg recipients (right). The number of total colonic cells (D) and CD44hi Tconvs (E) are 
shown for PBS and Treg recipients. The number of total cMLN cells (F) and CD44hi Tconvs (G) are also 
shown. Data points represent mean weights/group (A) or individual animals (D-G) (n=3). Means ± SEM are 
plotted. Statistical significance calculated by Mann-Whitney test (B) and Student’s t test (D-G). ns, not 
significant; *p<.05; **p<.01. 
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Figure 5.8 Treg transfer into DEREG recipients increases the Th1 response 6 days p.i. 
(A) Plots show the proportion (left) and absolute number (right) of colon CD4 T cells that are RORγT+ or T-
bet+, in Treg or PBS recipients at 6 days p.i. (B) The proportion and absolute number of cMLN CD4 T cells 
expressing RORγT or T-bet are also shown. Data points represent individual animals (n=3). Means ± SEM 
are plotted. Statistical significance for each TF calculated by two-way ANOVA with Holm-Šídák test. ns, not 
significant; *p<.05; **p<.01; ***p<.001. 
 
5.3.2 Transfer of total Tregs from uninfected donors 
Gating of Tregs and Tconvs isolated from uninfected FoxROR donors are shown, with 
analysis of sorted RFP+ Tregs and CD44lo Tconvs displayed to confirm sort purity (Fig 
5.9A). Following FACS sorting, 3x105 RFP+ Tregs or CD44lo Tconvs were transferred into 
DEREG recipients. This number corresponds to the mean number of Tregs harvested 
from each donor’s lymph nodes. Following infection, DT treatment and cell transfer, 
recipients were culled 6 days p.i. and colons and cMLN were analysed. 
In Fig 5.9B, weight change is shown for Treg or Tconv recipients in this experiment 
(hereby referred to as transfer B) and are overlaid with recipients of PBS or Tregs from 
STM-infected donors. Like recipients in the first transfer (hereby referred to as transfer A). 
Tconv recipients lost ~5% of initial weight. On the other hand, recipients of Tregs from 
uninfected donors recovered more weight than other groups and were significantly heavier 
than recipients of Tregs from infected animals or Tconv 6 days p.i., (Fig 5.9B). In contrast 
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to the increased number of total cells and CD44hi Tconvs in STM Treg recipients observed 
in transfer A, Treg recipients in transfer B had similar cell numbers to Tconv recipients 
(Fig 5.9D-F), with a reduced number of CD44hi Tconvs in the cMLN (Fig 5.9G). In transfer 
B, there was little change in the proportion of Tconvs expressing T-bet or RORγT (Fig 
5.10A,B). Treg recipients had a lower number of RORgT+ Tconvs in the cMLN than Tconv 
recipients, but no other changes were significant (Fig 5.10). As such, transfer of Tregs 
from uninfected donors did not skew the Th bias compared to Tconv recipients. 
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Figure 5.9 Recipients of Tregs from uninfected donors show signs associated with reduced 
inflammation compared to Tconv recipients. 
(A) FACS plots show gates used to sort Tregs and CD44lo Tconvs from lymph nodes of uninfected donors 
(left). Plots show purity of sorted CD44lo Tconvs (centre) and Tregs (right). (B) Weight change following STM 
infection, DT treatment, and cell transfer. (C) STM bacteria recovered from faeces from recipients of Tconvs 
(green) or Tregs (orange). The number of total colonic cells (D) and CD44hi Tconvs (E) are shown for 
recipients of Tconvs (green), Tregs (orange), and PBS (blue) and Tregs from infected donors (red), as shown 
previously (Fig 5.5). The number of total cMLN cells (F) and CD44hi Tconvs (G) are also shown. Data points 
represent mean weights/group (A) or individual animals (D-G) (n=3-4). Means ± SEM are plotted. Statistical 
significance calculated by Mann-Whitney (B) and Student’s t test (D-G) pairwise, within experiments. ns, not 
significant; *p<.05; **p<.01; ****p<.0001. 
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Figure 5.10 Treg transfer does not alter the colonic Th bias compared to recipients of Tconvs. 
(A) Plots show the proportion (left) and absolute number (right) of colon CD4 T cells that are RORγT+ or T-
bet+, in recipients of Tconvs (green) or Tregs (orange) at 6 days p.i. (B) The proportion and absolute number 
of cMLN CD4 T cells expressing RORγT or T-bet are also shown. Data points represent individual animals 
(n=3-4). Means ± SEM are plotted. Statistical significance for each TF calculated by two-way ANOVA with 
Holm-Šídák test. ns, not significant; *p<.05. 
The subdued modulation of the Tconv response in transfer B, and indeed the increased 
signs of inflammation observed in transfer A, raises questions about the fate of transferred 
cells. In both transfers, no RFP+ cells could be detected in recipients (Fig 5.11). Possible 
explanations for a lack of detectable RFP+ cells include transferred cells being retained in 
unassessed tissues like the spleen, a failure of transferred cells to survive, or 
downregulation of RFP post-transfer. This highlights that viability and plasticity of Tregs 
post-transfer are potentially important factors. 
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Figure 5.11 RFP+ CD4 T cells are not detected following transfer. 
Representative plots of unfixed colonic CD4 T cells from two transfer experiments including recipients of PBS, 
Tregs from infected donors, Tconvs from uninfected donors and Tregs from uninfected donors (left to right). 
Although these Treg transfer experiments failed to regulate Treg depletion-mediated 
dysregulation, they identify a potentially important distinction between the phenotype and 
function of Tregs from uninfected or STM-infected donors. Potential mechanisms that 
could underlie a disparity include differences in suppressive function or commitment to a 
regulatory phenotype. To investigate the difference between Tregs in these transfers, 
suppression assays were carried out to compare the suppressive potential of Tregs from 
STM-infected and uninfected mice. 
5.4 Suppression assay with Tregs from infected and 
uninfected animals 
Following adoptive transfers, in vitro assays were conducted to compare the suppressive 
potential of Tregs from infected and uninfected animals. Briefly, Tconvs from STM-
infected mice were FACS sorted and stained with cell trace violet (CTV) proliferation dye. 
These cells were used as responder T cells (Tresp) and were cultured with FACS sorted 
RFP+ Tregs from STM-infected or uninfected mice. Different Treg:Tresp ratios were        
co-cultured, including 1:2, 1:4 and 1:8. Purified splenic DCs and αCD3ε antibodies were 
added to provide co-stimulation and TCR stimulation, respectively. After 84 hrs, cells were 
harvested and Tresp proliferation was determined by CTV signal, as a readout for Treg-
mediated suppression. 
CTV signal in Tresps after culture is shown as a representative pseudocolour dot plot and 
histogram (Fig 5.12A). Histogram peaks identify decreasing CTV levels (from right to left), 
corresponding to successive generations of Tresp proliferation (Fig 5.12A, left, centre left). 
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A sample cultured without Tregs is shown as a positive control and appears as a single 
CTVlo peak, demonstrating most Tresps have proliferated through at least 7 generations 
(Fig 5.12A, centre right). A sample cultured without CD3ε shows cells appearing as a 
single CTVhi peak, demonstrating cells have not proliferated, as expected without TCR 
stimulation (Fig 5.12A, right).  
Representative histograms from cultures with Tregs from infected and uninfected mice 
are shown in Fig 5.12B. In these plots, CD44hi Tconvs (green), CD44lo Tconvs (blue) and 
FoxP3+ Tregs (red) are overlaid. In plots from cultures with a 1:2 Treg:Tresp ratio, a peak 
of CTVhi unproliferated cells are mostly CD44lo, and a peak of CTV  ̄cells contains both 
Tregs and CD44hi Tconvs. Between these peaks, 7 peaks of proliferated CTV+ cells can 
be identified as distinct generations and are mostly CD44hi Tconvs (Fig 5.12, top). At lower 
Treg:Tconv ratios, the effect of Tregs is reduced and successive generations are no 
longer distinguishable. Assays with 1:8 ratios are indistinguishable from 1:0 negative 
controls (Fig 5.12B, bottom; Fig 5.12A, centre right).  
Comparison of Tresp proliferation indicators such as proportions of unproliferated cells, 
CTV  ̄ cells or subgroups of different Tresp generations, showed no difference between 
assays with Tregs from infected or uninfected mice (Fig 5.13A). A detailed comparison 
was then made between assays using five indicators generated by formulae based on 
CTV proliferation data (Fig 5.13B). Values were plotted and there was no significant 
difference between groups using any of these statistics applied to 1:2 and 1:4 ratios.  
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Figure 5.12 Tregs from infected and uninfected donors suppress responder T cells in vitro. 
(A) Representative plots of cell trace violet (CTV) staining of CD4 T cells are displayed as a pseudocolour 
plot or histogram following an 84 hr suppression assay. Plots on the right show proliferation in cultures without 
Tregs or without CD3ε. (B) Representative histograms depict CTV staining in CD44hi Tconvs (green), CD44lo 
Tconvs (blue) and FoxP3+ Tregs (red) following culture of responder T cells (Tresps) with serial dilutions of 
Tregs from donors that were uninfected or STM-infected. Treg:Tresp ratios depicted are 1:2, 1:4 and 1:8. 
Although Tregs from infected and uninfected donors have undistinguishable suppressive 
potential in these assays, samples were further analysed to assess potential differences 
between groups. Tconv and Treg expression of T-bet and RORγT were compared 
between groups to determine if Tregs expressed different TFs following culture and 
whether these Tregs skew the Th bias of Tconvs in vitro. Following culture however, both 
FoxP3- Tconvs and FoxP3+ Tregs were predominantly T-bet+RORγT+, with no detectable 
difference between assay conditions (Fig 5.13C). 
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Figure 5.13 Tregs from STM-infected and uninfected mice are similarly suppressive and do not alter 
T-bet or RORγT expression in Tconvs in vitro. 
(A) Representative histograms of CD4 T cells show gates applied between peaks and identifying un-
proliferated (generation 0) cells, two groups of proliferated cells, and CTV- cells. (B) Five formulae were used 
to calculate proliferation values for cultures with two proportions of Tregs from uninfected (blue) and STM-
infected donors (red). (C) Representative plots show CD4 T cells following suppression assays with 1:2 
Treg:Tresp ratio with Tregs from uninfected (top) and STM-infected donors (bottom). Tconvs (green) and 
Tregs (red) are stained for T-bet and RORγT. 
The final comparison between assays addressed the hypothesis that Tregs from STM-
infected donors are more prone to become pro-inflammatory following transfer. Since 
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Tregs were not CTV stained, any Tregs would be present in the CTV ̄ population. The 
proportion of CTV  ̄cells expressing RFP or FoxP3 were therefore compared to determine 
if Tregs from infected mice might be more likely to downregulate FoxP3 (Fig 5.14). 
Representative CTV histograms with RFP- cells (blue) and RFP+ cells (red) show that 
cultures with Tregs from infected mice have a lower proportion of CTV  ̄cells that are RFP+ 
(Fig 5.14A). When graphed, CTV  ̄cells from cultures with Tregs from STM-infected mice 
have a lower proportion of RFP+ cells at 1:2 and 1:4 ratios (Fig 5.14B, left). These cultures 
also have a lower proportion of FoxP3+ cells at 1:4 ratios and trend towards lower 
proportions of FoxP3+ cells at 1:2 and 1:8 ratios (Fig 5.14B, right). 
 
Figure 5.14 A higher proportion of CTV ̄ cells are RFP  ̄ in assays with Tregs from infected donors. 
(A) Representative histograms show CTV+ and CTV- CD4 T cells, with RFP+ (red) and RFP- (blue) populations 
overlaid. The proportion of CTV ̄ cells that are RFP+ or RFP  ̄are indicated in red and blue text, respectively. 
(B) The proportion of CTV ̄ cells that express FoxP3 (left) and RFP (right) are plotted from cultures with Tregs 
from STM-infected (red) and uninfected donors (orange). Data points represent individual animals (n=4) 
Means ± SEM are plotted. Statistical significance calculated for each group by two-way ANOVA with Holm-
Šídák test ns, not significant; *p<.05; **p<.01; ***p<.001; ****p<.0001. 
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These results are consistent with the hypothesis that Tregs from infected mice are more 
prone to downregulate RFP and FoxP3 expression, which suggests that they have a less 
stable regulatory phenotype. Although this difference did not result in a detectable 
difference in Tresp proliferation in vitro, increased instability in Tregs from infected mice 
might plausibly contribute to increased inflammation observed in recipients of Tregs from 
infected donors. 
Together, experiments in this chapter demonstrate that Tregs play an important role in 
shaping the CD4 T cell response and further highlight complexities in their heterogeneity, 
ontogeny, function and plasticity. Treg depletion experiments show that Tregs are 
required for the early colonic Th17 and contribute to the later Th1 responses to STM. Treg 
transfer experiments, designed to determine if subpopulations of Treg are sufficient to 
drive Th bias, were side-tracked when initial experiments revealed that Tregs from 
infected donors increased inflammation in DEREG recipients. Another transfer 
experiment showed that Tregs transferred from uninfected donors did not increase 
inflammation, and in vitro suppression assays demonstrated that Tregs from infected 
donors are potentially less stable and more likely to downregulate RFP and FoxP3. In 
summary, these results show that Tregs not only inhibit Tconvs, but play an important role 
in shaping Th bias, and in some situations can increase inflammation. This raises further 
questions about the complex role of Tregs in controlling the Tconv response to infection. 
5.5 Discussion 
In the previous chapter, a dynamic and multi-stage CD4 T cell response to STM was 
characterised and a reciprocity between Tconvs and Tregs was identified. Here we sought 
to determine if the dynamic Th response was controlled by Tregs expressing the same 
TFs, which would explain their reciprocity and support the hypothesis that Tregs 
expressing effector TFs are selectively suppressing Th subsets. 
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5.5.1 Treg depletion 
The aim of these Treg depletion experiments was to determine if Tregs were necessary 
to shape the Tconv bias following STM infection. The use of DEREG mice has advantages 
and disadvantages compared to other depletion techniques. Treg depletion using in vivo 
αCD25 treatment depletes a lower proportion of Tregs and is less specific because it also 
depletes a population of CD25hi Tconvs (Seddiki et al., 2006). αCD25 treatment depletes 
~70% of FoxP3+ Tregs but leaves a population of FoxP3+CD25lo Tregs intact (Setiady et 
al., 2010). On the other hand, DT treatment of DEREG mice targets all FoxP3+ cells with 
>95% FoxP3+ Tregs depleted 24 hrs post-treatment (Lahl et al., 2007; Mayer et al., 
2014a). This depletion is transient however, with Tregs re-emerging within days of DT 
treatment (Berod et al., 2014; Lahl and Sparwasser, 2011; Nyström et al., 2014). While 
depletion is transient, this model allows time-sensitive characterisation of Treg effects 
without causing systemic autoimmunity seen in sustained Treg ablation. 
In the previous chapter, day 6 p.i. was identified as a peak of the early Th17 response 
and day 11 p.i. was identified as a timepoint where a Th1 bias was re-established (Fig 
4.4B,C). Treg depletion experiments were designed to assess whether Tregs are required 
to control Th bias at these timepoints. Treg depletion in DEREG mice is most complete 
24 hrs after DT treatment but the proportion of colon CD4 T cells that are FoxP3+ remains 
~90% below levels seen in littermate controls 5 days post-treatment (Fig 5.1). In the first 
DEREG experiment, DT was administered at days 1 and 2 p.i. and mice were culled at 
day 6 p.i. This time course meant that Tregs were at least partially depleted from day 1 
p.i. until the terminal endpoint, with the greatest depletion at day 2-4 p.i. As such, day 6 
p.i. was not the timepoint with highest rate of Treg depletion but these experiments were 
designed to maximise the effect of depletion on the Tconv response at 6 days p.i.  
In the second Treg depletion experiment, DT was administered at day 6 and 7 p.i., and 
mice were culled at 11 days p.i. These timings were selected because they maintained a 
5 day period between the first DT treatment and experimental endpoint, as used with the 
first DEREG experiment. It also allowed a focused assessment of the effect of Tregs on 
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the Tconv response from day 6 to 11 p.i., without effecting the Tconv response before day 
6 p.i.  
Treg depletion at day 1 and 2 p.i. caused increased numbers and activation of colonic 
CD4 T cells (Fig 5.2F,G), consistent with previous reports (Boehm et al., 2012; Kim et al., 
2009, 2007; Lahl and Sparwasser, 2011; Nyström et al., 2014). Treg depletion did not 
significantly reduce the number of STM CFUs recovered from faeces however (Fig 5.2D), 
in contrast to a previous report of reduced bacterial load in STM-infected DEREG animals 
(Johanns et al., 2010). This previous report is consistent with the hypothesis that Tregs 
are restraining Tconvs and inhibiting bacterial clearance. This experiment measured 
bacterial load in systemic tissues with a systemic model of infection however, so this 
cannot be considered a direct comparison. Further DEREG experiments measuring STM 
CFUs in intestinal LP or MLNs might elucidate whether Treg depletion reduces bacterial 
burden in this model. 
In the second DEREG experiment, Treg depletion 6-7 days p.i. had no impact on faecal 
STM recovery and there was no significant increase in the number of CD4 T cells 11 days 
p.i., although there was a trend towards an increase in total CD4 T cells and CD44hi 
Tconvs (Fig 5.4D-G). The reduced impact on cell numbers at this later time point suggests 
that Tregs play a less important role in constraining the number of CD4 T cells at this 
phase of infection. One explanation is that by 6 days p.i., Tconvs have already reached 
near-maximum capacity for expansion and activation. Another explanation which is not 
incompatible with the first, is that Tregs become less suppressive at later stages of 
infection, as previously reported (Johanns et al., 2010). As stated, this report is based on 
a different model, but it is consistent with our findings that later Treg depletion has less 
impact on the number of colonic CD4 T cells. While there are unanswered questions about 
the effect of Treg depletion on bacterial load and number of CD4 T cells, the main aim of 
these experiments was to assess the impact of Treg depletion on Th bias in the colon, 
where the reciprocal dynamic had been demonstrated. 
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Assessing TF expression by colonic Tconvs shows that early Treg depletion drives a 
selective expansion of Th1 cells and prevents the Th17 bias normally seen at day 6 p.i. 
(Fig 5.3). Treg depletion at day 6-7 p.i. drives an increase in the number of Th1 and Th17 
cells, but selectively increases the proportion of Th17 cells (Fig 5.5A,B). At both 
timepoints, Treg depletion disrupts the balance between Th1 and Th17 cells. These 
results demonstrate that Tregs play an important role in shaping both the early Th17 
response and later Th1 following STM infection. This indicates that the reciprocal 
dynamics described earlier are not just correlative, but that the dynamic Tconv response 
requires Tregs. These results are consistent with the hypothesis that Th bias is shaped 
by selective suppression by sub-populations of Tregs. Further experiments are warranted 
to confirm the hypothesis that Tregs drive Th bias by selective suppression. 
One way to address this hypothesis is using Tbx21RFP-creFoxP3fl mice to selectively 
deplete T-bet+ Tregs, as described by Levine et al. (2017). RorccreFoxP3fl could also be 
generated to assess the role of targeted depletion of RORγT+ Tregs. This would allow us 
to determine the effect of manipulating specific Treg populations instead of depleting all 
Tregs at timepoints known to have a higher proportion of T-bet+ or RORγT+ cells. Another 
approach to assess the role of specific Treg populations is to adoptively transfer purified 
subpopulations of Tregs into STM-infected recipients. 
5.5.2 Treg transfers experiments  
Having demonstrated that Tregs are necessary for controlling the dynamic Th response 
following STM infection, our next aim was to determine if Tregs are sufficient to enable 
Tconv polarisation. To answer this question, adoptive transfer experiments were designed 
so that populations of Tregs that are T-bet+ or RORγT+ could be transferred into DEREG 
recipients. If the hypothesis is correct that Tregs can drive Th polarisation by selectively 
suppressing Th subsets, we would expect transfer of T-bet+ Tregs to suppress Th1 cells 
and enable a Th17 bias. On the other hand, we would expect RORγT+ Tregs to selectively 
suppress Th17 cells and enable a Th1 bias. 
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Treg transfers have been used widely and were an important technique for the early 
characterisation of Tregs and their potential to modulate inflammation (Maloy et al., 2003; 
Uhlig et al., 2006). Treg-depleted DEREG recipients are replete of all lymphocytes except 
FoxP3+ Tregs. As such, the effects of transferred cells will not be diluted by an 
endogenous Treg population and the immune status of recipients is more physiologically 
relevant than Rag-/- mice, frequently used for Treg transfers. These experiments were 
designed to correspond with the day 6 Treg-depletion experiment carried out previously. 
The transfers initially planned involved sorting subpopulations of Tregs from 
FoxP3RFPRORγTGFP donors: GFP+RFP+ cells would identify RORγT+ Tregs and 
CXCR3+GFP-RFP+ cells would be used as surrogates for T-bet+ Tregs, as described 
previously (Levine et al., 2017).  
Tregs were isolated from donor lymph nodes (LN) instead of colonic mucosa because LN 
Tregs can be processed without tissue digest, reducing processing time and increasing 
viability. Even viable colonic Tregs undergo significant stress during digest, which has 
unknown functional effects. Furthermore, colonic Tregs have been shown to express low 
levels of CXCR3, so it would be challenging to use this receptor as a surrogate for T-bet 
in this tissue (Fig 4.9C). Even if T-bet+ cells could be sorted, for example from T-bet-FoxP3 
reporters, it is not clear colonic Tregs would effectively upregulate CXCR3 following 
transfer. 
Tregs were sorted from infected donors for two reasons: First, because they would be 
more phenotypically similar to Tregs depleted from infected recipients and potentially 
more likely to restore a regulation following Treg depletion. TF expression, cytokine 
production and Helios expression have all been shown to change following infection. 
Antigen specificity of Tregs that expand following infection might also be altered compared 
to mock-infected mice. Second, the number of Tregs expressing T-bet and CXCR3 
increase following infection and it would require fewer donors to isolate enough T-
bet/CXCR3+ Tregs to transfer. STM-infected DEREG recipients were DT treated and 
Tregs were transferred at day 2 p.i., 4 days before recipients were culled (Fig 5.6A). 
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Transferred Tregs were not susceptible to DT-mediated deletion because they were not 
from DEREG donors.  
The initial transfer of total RFP+ Tregs was conducted to confirm that transferred Tregs 
would restore a more regulated Tconv response, as in Treg-replete WT littermates (Fig 
5.3). The unexpected increase in the number of CD4 T cells and CD44hi Tconvs, in 
addition to the increased Th1 response, suggested that Treg transfer was exacerbating 
inflammation rather than controlling it. While unexpected, Tregs have previously been 
reported to drive inflammation following transfer.  
Duarte et al. (2009) reported that 50% of Tregs transferred into Rag2-/- mice lost FoxP3 
expression and could drive pathology in recipients. They also reported that IL-2 could 
prevent FoxP3 downregulation. Tregs with transient FoxP3 expression have been 
identified in several models, where they have been reported to become ‘ex-Tregs’ 
following transfer, producing inflammatory cytokines and inducing inflammatory disease 
(Oldenhove et al., 2009; Tosiek et al., 2016; Tsuji et al., 2009; Zhou et al., 2009). Despite 
this potential for plasticity and a pro-inflammatory phenotype, many Treg transfers have 
been shown to reduce Tconv-mediated inflammation, including several using DEREG 
recipients (van der Veeken et al., 2016; Yu et al., 2018). Some reports have shown that 
the proportion of Tregs that downregulate FoxP3 increase in inflammatory conditions 
(Yang et al., 2008; Zhou et al., 2009). These studies and results from our initial transfer 
support the idea that Tregs from STM-infected hosts may have an unstable regulatory 
phenotype and therefore could drive inflammation following transfer. To test the 
hypothesis that Tregs from infected donors induce more inflammation in recipients than 
Tregs from uninfected donors, we carried out transfer B. 
Transfer B differed from transfer A in three ways: first, Tregs were purified from uninfected 
donors; second, the number of Tregs transferred was 3x105, half the number transferred 
in transfer A; and third, a matched number of CD44lo Tconvs were transferred as a non-
Treg control instead of PBS. Tregs from uninfected mice were used to indicate whether 
the inflammation induced by transfer A was dependent on donors having been infected. 
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The reduced number of Tregs used in transfer B was a result of a reduced number of 
Tregs present in uninfected FoxROR donors. As such, the number of Tregs transferred in 
both experiments was approximately the same number as were harvested from donor 
LNs. CD44lo Tconvs were used as controls instead of PBS to compensate for any non-
Treg specific effects of transferred cells. Although both FoxROR and DEREG strains are 
engineered on C57BL/6 backgrounds, we wanted to exclude the potential that a GvHD-
type response was causing inflammation. 
Transfer B demonstrated that recipients of Tregs from uninfected donors lost less weight 
than recipients of Tconvs (Fig 5.9B) and had a decreased number of CD44hi Tconvs in 
the cMLNs (Fig 5.9D-G). Despite these signs that Treg recipients may have had less 
inflammation, there was no significant difference in Th bias between the two groups (Fig 
5.10A,B). These results indicate that Tregs from uninfected donors did not increase 
inflammation compared to Tconvs and may cause a moderate reduction of inflammation 
as measured by weight change and the number of CD44hi cMLNs. Treg transfer did not 
recover the Th balance towards the balance characterised in Treg-replete mice (Fig 5.3, 
Fig 5.10). 
Together, results from transfer A and B suggest that Tregs from infected donors induce 
greater inflammation than Tregs from uninfected donors. These data do not definitively 
support this hypothesis however, since different controls were used, and the number of 
cells transferred was inconsistent between experiments. Despite these issues, data show 
that Tregs from infected donors induce increased inflammation compared to PBS controls 
and recipients of Tregs from uninfected donors show signs of reduced inflammation 
compared to Tconv recipients. Experimental repeats with consistent numbers of 
transferred cells and inclusion of PBS and Tconv controls would help clarify these results. 
In light of previous research showing FoxP3+ Tregs can become inflammatory ‘ex-Tregs’ 
(Bhela et al., 2017; Tosiek et al., 2016), these results raise questions about the fate of 
transferred RFP+ Tregs. It is unknown if transferred cells maintain a FoxP3 expression 
because no RFP+ cells were detectable in Treg recipients from either transfer (Fig 5.11). 
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Possible explanations for the lack of RFP+ cells include poor viability, retention of 
transferred cells in other tissues, or down-regulation of RFP, which is faithfully co-
expressed with FoxP3 in donor mice (Wan and Flavell, 2005). Future experiments could 
utilise methods to facilitate tracking transferred Tregs, such as crossing FoxROR donors 
with a CD45.1 strain, labelling purified cells with dyes such as cell trace violet (CTV), or 
using other fate tracking models. These strategies would allow identification of transferred 
cells independently of FoxP3 expression and would facilitate an assessment of other 
phenotypic changes in transferred cells, including stability of FoxP3 expression or 
upregulation of inflammatory markers.  
Once the fate of the transferred cells is characterised, transfer experiments could be 
optimised by adjusting the timing of transfers and depletions, and the number of cells 
transferred to try to recover a regulated response. After optimisation, other adaptations 
could be made, including assessing the impact of transfers at different timepoint following 
infection and with different Treg populations. The use of more specific Treg depletion 
models could also be employed to allow a more focused assessment of Treg 
subpopulations and their potential to shape the Tconv response to STM. For example, 
Tregs expressing T-bet or RORγT could be transferred into Tbx21RFP-creFoxP3fl or 
RorccreFoxP3fl recipients that have been selectively depleted of either T-bet+ or RORγT+ 
Tregs. 
While there are many ways to develop Treg transfer models to assess the potential for 
Tregs to shape the Tconv response, our next aim was to assess why Tregs from 
uninfected or infected donors appeared to have different effects in recipients. One 
hypothesis for this difference is that Tregs from infected donors are impaired in their 
suppressive potential. Another hypothesis is that Tregs from infected animals are less 
committed to a regulatory phenotype and are more prone to downregulate FoxP3 and 
become pro-inflammatory. To test these hypotheses, a suppression assay was conducted 
to compare their suppressive potential and plasticity in vitro. 
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5.5.3 Suppression assays 
Suppression assays, that measure the potential for Tregs to suppress proliferation of 
responder T cells (Tresps), have been used extensively to characterise in vitro Treg 
suppression (Earle et al., 2005; Gerriets et al., 2016; Miyara and Sakaguchi, 2007; Vu et 
al., 2007). Here we used suppression assays to evaluate the potential for Tregs from 
infected or uninfected donors to suppress Tresps with some of the variables inherent in 
adoptive transfer models removed. Assays were carried out as previously reported 
(Collison and Vignali, 2011), but with two adaptations. First, DCs were added to cultures 
to provide co-stimulation instead of αCD28 antibody. DCs were used so assays would 
incorporate effects of co-inhibitory molecules known to interact with DCs, including CTLA-
4 and LAG3. This is a potentially important aspect of Treg suppression in vivo, since 
reduced CTLA-4 expression has been associated with reduced Treg suppressive potency 
following STM infection (Johanns, 2010). Second, CTV was used as a proliferation dye 
instead of CFSE because it has improved resolution of peaks, allows tracking of more 
generations, and is less toxic (Quah and Parish, 2012). 
These assays successfully identified up to 8 generations of proliferation, although there 
was no detectable difference in Tresp proliferation between cultures with Tregs from 
infected or uninfected animals (Fig 5.13). Proliferation profiles were compared between 
groups based on statistics generated by formulae assessing the fraction of cells divided, 
the probability that cells have divided, the fold-expansion of cells during culture and the 
average number of divisions (Fig 5.13B). Besides proliferation, there was no difference in 
the expression of T-bet or RORγT by Tconvs or Tregs following co-culture: 80% of Tregs 
and Tconvs were T-bet+RORγT+ (Fig 5.13C). This highlights the profound effect of culture 
conditions on the TF profile of these cells, since there is a higher proportion of T-bet+ and 
T-bet+RORγT+ Tregs in STM-infected animals in vivo (Fig 4.3B). As such, any difference 
in TF profile (known) or potential suppression (unknown) between Tregs from infected and 
uninfected animals is lost during co-culture. 
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Despite similar Tresp suppression, a lower proportion of CTV  ̄cells were RFP+ or FoxP3+ 
in cultures with Tregs from infected mice (Fig 5.14). One interpretation of these data is 
that Tregs from infected mice are more likely to downregulate FoxP3, which is consistent 
with the hypothesis that Tregs from infected donors are more likely to become pro-
inflammatory. 
One caveat with this interpretation is it overlooks the possibility that Tresps have 
proliferated beyond the limit of CTV detection, and could be another source of RFP ̄   cells 
in the CTV  ̄ peak. Representative histograms indicate a gap between the 7th-8th 
generation Tresp peak and the CTV  ̄ peak, although it is impossible to rule out the 
presence of some highly proliferated Tresps within these cells (Fig 5.13A). In future 
experiments, verification of the source of CTV  ̄cells could be achieved by using CD45.1 
Treg donors or staining Tregs with another dye, such as CFSE or Cell Trace Orange, 
which can be distinguished from CTV staining. Another improvement to this protocol 
would be a reduction in CD3ε concentrations or a shorter assay timecourse. Besides 
reducing the potential contamination of CTV  ̄populations with highly proliferated Tresps, 
this would reduce the number of proliferative generations and allow comparison of Tregs 
at lower Treg:Tresp ratios. 
Despite these limitations, the differences between CTV  ̄populations indicate that Tregs 
from infected mice might be more prone to downregulate FoxP3/RFP. Although this 
increased plasticity could play a role in vivo, these differences have not impacted the 
Tresp proliferation in vitro. These assays obfuscate many in vivo dynamics however, 
including differences in TF expression and the potential role of selective suppression by 
co-localisation. Indeed, the aspect of site-specific regulation is not incorporated in these 
models. As such, these results may reveal as much about the assay limitations as they 
do about in vivo dynamics. 
In summary, this suppression assay shows there is no inherent, context-independent 
difference in suppressive potential between Tregs from infected and uninfected animals. 
Cultures with Tregs from infected mice have a lower proportion of CTV  ̄cells that are RFP+ 
155 
or FoxP3+ however, which is consistent with higher plasticity and less commitment to a 
regulatory phenotype. Although further repeats are required, these results support the 
hypothesis that Tregs from infected mice drive inflammation by downregulating FoxP3 
and becoming pro-inflammatory ‘ex-Tregs’. This could explain the increased inflammation 
in transfer A that did not occur in transfer B. 
5.5.4 Conclusion 
The primary aims of experiments in this chapter were to determine if Tregs were 
necessary and sufficient to shape the dynamic CD4 T cell response to STM. These aims 
followed from our earlier characterisation of a reciprocal dynamic between Tregs and 
Tconvs expressing the same TFs. Treg depletion experiments demonstrated that Tregs 
are required for the early Th17 and later Th1 phases of the Tconv response. Because an 
increased proportion of Tregs are T-bet+ 6 days p.i. and RORγT+ 11 days p.i. (Fig 4.4), 
these results are consistent with the hypothesis that selective suppression shapes the Th 
bias following infection.  
Next, adoptive transfers were planned to determine if Tregs expressing T-bet or RORγT 
were sufficient to skew Th polarisation towards a Th17 or Th1 bias, respectively. 
Unexpectedly, initial transfers suggested that total Tregs from infected donors may 
increase inflammation and Tconv dysregulation, while Tregs from uninfected mice did not 
have this effect (Fig 5.7-5.10). While further experiments are needed to track the fate of 
transferred cells, Treg transfers and suppression assays support the hypothesis that 
Tregs from STM-infected animals are highly plastic and could become pro-inflammatory 
in vivo. 
In addition to selective suppression, the potential for CD4 T cells to up- or downregulate 
FoxP3 expression is an alternative explanation for the reciprocity between populations of 
Tconvs and Tregs expressing the same TFs. This plasticity could be another factor that 
influences the dynamic CD4 T cell response to STM. Indeed, the ideas of selective 
suppression and Treg plasticity are not mutually exclusive; both processes could 
contribute to the T cell response to STM. 
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In summary, this work reveals an essential role for Tregs to shape the CD4 T cell response 
to STM. Results presented here highlight a role for Tregs to not only inhibit the Tconv 
response, but direct Th bias in a site-specific and time-dependent manner. These results 
also highlight unanswered questions. We have characterised a reciprocity between Tregs 
and Tconvs and demonstrated that Tregs are required for the dynamic Th bias; but we 
have not revealed direct evidence of selective suppression or other mechanisms for Treg 
control of Th bias. Although we have shown data supporting Treg plasticity, we have not 
demonstrated that Tregs downregulate FoxP3 during the natural course of STM infection.  
Further studies are warranted to elucidate the in vivo plasticity of Tregs following infection 
and mechanisms that could underlie selective suppression, including co-localisation. 
Ongoing work will contribute to a large body of research being undertaken globally to 
elucidate Treg diversity, ontogeny, activation, plasticity and their mechanisms of 
suppression in a wide range of settings. Together, this research will improve our 
understanding of Treg function and inform the next generation of Treg targeted 
therapeutics. 
 
157 
Chapter 6 General discussion 
The aim of this work was to investigate the potential for Tregs to shape the CD4 T cell 
response to intestinal infection. To test the hypothesis that Tregs can shape the Th bias 
in a time and site-specific manner, an STM infection model was developed. This model 
facilitated a detailed characterisation of the CD4 T cell response to infection, including a 
reciprocal dynamic between Tconvs and Tregs, and an essential role for Tregs to maintain 
Th bias. 
6.1 Summary of key findings 
In the STM model we developed, infection with strain BRD509-2W1S in streptomycin pre-
treated mice caused consistent, non-lethal infection with clear signs of colitis that resolved 
within 2 weeks. This allowed both 2W1S-specific and other T cells to be characterised in 
mucosal and lymphoid sites. A long-lasting 2W1S-specific CD4 T cell response was 
detected in multiple tissues for over 90 days, with the highest number of these cells in the 
large intestine. While 2W1S-specific T cells are consistently Th1 cells, analysis of 2W1S 
tetramer-negative T cells revealed a dynamic and tissue-specific response. In the colon 
but not draining lymph nodes, there is an early and transient Th17 response and a later, 
sustained Th1 response. This dynamic Th response is paralleled by a reciprocal dynamic 
in Tregs; an early proportional increase in T-bet+ Tregs is followed by an increased 
proportion of RORgT+ Tregs. Finally, Treg depletion experiments showed that Tregs are 
essential for the early colonic Th17 response and contribute to the later Th1 response. 
The Treg-dependent Th bias and the Tconv-Treg reciprocity are consistent with the 
hypothesis that Tregs shape the Tconv response by selective suppression. The proposed 
influence of Tregs on the colonic Th bias is diagrammed in Fig 6.1. 
The Th1 response to STM has been previously reported in multiple models, but the Th17 
response has been less well studied, partly because it is transient and occurs only in the 
intestines. The early Th17 response described here is consistent with previous work 
identifying an early expansion and contraction of flagellin-specific Th17 cells in the 
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intestine (Lee et al., 2012b). It is also consistent with research using calves, non-human 
primates and humans, suggesting that Th17 cells reduce pathology and reduce the risk 
of systemic infection (Godinez et al., 2011; Keestra et al., 2011; Raffatellu et al., 2008; 
van de Vosse and Ottenhoff, 2006). 
 
Figure 6.1 The dynamic Th bias in the colon is shaped by Tregs. 
Schematic diagram of the dynamic Th bias in colonic Tconvs following STM infection. Early after STM 
infection, there is a Th17 bias associated with an increased proportion of T-bet+ Tregs. Later, a Th1 bias is 
established in parallel with an increased proportion of RORγT+ Tregs. The potential for Tregs to shape the Th 
bias at each stage of the Tconv response is represented by vertical arrows. The baseline Th bias is indicated 
by a dashed grey line. 
The STM colitis model is a convenient platform to study a dynamic, site-specific CD4 T 
cell response. Initial characterisation of this response revealed a reciprocal dynamic that 
led to Treg depletion and transfer experiments. Together, these experiments elucidate a 
nuanced role for Tregs to shape Th bias, instead of just suppressing the overall response. 
Selective suppression of Th subsets by Tregs would explain both the reciprocal dynamic 
and the Treg-dependent bias described, although the mechanism of selective suppression 
is unclear. In addition to selective suppression, this research highlights unanswered 
questions about antigen specificity, Treg ontogeny, and site-specific control. Each of these 
topics will be discussed below. 
6.2 Antigen specificity of CD4 T cells 
STM strain BRD509-2W1S allows tracking of CD4 T cells that express TCR receptors 
specific for the 2W1S peptide. Despite dynamic shifts in Th bias and Treg populations 
following infection, 2W1S-speific T cells maintained a consistent Th1 phenotype. This 
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indicates that specific TCRs may predispose T cells to adopt a specific Th phenotype. 
Previous research using an oral STM infection model showed that Tconvs specific for 
TTSS peptides are predominantly Th1 cells, while those specific for flagellin peptides can 
be Th1 or Th17 cells (Lee et al., 2012b). Why 2W1S-specific T cells are consistently 
restricted to a Th1 phenotype in this model is unclear. 
As the focus of this research shifted to the bulk, presumably polyclonal T cell response, 
the antigen specificity of cells of interest became less clear. It could be speculated that 
the non-2W1S-specific Tconvs contain a diverse population of STM- and non-STM-
specific TCRs. The role of non-STM specific T cells is difficult to assess with this model, 
but non-cognate activation of ‘bystander’ cells may play an important role in the overall 
response to STM. While the TCR repertoire of different Th subsets at different time points 
warrants attention, the impact of this repertoire on the dynamic Th bias described here, 
whether STM-specific or not, remains unknown. 
The uncertainty about Tconv antigen-specificity also applies to Tregs. Treg antigen-
specificity during infection is poorly understood. During homeostasis, Tregs that are 
specific for self-antigen are selected in the thymus, and these play an important role in the 
prevention of autoimmunity (Huter et al., 2008; Sakaguchi et al., 2001). It has also been 
shown that Tregs specific for microbial and food antigens are important for inhibiting food 
intolerance or immunopathology induced by the microbiota (Kim et al., 2016; Lathrop et 
al., 2011). While the role for antigen-specific Tregs during homeostasis is well reported, it 
is less clear what role pathogen-specific Tregs play during infection or following resolution. 
Pathogen-specific Tregs have been identified following influenza, LCMV and S. Typhi 
infection (McArthur et al., 2015; Su et al., 2016). It is unclear however, whether pathogen-
specific Tregs are necessary to control the immune response to infection, whether they 
regulate responses to specific epitopes, and what effect Treg pathogen-specificity has on 
the clearance of infection or immunopathology. 
While STM-specific Tregs may play an important role in shaping the T cell response, no 
2W1S-specific Tregs were detected in any tissue or at any timepoint. While Tregs may be 
160 
specific to other STM antigens, it is unclear whether this specificity is required to modulate 
the Tconv response to STM. This is because, following activation, Tregs can modulate 
nearby Tconvs regardless of their antigen-specificity. Treg activation could be achieved 
by a range of mechanisms including cognate activation by STM antigen, self-antigen, self-
mimicking STM antigen, commensal microbial antigen, or cross-reactive STM antigens. 
Finally, Tregs can be activated by non-cognate activation (Szymczak-Workman et al., 
2009; Vignali et al., 2008). Further research is warranted to elucidate the role of antigen 
specificity of Treg during infection. This will improve our understanding of how Tregs 
become activated and may reveal therapeutic approaches to target specific Tregs and 
manipulate the immune response to infections or vaccines with improved precision.  
6.3 Ontogeny of Tregs 
In addition to questions about antigen-specificity, this research raises questions about the 
ontogeny of Tregs that respond to STM infection. While Helios is an imperfect marker of 
tTregs, it could be speculated that Helioshi Tregs, which can co-expresses GATA3 but not 
RORγT, represents a largely tTreg population. On the other hand, Helioslo Tregs, that can 
co-express RORγT but not GATA3, could represents a largely pTreg population. If this 
were true it would indicate that tTregs play a major role in the immune response to STM 
in the colon. Although tTregs are selected in the thymus for expression of self-reactive 
TCRs, they have been shown to play a role modulating immune response during infection 
(Lee et al., 2012a; Pacholczyk et al., 2007; Shevach and Thornton, 2014). Cognate 
activation of tTregs could occur following presentation of cross-reactive STM peptides or 
by self-antigen presented by APCs in the vicinity of damaged or infected host cells. Further 
research is required to determine the individual or synergistic role of tTregs and pTregs in 
shaping the immune response to STM infection. As with antigen-specificity, delineating 
the contribution of Tregs with different ontogeny may reveal therapeutic targets or inform 
the development of tools that employ Tregs in a clinical setting. 
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6.4 Site-specific control of T cell responses 
The dynamic Th bias, the reciprocal dynamic between Tconvs and Tregs, and the Treg 
dependent control of Th bias occur in the colonic mucosa but not in the cMLN. This raises 
questions about where and when the CD4 T cell response to STM develops. 
Understanding the sites where T cells are activated, where they migrate and where they 
are retained, provides a fundamental insight into how the T cell response develops and 
how it is controlled. It also reveals insights about how to improve targeting response to 
reduce immunopathology or enhance responses to infections, tumours or vaccine 
immunogens.  
While the MLNs are important sites of T cell priming in the intestines, the GALT can also 
be an important induction site. Previous research has shown that STM-specific T cells are 
activated in PPs <6 hrs p.i., a process dependent on CCR6+ DCs (McSorley et al., 2002; 
Salazar-Gonzalez et al., 2006). While the early T cell response may be primed in the 
MLNs and GALT, a high number of 2W1S-specific T cells are sustained in the colon. As 
such, it can be speculated that the CD4 T cells that are primed in the cMLN and CP/PP 
migrate to the colon where they proliferate and are retained. Because the entire colon, 
including LP and ILFs were digested together in these experiments, it is difficult to 
delineate whether cells are situated in lymphoid tissue or dispersed through the LP. While 
it is difficult to spatially discriminate ILFs and the LP, it can be speculated that Treg 
suppression occurs in either region, since STM can penetrate both sites. 
The site-specific reciprocal dynamics between Tconvs and Tregs, and the Treg-
dependent Th bias could be explained by selective suppression of Th subsets. It could be 
further hypothesised that this selective suppression is driven by co-localisation of Tregs 
and Th subsets expressing the same ‘master’ TFs, since these TFs can regulate the 
expression of specific chemokine receptors. If this hypothesis is correct, Tregs that 
differentiate under the control of these TFs, can be primed to upregulate chemokine 
receptors, migrate to the same sites as Th subsets and carry out selective suppression 
by targeting Tconvs and DCs through contact dependent and independent mechanisms. 
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A cartoon depiction of co-localisation mediated selective suppression is depicted in Fig. 
6.2. 
The hypothesis that selective suppression is mediated by co-localisation is attractive 
because it explains the site-specific reciprocal dynamics and the requirement for Tregs to 
maintain the dynamic Th bias. Although results here do not directly support this 
hypothesis, other reports have shown that co-localisation of T-bet+ Tregs with Th1 cells is 
essential for optimal selective suppression (Levine et al., 2017). Immunofluorescence 
microscopy could help elucidate whether Th1 cells colocalise with and T-bet+ Tregs or if 
Th17 cells co-localise with RORγT+ Tregs following STM infection. It would also be 
interesting to determine if co-localisation occurs in MLNs and/or mucosal tissue. While 
further research is needed to validate the hypothesis of co-localisation, the concept of 
selective suppression itself has important implications for understanding the development 
of T cell responses. 
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Figure 6.2 Co-localisation as a potential mechanism for selective suppression of Th subsets. 
Co-localisation could drive selective suppression of Th subtypes and is consistent with the site-specific 
reciprocal dynamics reported here. (A) During the early colonic Th17 response, T-bet+ Tregs (red), primed in 
GALT or MLNs upregulate CXCR3, migrate through the peripheral blood and home to CXCL9 or CXCL10 in 
the colon, e.g. in the proximity of HEV endothelial cells. These T-bet+CXCR3+ Tregs could suppress Th1 cell 
(blue) expansion in the colon by targeting DCs (grey) and T cells that home to the same regions, allowing 
Th17 cells (yellow) to expand and produce cytokines such as IL-17 and IL-22. (B) According to this model, 
the later Th1 bias could be driven by RORγT+ Tregs (purple) that upregulate CCR6 in the MLN or GALT before 
migrating through blood vessels and home to CCL20 rich areas, e.g. near FAE. In these regions, 
RORγT+CCR6+ Tregs could target DCs and T cells to inhibit the Th17 response and facilitate a Th1 expansion. 
B 
A 
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6.5 Selective suppression and the equilibrium model of 
immunity 
The idea that Tregs expressing ‘master’ TFs might selectively suppress Th subsets is not 
a new concept. This concept has been proposed by immunologists including Shimon 
Sakaguchi and Daniel Campbell, and supported by research showing that T-bet+ Tregs 
can suppress Th1 cells and RORγT/STAT3+ Tregs can selectively suppress Th17 cells 
in some contexts (Chaudhry et al., 2009; Duhen et al., 2012; Koch et al., 2009; Wing and 
Sakaguchi, 2012). This model has not been universally accepted however and it 
contradicts the equilibrium model of immunity, proposed by Gerard Eberl and others 
(Eberl, 2016; Park and Eberl, 2018). 
According to the equilibrium model, type 1, type 2, or type 3 responses are defined by T-
bet, GATA3/IRF4 or RORγT expression, respectively. In this model, immune responses 
are biased towards one of these types, incorporating a cohesive response where Tconvs 
and Tregs expressing the same master TFs expand and contract together. In a type 1 
response for example, environmental factors will induce T-bet expression in Tconvs and 
Tregs, so that T-bet+ Tregs and Th1 cells will expand in parallel. An important aspect of 
the equilibrium model is that it suggests a balanced immune response is maintained 
because Tregs that arise in one response type will selectively supress the Th subsets of 
the other responses. In this way the equilibrium model directly contradicts the selective 
suppression model, which proposes Tregs selectively suppress Th subsets that express 
the same TF. Schematic representations of the selective suppression model and the 
equilibrium model of immunity are shown in Fig 6.3.  
In support of the equilibrium model, research has shown that RORγT+ Tregs suppress 
Th2 responses, and that GF mice with impaired RORγT+ Tregs have a dysregulated Th2 
response (Ohnmacht et al., 2015). On the other hand, microbiota depletion or targeting 
RORγT+ Tregs has also been reported to drive a dysregulated Th17 response (Lochner 
et al., 2011; Sefik et al., 2015). These conflicting results may be partially dependent on 
the models used or other variables. While it is logical to assume that lymphocytes that 
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express the same TFs form a ‘type’ response that suppresses other types; there is 
growing evidence that Tregs selectively suppress Tconvs of the same type (Britton et al., 
2019; Levine et al., 2017). 
 
Figure 6.3 Selective suppression and equilibrium models of Th bias. 
(A) In the model of selective suppression, supported by data here, Tregs expressing Th ‘master’ TFs 
selectively suppress Th subsets that express the same TFs, and indirectly facilitate expansion of other Th 
subsets (represented by ‘+’). (B) According to this selective suppression model, an increased proportion of 
RORγT+ Tregs selectively suppress Th17 cells, which facilitates an expansion of Th1 cells. (C) The equilibrium 
model of immunity proposes that Th subsets and Tregs expressing the same TFs expand and contract in 
parallel. (D) According to this model, Th1 responses incorporate increases in T-bet+ Tregs and Th1 cells, and 
function synergistically to suppress other (non-Th1) Th subsets. 
Results from research described here, including the reciprocal dynamics between Tregs 
and Th subsets, are consistent with a selective suppression model and not with the 
equilibrium model. Both models are over-simplified constructs however; in vivo dynamics 
are more complex and could incorporate aspects of both models depending on context. 
These models and the research described here focus on Treg control of CD4 T cell 
responses. This focus has overlooked other important cell types, including ILCs. Recent 
work has highlighted the important role for RORγT+ ILC3s to produce IL-2 and maintain 
Treg populations in the intestines (Zhou et al., 2019). This has potentially important 
implications for understanding how Tregs can be sustained in the absence of Tconv-
derived IL-2. Because ILCs can express the same ‘master’ TFs and chemokine receptors 
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as Th subsets and Tregs, ILCs may also support site-specific immune-modulation, 
dependent on co-localisation of multiple cell types. While the control of CD4 T cell 
responses is likely more complex and nuanced than these results or other models convey, 
this research can provide important insights into the dynamics that underlie the dynamic 
and site-specific T cell response.  
6.6 Final conclusions 
This research has shown that there is a dynamic Th response in the colon and a reciprocal 
dynamic between Tconvs and Tregs expressing the same TFs. Treg depletion 
experiments indicate that the early Th17 response and the later Th1 bias are shaped by 
Tregs. These results reveal an important role for Tregs to influence the CD4 T cell 
response in a fine-tuned manner. This raises further questions about the development of 
site-specific T cell responses, the phenotype and function of Treg populations that 
respond to infection, the potential for selective suppression, and the impact this has on 
the overall immune response. These results not only have implications for understanding 
how the T cell response to STM colitis is controlled, but also for how T cell responses are 
balanced during infection or inflammation in general. By investigating the potential for 
Tregs to shape or skew Th bias, there will be opportunities to improve and fine-tune 
therapeutic options for cancer, infectious disease vaccines, autoimmunity, inflammatory 
diseases and transplant rejection. Further work is therefore clearly warranted to improve 
our basic understanding of how Tregs shape immune responses. 
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